{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Test Spacy Matcher"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "text = \"Managing dissociative symptoms following the use of esketamine nasal spray: a case report.^\\nPatients with treatment-resistant depression (TRD) treated with esketamine nasal spray commonly experience transient symptoms of dissociation. Manifestations of dissociation, such as feelings of detachment from the environment, can cause considerable anxiety for patients. Nonpharmacologic interventions may help clinicians to manage associated anxiety and confusion due to dissociation following administration of esketamine nasal spray. We present the case of a 64-year-old woman with major depressive disorder who participated in a clinical trial evaluating the efficacy and safety of esketamine nasal spray in conjunction with an oral antidepressant for TRD. The patient received flexible doses of esketamine nasal spray (56 or 84 mg) twice weekly for 4 weeks. On treatment day 1, the patient was administered 56 mg of esketamine nasal spray using two nasal spray devices (28 mg per device). Twenty minutes after the first esketamine nasal spray device was administered, the patient experienced a dissociative episode lasting 40 minutes that caused anxiety and confusion. The patient was encouraged to listen to music during treatment sessions, which resulted in notable improvement of her symptoms. Listening to music of choice immediately following esketamine nasal spray administration along with reassurance from staff may help manage confusion and anxiety associated with dissociation.\"\n",
    "\n",
    "data_file = \"prodigy/input/psychdelic_study_100_20240411.jsonl\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from prodigy.models.matcher import PatternMatcher\n",
    "import spacy\n",
    "from prodigy.components.preprocess import add_tokens\n",
    "from prodigy.components.loaders import JSONL\n",
    "from prodigy import recipe, log, get_stream\n",
    "\n",
    "\n",
    "spacy_model = \"blank:en\"\n",
    "labels = ['APPLICATIONS']\n",
    "patterns = \"prodigy/patterns.jsonl\"\n",
    "lang = \"en\"\n",
    "nlp = spacy.load(spacy_model)\n",
    "stream = get_stream(data_file, rehash=True, dedup=True, input_key=\"text\")\n",
    "matcher = PatternMatcher(\n",
    "        nlp,\n",
    "        label_span=False, # no label added to the span\n",
    "        label_task=False, # no label on top level task\n",
    "        combine_matches=True, # show all matches in one task\n",
    "        all_examples=True, # alle examples are returned\n",
    "        task_hash_keys=(\"label\",)\n",
    "    )\n",
    "\n",
    "\n",
    "matcher = matcher.from_disk(patterns)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0.5\n",
      "{'record_id': 6828, 'keywords': \"['Administration, Intranasal', '*Depressive Disorder, Major/drug therapy', '*Dissociative Disorders/chemically induced/therapy', 'Female', 'Humans', '*Ketamine/administration & dosage/adverse effects', 'Middle Aged', 'Nasal Sprays']\", 'text': 'Managing dissociative symptoms following the use of esketamine nasal spray: a case report.^\\nPatients with treatment-resistant depression (TRD) treated with esketamine nasal spray commonly experience transient symptoms of dissociation. Manifestations of dissociation, such as feelings of detachment from the environment, can cause considerable anxiety for patients. Nonpharmacologic interventions may help clinicians to manage associated anxiety and confusion due to dissociation following administration of esketamine nasal spray. We present the case of a 64-year-old woman with major depressive disorder who participated in a clinical trial evaluating the efficacy and safety of esketamine nasal spray in conjunction with an oral antidepressant for TRD. The patient received flexible doses of esketamine nasal spray (56 or 84 mg) twice weekly for 4 weeks. On treatment day 1, the patient was administered 56 mg of esketamine nasal spray using two nasal spray devices (28 mg per device). Twenty minutes after the first esketamine nasal spray device was administered, the patient experienced a dissociative episode lasting 40 minutes that caused anxiety and confusion. The patient was encouraged to listen to music during treatment sessions, which resulted in notable improvement of her symptoms. Listening to music of choice immediately following esketamine nasal spray administration along with reassurance from staff may help manage confusion and anxiety associated with dissociation.', 'doi': '10.1097/yic.0000000000000327', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/32804743/', 'secondary_title': 'Int Clin Psychopharmacol', '_input_hash': 1585752306, '_task_hash': -289825574, 'spans': [{'text': '64', 'start': 556, 'end': 558, 'pattern': 2095658839}, {'text': '56', 'start': 818, 'end': 820, 'pattern': 2095658839}, {'text': '84', 'start': 824, 'end': 826, 'pattern': 2095658839}, {'text': '56', 'start': 906, 'end': 908, 'pattern': 2095658839}, {'text': '28', 'start': 969, 'end': 971, 'pattern': 2095658839}, {'text': '40', 'start': 1122, 'end': 1124, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 3733, 'keywords': \"['midomafetamine', 'adolescent', 'anxiety disorder', 'article', 'child', 'child behavior', 'Child Behavior Checklist', 'childhood', 'controlled study', 'depression', 'drug dependence', 'euphoria', 'female', 'human', 'leisure', 'male', 'population research', 'priority journal', 'risk assessment', 'social behavior', 'social status', 'symptomatology']\", 'text': \"Symptoms of anxiety and depression in childhood and use of MDMA: Prospective, population based study.^\\nObjective: To investigate whether using ecstasy (3,4- methylenedioxymethamphetamine, MDMA) is preceded by symptoms of behavioural and emotional problems in childhood and early adolescence. Design: Prospective, longitudinal, population based study Setting: The Dutch province of Zuid-Holland. Participants: A sample of 1580 individuals, followed up across a 14 year period, from childhood into adulthood. Main outcome measures: The first assessment took place in 1983 before MDMA appeared as a recreational drug in the Netherlands and included the child behaviour checklist to obtain standardised parents' reports of their children's behavioural and emotional problems. Use of the drug was assessed with the composite international diagnostic interview 14 years later. Results: Eight syndrome scales of childhood behaviour were examined. Scores in the deviant range for the scales designated as anxious or depressed in childhood were significantly related to use of MDMA in adolescents and adults, resulting in an increased risk (hazard ratio 2.22, 95% confidence interval 1.20 to 4.11, P = 0.01). Conclusions: Individuals with childhood symptoms of anxiety and depression may have an increased tendency to use MDMA in adolescence or young adulthood. Its effects are supposed to include enhanced feelings of bonding with other people, euphoria, or relaxation. Especially individuals with symptoms of anxiety or depression may be susceptible to these positive effects.\", 'doi': '10.1136/bmj.38743.539398.3A', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/16500927/', 'secondary_title': 'British Medical Journal', '_input_hash': -672150405, '_task_hash': -1762154941, 'spans': [{'text': 'MDMA', 'start': 59, 'end': 63, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 143, 'end': 150, 'pattern': 611274830}, {'text': 'MDMA', 'start': 188, 'end': 192, 'pattern': -495411397}, {'text': '1580', 'start': 421, 'end': 425, 'pattern': 2095658839}, {'text': '14', 'start': 460, 'end': 462, 'pattern': 2095658839}, {'text': '1983', 'start': 565, 'end': 569, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 577, 'end': 581, 'pattern': -495411397}, {'text': '14', 'start': 855, 'end': 857, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1068, 'end': 1072, 'pattern': -495411397}, {'text': '2.22', 'start': 1145, 'end': 1149, 'pattern': 2095658839}, {'text': '95', 'start': 1151, 'end': 1153, 'pattern': 2095658839}, {'text': '1.20', 'start': 1175, 'end': 1179, 'pattern': 2095658839}, {'text': '4.11', 'start': 1183, 'end': 1187, 'pattern': 2095658839}, {'text': '0.01', 'start': 1193, 'end': 1197, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1313, 'end': 1317, 'pattern': -495411397}], 'meta': {'pattern': '7, 8, 7, 14, 14, 14, 7, 14, 7, 14, 14, 14, 14, 14, 7'}}\n",
      "0.5\n",
      "{'record_id': 9119, 'keywords': \"['psychedelics', 'psychotherapy', 'review', 'ego', 'mental health', 'Drug Therapy', 'Psychedelic Drugs', 'Anxiety Disorders', 'Major Depression', 'Obsessive Compulsive Disorder', 'Posttraumatic Stress Disorder', 'Substance Use Disorder']\", 'text': 'A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future.^\\nResearch on psychedelics has seen a recent revival, with many clinical trials focused on their therapeutic potential to treat a range of mental health conditions. The purpose of this systematic review was to evaluate clinical trials of psychedelic-assisted psychotherapy for mental health conditions from the present wave of psychedelic research (1990s to present). A total of 43 studies met criteria and were included. The conditions reviewed were substance use disorders; anxiety and/or depression, often associated with terminal illness; posttraumatic stress disorder; and obsessive–compulsive disorder. Quantitative results indicate that psychedelics can significantly reduce clinical outcomes associated with these mental health conditions. Common themes identified from qualitative reports included increased acceptance and processing of emotions, connectedness to others, forgiveness, self-compassion, insights into the self, peak or mystical experiences, ego dissolution, positive changes in worldview, motivation and commitment to change, changes in the relationship to the substance of abuse for those with substance use disorder, and acceptance of death for those with terminal illness. No serious, long-term adverse events were reported directly attributable to drug ingestion. We discuss the strengths and limitations of the research base, along with suggestions for clinical practice, potential therapeutic mechanisms, and directions for future research. Despite promising results, further work is needed to determine which psychedelic is best suited for diverse mental health conditions, the most appropriate type of psychotherapy to employ, and the psychological and neurobiological mechanisms underlying clinical benefits. (PsycInfo Database Record (c) 2022 APA, all rights reserved)', 'doi': '10.1037/cns0000237', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/38487318/', 'secondary_title': 'Psychology of Consciousness: Theory, Research, and Practice', '_input_hash': 1512075005, '_task_hash': 1398835868, 'spans': [{'text': '1990s', 'start': 503, 'end': 508, 'pattern': 2095658839}, {'text': '43', 'start': 533, 'end': 535, 'pattern': 2095658839}, {'text': '2022', 'start': 1926, 'end': 1930, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 8746, 'keywords': \"['Administration, Intravenous', 'Adult', '*Bipolar Disorder/complications/diagnosis/drug therapy/psychology', '*Depressive Disorder, Major/complications/diagnosis/drug therapy/psychology', 'Diagnostic and Statistical Manual of Mental Disorders', 'Drug Monitoring/methods', 'Drug Resistance', 'Electroencephalography/methods', 'Excitatory Amino Acid Antagonists/administration & dosage/adverse effects', 'Female', 'Humans', '*Ketamine/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Suicidal Ideation', '*Suicide/psychology', 'Treatment Outcome', 'Wakefulness/*drug effects', '*Suicide Prevention']\", 'text': 'Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.^\\nOBJECTIVE: Insomnia and disrupted sleep are associated with increased risk of suicide. The N-methyl-d-aspartate antagonist ketamine has been associated with reduced suicidal thoughts, but the mechanism of action is unknown. This study sought to evaluate differences in nocturnal wakefulness in depressed individuals who did and did not have an antisuicidal response to ketamine. METHODS: Thirty-four participants with baseline suicidal ideation diagnosed with either DSM-IV major depressive disorder (n = 23) or bipolar depression (n = 11) between 2006 and 2013 completed nighttime electroencephalography (EEG) the night before and the night after a single ketamine infusion (0.5 mg/kg over 40 minutes). Suicidal ideation was assessed at baseline and the morning after ketamine infusion via several measures, including the Hamilton Depression Rating Scale suicide item, the suicide item of the Montgomery-Asberg Depression Rating Scale, and the first 5 items of the Scale for Suicide Ideation. A generalized linear mixed model evaluated differences in nocturnal wakefulness, as verified by EEG, between those who had an antisuicidal response to ketamine and those who did not, controlling for baseline nocturnal wakefulness. Results were also compared to the sleep of healthy controls (n = 22). RESULTS: After analyses adjusted for baseline sleep, participants with an antisuicidal response to ketamine showed significantly reduced nocturnal wakefulness the night after ketamine infusion compared to those without an antisuicidal response (F₁,₂₂ = 5.04, P = .04). Level of nocturnal wakefulness after antisuicidal response to ketamine did not differ significantly from nocturnal wakefulness in the control sample but did differ at a trend level (F₁,₄₀ = 3.15, P = .08). CONCLUSIONS: Reductions in wakefulness following ketamine may point to a biological mechanism underlying the effect of ketamine on suicidal ideation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00088699.', 'doi': '10.4088/JCP.15m10440', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/27929610/', 'secondary_title': 'J Clin Psychiatry', '_input_hash': 270434873, '_task_hash': -504743127, 'spans': [{'text': 'Ketamine', 'start': 32, 'end': 40, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 276, 'end': 284, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 522, 'end': 530, 'pattern': -1436149968}, {'text': '23', 'start': 658, 'end': 660, 'pattern': 2095658839}, {'text': '11', 'start': 689, 'end': 691, 'pattern': 2095658839}, {'text': '2006', 'start': 701, 'end': 705, 'pattern': 2095658839}, {'text': '2013', 'start': 710, 'end': 714, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 810, 'end': 818, 'pattern': -1436149968}, {'text': '40', 'start': 844, 'end': 846, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 922, 'end': 930, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1298, 'end': 1306, 'pattern': -1436149968}, {'text': '22', 'start': 1443, 'end': 1445, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1547, 'end': 1555, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1623, 'end': 1631, 'pattern': -1436149968}, {'text': '5.04', 'start': 1701, 'end': 1705, 'pattern': 2095658839}, {'text': '.04', 'start': 1711, 'end': 1714, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1779, 'end': 1787, 'pattern': -1436149968}, {'text': '3.15', 'start': 1907, 'end': 1911, 'pattern': 2095658839}, {'text': '.08', 'start': 1917, 'end': 1920, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1972, 'end': 1980, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2042, 'end': 2050, 'pattern': -1436149968}, {'text': 'NCT00088699', 'start': 2124, 'end': 2135, 'pattern': 2095658839}], 'meta': {'pattern': '9, 9, 9, 14, 14, 14, 14, 9, 14, 9, 9, 14, 9, 9, 14, 14, 9, 14, 14, 9, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 394, 'keywords': \"['bipolar depression', 'depression', 'ketamine', 'suicide', 'unipolar depression']\", 'text': \"Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation.^\\nBACKGROUND: Psychiatric disorders are associated with more than 90% of reported suicide attempts worldwide, but few treatments have demonstrated a direct effect in reducing suicide risk. Ketamine, originally an anesthetic, has been shown anti-suicide effects in clinical trials designed to treat depression. However, changes at the biochemical level were assessed only in protocols of ketamine with very limited sample sizes, particularly when the subcutaneous route was considered. In addition, the inflammatory changes associated with ketamine effects and their correlation with response to treatment, dose-effect, and suicide risk warrant further investigation. Therefore, we aimed to assess whether ketamine results in better control of suicidal ideation and/or behavior in patients with depressive episodes and whether ketamine affects psychopathology and inflammatory biomarkers. MATERIALS AND METHODS: We report here the design of a naturalistic prospective multicenter study protocol of ketamine in depressive episodes carried out at Hospital de Clínicas de Porto Alegre (HCPA) and Hospital Moinhos de Vento (HMV). The study was planned to recruit adult patients with Major depressive disorder (MDD) or Bipolar disorder (BD) types 1 or 2, who are currently in a depressive episode and show symptoms of suicidal ideation and/or behavior according to the Columbia-Suicide Severity Rating Scale (C-SSRS) and have been prescribed ketamine by their assistant psychiatrist. Patients receive ketamine subcutaneously (SC) twice a week for 1 month, but the frequency can be changed or the dose decreased according to the assistant physician's decision. After the last ketamine session, patients are followed-up via telephone once a month for up to 6 months. The data will be analyzed using repeated measures statistics to evaluate the reduction in suicide risk as a primary outcome, as per C-SSRS. DISCUSSION: We discuss the need for studies with longer follow-ups designed to measure a direct impact on suicide risk and that additional information about the safety and tolerability of ketamine in particular subset of patients such as those with depression and ideation suicide. In line, the mechanism behind the immunomodulatory effects of ketamine is still poorly understood. TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT05249309.\", 'doi': '10.3389/fpsyt.2023.1147298', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36970275/', 'secondary_title': 'Front Psychiatry', '_input_hash': 236422740, '_task_hash': -1025749100, 'spans': [{'text': 'Ketamine', 'start': 0, 'end': 8, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 88, 'end': 96, 'pattern': -1436149968}, {'text': '90', 'start': 224, 'end': 226, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 347, 'end': 355, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 545, 'end': 553, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 697, 'end': 705, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 863, 'end': 871, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 984, 'end': 992, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1155, 'end': 1163, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1594, 'end': 1602, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1653, 'end': 1661, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1827, 'end': 1835, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2245, 'end': 2253, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2401, 'end': 2409, 'pattern': -1436149968}, {'text': 'NCT05249309', 'start': 2498, 'end': 2509, 'pattern': 2095658839}], 'meta': {'pattern': '9, 9, 14, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 4252, 'keywords': \"['Adult', 'Anesthetics, Intravenous/administration & dosage/adverse effects', 'Cognition/*drug effects', '*Depression/diagnosis/drug therapy/physiopathology/psychology', 'Female', 'Humans', '*Ketamine/administration & dosage/adverse effects', 'Male', '*Midazolam/administration & dosage/adverse effects', 'Neurocognitive Disorders/chemically induced/diagnosis', 'Neuropsychological Tests', 'Patient Acuity', 'Reaction Time/*drug effects', '*Suicidal Ideation', 'Treatment Outcome']\", 'text': 'Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation.^\\nObjective: Subanesthetic ketamine rapidly reduces depressive symptoms and suicidal ideation in some depressed patients. Its effects on neurocognitive functioning in such individuals with significant suicidal ideation is not well understood, even though certain neurocognitive deficits are associated with suicide behavior beyond clinical symptoms. Methods: In this study, depressed patients with clinically significant suicidal ideation (n\\u2009=\\u200978) underwent neuropsychological testing before and 1 day after double-blind treatment with intravenous ketamine (n\\u2009=\\u200939) or midazolam (n\\u2009=\\u200939). A subgroup randomized to midazolam whose ideation did not remit after initial infusion received open ketamine and additional neurocognitive testing a day after this treatment. The primary outcome was change in performance on this neurocognitive battery. The study was conducted between November 2012 and January 2017. Results: Blinded ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam, as we had reported previously. Ketamine, relative to midazolam, was also associated with specific improvement in reaction time (Choice RT) and interference processing/cognitive control (computerized Stroop task)-the latter a measure that has been associated with past suicide attempt in depression. In midazolam nonremitters later treated with open ketamine and retested, reaction time and interference processing/cognitive control also improved relative to both of their prior assessments. Neurocognitive improvement, however, was not correlated with changes in depression, suicidal thinking, or general mood. Conclusions: Overall, ketamine was found to have a positive therapeutic effect on neurocognition 1 day after treatment on at least 1 measure associated with suicidal behavior in the context of depression. Results suggest additional independent therapeutic effects for ketamine in the treatment of depressed patients at risk for suicidal behavior. Trial Registration: ClinicalTrials.gov identifier: NCT01700829.', 'doi': '10.4088/JCP.21m13921', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/34727422/', 'secondary_title': 'J Clin Psychiatry', '_input_hash': 421752735, '_task_hash': -936485801, 'spans': [{'text': 'Ketamine', 'start': 11, 'end': 19, 'pattern': -1436149968}, {'text': '24', 'start': 58, 'end': 60, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 139, 'end': 147, 'pattern': -1436149968}, {'text': '78', 'start': 556, 'end': 558, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 660, 'end': 668, 'pattern': -1436149968}, {'text': '39', 'start': 674, 'end': 676, 'pattern': 2095658839}, {'text': '39', 'start': 696, 'end': 698, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 802, 'end': 810, 'pattern': -1436149968}, {'text': '2012', 'start': 996, 'end': 1000, 'pattern': 2095658839}, {'text': '2017', 'start': 1013, 'end': 1017, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1036, 'end': 1044, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1161, 'end': 1169, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1479, 'end': 1487, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1763, 'end': 1771, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2009, 'end': 2017, 'pattern': -1436149968}, {'text': 'NCT01700829', 'start': 2139, 'end': 2150, 'pattern': 2095658839}], 'meta': {'pattern': '9, 14, 9, 14, 9, 14, 14, 9, 14, 14, 9, 9, 9, 9, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 1990, 'keywords': \"['Humans', '*Thalamus/physiology', '*Pulvinar', 'Magnetic Resonance Imaging', 'Cerebral Cortex/diagnostic imaging', 'Parietal Lobe', 'Neural Pathways', 'Lsd', 'Psychedelics', 'Striatum', 'Thalamo-cortical connectivity', 'Thalamus']\", 'text': \"LSD-induced changes in the functional connectivity of distinct thalamic nuclei.^\\nThe role of the thalamus in mediating the effects of lysergic acid diethylamide (LSD) was recently proposed in a model of communication and corroborated by imaging studies. However, a detailed analysis of LSD effects on nuclei-resolved thalamocortical connectivity is still missing. Here, in a group of healthy volunteers, we evaluated whether LSD intake alters the thalamocortical coupling in a nucleus-specific manner. Structural and resting-state functional Magnetic Resonance Imaging (MRI) data were acquired in a placebo-controlled study on subjects exposed to acute LSD administration. Structural MRI was used to parcel the thalamus into its constituent nuclei based on individual anatomy. Nucleus-specific changes of resting-state functional MRI (rs-fMRI) connectivity were mapped using a seed-based approach. LSD intake selectively increased the thalamocortical functional connectivity (FC) of the ventral complex, pulvinar, and non-specific nuclei. Functional coupling was increased between these nuclei and sensory cortices that include the somatosensory and auditory networks. The ventral and pulvinar nuclei also exhibited increased FC with parts of the associative cortex that are dense in serotonin type 2A receptors. These areas are hyperactive and hyper-connected upon LSD intake. At subcortical levels, LSD increased the functional coupling among the thalamus's ventral, pulvinar, and non-specific nuclei, but decreased the striatal-thalamic connectivity. These findings unravel some LSD effects on the modulation of subcortical-cortical circuits and associated behavioral outputs.\", 'doi': '10.1016/j.neuroimage.2023.120414', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/37858906/', 'secondary_title': 'Neuroimage', '_input_hash': -180470857, '_task_hash': 1959508998, 'spans': [{'text': 'LSD', 'start': 0, 'end': 3, 'pattern': -496918669}, {'text': 'LSD', 'start': 162, 'end': 165, 'pattern': -496918669}, {'text': 'LSD', 'start': 286, 'end': 289, 'pattern': -496918669}, {'text': 'LSD', 'start': 425, 'end': 428, 'pattern': -496918669}, {'text': 'LSD', 'start': 653, 'end': 656, 'pattern': -496918669}, {'text': 'LSD', 'start': 898, 'end': 901, 'pattern': -496918669}, {'text': 'LSD', 'start': 1366, 'end': 1369, 'pattern': -496918669}, {'text': 'LSD', 'start': 1401, 'end': 1404, 'pattern': -496918669}, {'text': 'LSD', 'start': 1582, 'end': 1585, 'pattern': -496918669}], 'meta': {'pattern': '0, 0, 0, 0, 0, 0, 0, 0, 0'}}\n",
      "0.5\n",
      "{'record_id': 7702, 'keywords': \"['Adult', 'Dose-Response Relationship, Drug', 'Female', 'Hallucinogens/*adverse effects', 'Humans', 'Illicit Drugs', 'Male', 'Mental Disorders/*chemically induced/psychology', 'N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects', 'Retrospective Studies', 'Serotonin/metabolism', 'Substance-Related Disorders/*psychology', 'Time Factors']\", 'text': \"MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients.^\\nThe present study examined the characteristics and the possible psychopathological consequences of ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) use. One hundred and fifty consecutive patients, presenting to the Padova (Italy) Addiction Treatment Unit and who had taken ecstasy on at least one occasion, were examined and studied using a semi-structured interview. Ninety-five percent of the patients had experimented with another drug of abuse at least once in their lifetime. Ecstasy was mainly self-administered at disco clubs, and reported acute psychoactive effects confirmed previous reports. Fifty-three percent of the total sample were found to be affected by one or more psychopathological problems; the most frequent were depression, psychotic disorders, cognitive disturbances, bulimic episodes, impulse control disorders, panic disorders, social phobia. Those who were free from any psychopathological problem, compared to the others, had taken a smaller number of MDMA tablets in their lifetime, for a shorter duration and with a lower frequency. Again, they were less likely to have used alcohol together with ecstasy but more likely to have used opiates. Longer-term, larger dosage (acute or cumulative) MDMA consumers were found to be at high risk of developing psychopathological disturbances. The results are discussed, taking into account both the ecstasy suggested serotonin (5-hydroxytryptamine) neurotoxicity and the various methodological issues pertaining to this kind of large-scale clinical study describing people for whom MDMA is far from being the only drug of abuse.\", 'doi': '10.1016/s0376-8716(98)00051-9', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/9788011/', 'secondary_title': 'Drug Alcohol Depend', '_input_hash': 1206993487, '_task_hash': -549237682, 'spans': [{'text': 'MDMA', 'start': 0, 'end': 4, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 7, 'end': 14, 'pattern': 611274830}, {'text': '150', 'start': 75, 'end': 78, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 189, 'end': 196, 'pattern': 611274830}, {'text': 'MDMA', 'start': 198, 'end': 202, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 364, 'end': 371, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 572, 'end': 579, 'pattern': 611274830}, {'text': 'MDMA', 'start': 1071, 'end': 1075, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 1218, 'end': 1225, 'pattern': 611274830}, {'text': 'MDMA', 'start': 1313, 'end': 1317, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 1461, 'end': 1468, 'pattern': 611274830}, {'text': 'MDMA', 'start': 1644, 'end': 1648, 'pattern': -495411397}], 'meta': {'pattern': '7, 8, 14, 8, 7, 8, 8, 7, 8, 7, 8, 7'}}\n",
      "0.5\n",
      "{'record_id': 7083, 'keywords': \"['Adult', 'Clinical Trials, Phase I as Topic', '*Creativity', 'Dose-Response Relationship, Drug', 'Female', 'Hallucinogens/*administration & dosage', 'Humans', 'Intelligence/drug effects/physiology', 'Intelligence Tests', 'Male', 'Motivation/drug effects/physiology', 'Nootropic Agents/*administration & dosage', 'Photic Stimulation/methods', 'Problem Solving/drug effects/physiology', 'Thinking/*drug effects/physiology', 'Young Adult', 'Convergent thinking', 'Creativity', 'Divergent thinking', 'Field study', 'Microdosing', 'Psychedelics']\", 'text': 'Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.^\\nINTRODUCTION: Taking microdoses (a mere fraction of normal doses) of psychedelic substances, such as truffles, recently gained popularity, as it allegedly has multiple beneficial effects including creativity and problem-solving performance, potentially through targeting serotonergic 5-HT(2A) receptors and promoting cognitive flexibility, crucial to creative thinking. Nevertheless, enhancing effects of microdosing remain anecdotal, and in the absence of quantitative research on microdosing psychedelics, it is impossible to draw definitive conclusions on that matter. Here, our main aim was to quantitatively explore the cognitive-enhancing potential of microdosing psychedelics in healthy adults. METHODS: During a microdosing event organized by the Dutch Psychedelic Society, we examined the effects of psychedelic truffles (which were later analyzed to quantify active psychedelic alkaloids) on two creativity-related problem-solving tasks: the Picture Concept Task assessing convergent thinking and the Alternative Uses Task assessing divergent thinking. A short version of the Ravens Progressive Matrices task assessed potential changes in fluid intelligence. We tested once before taking a microdose and once while the effects were expected to be manifested. RESULTS: We found that both convergent and divergent thinking performance was improved after a non-blinded microdose, whereas fluid intelligence was unaffected. CONCLUSION: While this study provides quantitative support for the cognitive-enhancing properties of microdosing psychedelics, future research has to confirm these preliminary findings in more rigorous placebo-controlled study designs. Based on these preliminary results, we speculate that psychedelics might affect cognitive metacontrol policies by optimizing the balance between cognitive persistence and flexibility. We hope this study will motivate future microdosing studies with more controlled designs to test this hypothesis.', 'doi': '10.1007/s00213-018-5049-7', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/30357434/', 'secondary_title': 'Psychopharmacology (Berl)', '_input_hash': 1461992142, '_task_hash': -1777253229, 'spans': [], 'meta': {'pattern': ''}}\n",
      "0.5\n",
      "{'record_id': 3605, 'keywords': \"['Adult', 'Double-Blind Method', 'Excitatory Amino Acid Antagonists/administration & dosage/*pharmacology', 'Female', 'Healthy Volunteers', 'Humans', 'Ketamine/administration & dosage/*pharmacology', 'Male', 'Nerve Net/*drug effects/physiopathology', 'Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors', 'Schizophrenia/*chemically induced/physiopathology', 'Somatosensory Cortex/*drug effects/physiopathology', 'Temporal Lobe/*drug effects/physiopathology', 'Thalamus/*drug effects/physiopathology', 'Young Adult', 'functional MRI', 'glutamate', 'ketamine', 'schizophrenia', 'thalamus']\", 'text': 'Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia.^\\nBACKGROUND: Schizophrenia has been associated with disturbances of thalamic functioning. In light of recent evidence suggesting a significant impact of the glutamatergic system on key symptoms of schizophrenia, we assessed whether modulation of the glutamatergic system via blockage of the N-methyl-D-aspartate (NMDA)-receptor might lead to changes of thalamic functional connectivity. METHODS: Based on the ketamine model of psychosis, we investigated changes in cortico-thalamic functional connectivity by intravenous ketamine challenge during a 55-minute resting-state scan. Thirty healthy volunteers were measured with pharmacological functional magnetic resonance imaging using a double-blind, randomized, placebo-controlled, crossover design. RESULTS: Functional connectivity analysis revealed significant ketamine-specific changes within the thalamus hub network, more precisely, an increase of cortico-thalamic connectivity of the somatosensory and temporal cortex. CONCLUSIONS: Our results indicate that changes of thalamic functioning as described for schizophrenia can be partly mimicked by NMDA-receptor blockage. This adds substantial knowledge about the neurobiological mechanisms underlying the profound changes of perception and behavior during the application of NMDA-receptor antagonists.', 'doi': '10.1093/ijnp/pyv040', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/25896256/', 'secondary_title': 'Int J Neuropsychopharmacol', '_input_hash': 905516519, '_task_hash': 1878142548, 'spans': [{'text': 'Ketamine', 'start': 0, 'end': 8, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 521, 'end': 529, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 633, 'end': 641, 'pattern': -1436149968}, {'text': '55', 'start': 661, 'end': 663, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 925, 'end': 933, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 8798, 'keywords': \"['Antidepressive Agents/adverse effects', '*Depressive Disorder, Treatment-Resistant/drug therapy', '*Electroconvulsive Therapy', 'Humans', '*Ketamine/adverse effects', 'Treatment Outcome', 'Cognition', 'Depression', 'Electroconvulsive therapy', 'Ketamine', 'Treatment resistance']\", 'text': 'Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review.^\\nOBJECTIVE: Ketamine has repeatedly shown to have rapid and robust antidepressant effects in patients with treatment resistant depression (TRD). An important question is whether ketamine is as effective and safe as the current gold standard electroconvulsive therapy (ECT). METHODS: The literature was searched for trials comparing ketamine treatment with ECT for depression in the Pubmed/MEDLINE database and Cochrane Trials Library. RESULTS: A total of 137 manuscripts were identified, 6 articles were included in this review. Overall quality of the included studies was diverse with relevant risk of bias for some of the studies. Results suggest that ketamine treatment might give faster but perhaps less durable antidepressant effects. Side effects differed from ECT, in particular less cognitive impairment was apparent in ketamine treatment. LIMITATIONS: The included studies have limited sample sizes, use different treatment protocols and in most trials, longer term follow up is lacking. Furthermore, allocation bias appears likely in the non-randomized trials. CONCLUSIONS: Current available literature does not yet provide convincing evidence to consider ketamine as an equally effective treatment alternative to ECT in patients with TRD. There are indications for a more favourable short term cognitive side effect profile after ketamine treatment. Methodologically well-designed studies with larger sample sizes and longer follow up duration are warranted.', 'doi': '10.1016/j.jad.2020.11.123', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33307338/', 'secondary_title': 'J Affect Disord', '_input_hash': 973216164, '_task_hash': -2138615834, 'spans': [{'text': 'ketamine', 'start': 3, 'end': 11, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 129, 'end': 137, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 295, 'end': 303, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 449, 'end': 457, 'pattern': -1436149968}, {'text': '137', 'start': 572, 'end': 575, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 771, 'end': 779, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 945, 'end': 953, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1283, 'end': 1291, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1458, 'end': 1466, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 7942, 'keywords': \"['Antidepressive Agents/therapeutic use', 'Cognition', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Double-Blind Method', 'Humans', 'Infusions, Intravenous', '*Ketamine/pharmacology/therapeutic use', 'Memory, Short-Term', 'Treatment Outcome']\", 'text': \"Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.^\\nBACKGROUND: Ketamine demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). However, evaluation of ketamine's neurocognitive effect in TRD is unclear. We aim to (1) characterize baseline neurocognitive performance as a predictor of the change in severity of depressive symptoms over time, and (2) investigate the association of six versus single intravenous (IV) ketamine and neurocognitive changes from baseline to the end of treatment. METHODS: Subjects with TRD were randomized to receive either five IV midazolam followed by a single IV ketamine or six IV ketamine during a 12-day period. Depression symptom assessments occurred prior and 24\\xa0h after infusion days using the Montgomery-Åsberg Depression Rating Scale. Neurocognitive tasks were designed to test attention, memory, speed of processing, and set shifting using the CogState battery at baseline and at the end of treatment. RESULTS: Better complex working memory at baseline predicted improvement in MADRS scores of ketamine (vs midazolam) after 5 infusions. Most, but not all, neurocognitive functions remained stable or improved after repeated or single ketamine. There was a greater differential effect of treatment on speed of processing, set shifting, and spatial working memory that favors subjects in the six ketamine group. These cognitive improvements from baseline to the end of treatment were robust when controlling for age and changes in depression severity. CONCLUSION: The study suggests that six IV ketamine compared to single IV ketamine has a mood independent procognitive effect among TRD patients. Large scale studies are needed to confirm whether ketamine enhances cognitive function in TRD.\", 'doi': '10.1016/j.jad.2020.08.058', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/32871534/', 'secondary_title': 'J Affect Disord', '_input_hash': -1485511085, '_task_hash': 1603069199, 'spans': [{'text': 'ketamine', 'start': 79, 'end': 87, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 136, 'end': 144, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 251, 'end': 259, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 515, 'end': 523, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 693, 'end': 701, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 712, 'end': 720, 'pattern': -1436149968}, {'text': '12', 'start': 730, 'end': 732, 'pattern': 2095658839}, {'text': '24', 'start': 795, 'end': 797, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1133, 'end': 1141, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1273, 'end': 1281, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1433, 'end': 1441, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1632, 'end': 1640, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1663, 'end': 1671, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1785, 'end': 1793, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 9, 9, 14, 14, 9, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 1850, 'keywords': \"['Adult', '*Attention/drug effects', '*Auditory Perception/drug effects', 'Brain/drug effects/metabolism', 'Cross-Over Studies', 'Cues', 'Double-Blind Method', 'Female', 'Humans', 'Ketamine', 'Magnetic Resonance Imaging', 'Male', 'N,N-Dimethyltryptamine', 'Neurons/drug effects/*physiology', 'Organ Specificity', 'Psychoses, Substance-Induced/*physiopathology/psychology', 'Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors', 'Schizophrenia/physiopathology', 'Schizophrenic Psychology', 'Serotonin 5-HT2 Receptor Agonists', 'Task Performance and Analysis', '*Visual Perception/drug effects']\", 'text': 'Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis.^\\nDeficits in attentional functions belong to the core cognitive symptoms in schizophrenic patients. Alertness is a nonselective attention component that refers to a state of general readiness that improves stimulus processing and response initiation. The main goal of the present study was to investigate cerebral correlates of alertness in the human 5HT(2A) agonist and N-methyl-D-aspartic acid (NMDA) antagonist model of psychosis. Fourteen healthy volunteers participated in a randomized double-blind, cross-over event-related functional magnetic resonance imaging (fMRI) study with dimethyltryptamine (DMT) and S-ketamine. A target detection task with cued and uncued trials in both the visual and the auditory modality was used. Administration of DMT led to decreased blood oxygenation level-dependent response during performance of an alertness task, particularly in extrastriate regions during visual alerting and in temporal regions during auditory alerting. In general, the effects for the visual modality were more pronounced. In contrast, administration of S-ketamine led to increased cortical activation in the left insula and precentral gyrus in the auditory modality. The results of the present study might deliver more insight into potential differences and overlapping pathomechanisms in schizophrenia. These conclusions must remain preliminary and should be explored by further fMRI studies with schizophrenic patients performing modality-specific alertness tasks.', 'doi': '10.1177/0269881109103227', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/19304859/', 'secondary_title': 'J Psychopharmacol', '_input_hash': 1178385098, '_task_hash': 617334703, 'spans': [{'text': 'DMT', 'start': 60, 'end': 63, 'pattern': -394200700}, {'text': 'ketamine', 'start': 68, 'end': 76, 'pattern': -1436149968}, {'text': 'DMT', 'start': 703, 'end': 706, 'pattern': -394200700}, {'text': 'ketamine', 'start': 714, 'end': 722, 'pattern': -1436149968}, {'text': 'DMT', 'start': 849, 'end': 852, 'pattern': -394200700}, {'text': 'ketamine', 'start': 1167, 'end': 1175, 'pattern': -1436149968}], 'meta': {'pattern': '4, 9, 4, 9, 4, 9'}}\n",
      "0.5\n",
      "{'record_id': 4567, 'keywords': \"['SCHIZOPHRENIA/CHRONIC', 'LSD WITH', 'LYSERGIC ACID DIETHYLAMIDE', 'DIFFERENTIAL RESPONSIBILITY TO', 'NORMALS & SCHIZOPHRENICS', 'PSYCHOPHARMACOLOGY', 'No terms assigned']\", 'text': \"Differential behavior responsivity to LSD-25: Study in normal and schizophrenic adults.^\\n24 chronic schizophrenics and 24 normal volunteers—12 males and females each—were given 75 μg LSD and placebo with 1 week intervals by the double-blind method, and sensory-motor, perceptual and conceptual tasks with time-scores. Significant effect of LSD was found on 12 out of 20 tasks on normals and 6 tasks on schizophrenics. 'Methods groups by treatments analyses of variance' however indicate 'that in all 6 situations there are significant differences between conditions (LSD vs. placebo) and between groups (normals vs. schizophrenics).' The schizophrenic 'resistance' hypothesis is found to be 'a broad generalization' based on qualitative but not supported by quantitative findings. (28 ref.) (PsycINFO Database Record (c) 2016 APA, all rights reserved)\", 'doi': '10.1001/archpsyc.1963.01720120031005', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/13927128/', 'secondary_title': 'Archives of General Psychiatry', '_input_hash': -331804958, '_task_hash': 677483587, 'spans': [{'text': 'LSD-25', 'start': 38, 'end': 44, 'pattern': 2095658839}, {'text': '24', 'start': 89, 'end': 91, 'pattern': 2095658839}, {'text': '24', 'start': 119, 'end': 121, 'pattern': 2095658839}, {'text': 'volunteers—12', 'start': 129, 'end': 142, 'pattern': 2095658839}, {'text': '75', 'start': 177, 'end': 179, 'pattern': 2095658839}, {'text': 'LSD', 'start': 183, 'end': 186, 'pattern': -496918669}, {'text': 'LSD', 'start': 340, 'end': 343, 'pattern': -496918669}, {'text': '12', 'start': 357, 'end': 359, 'pattern': 2095658839}, {'text': '20', 'start': 367, 'end': 369, 'pattern': 2095658839}, {'text': 'LSD', 'start': 567, 'end': 570, 'pattern': -496918669}, {'text': '28', 'start': 782, 'end': 784, 'pattern': 2095658839}, {'text': '2016', 'start': 821, 'end': 825, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 14, 14, 0, 0, 14, 14, 0, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 5025, 'keywords': \"['Adult', 'Antidepressive Agents/therapeutic use', '*Bipolar Disorder/drug therapy', 'Body Mass Index', 'Canada', '*Depressive Disorder, Major/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Humans', '*Ketamine/therapeutic use', 'Obesity/complications/drug therapy/epidemiology', 'Retrospective Studies', 'Adiposity', 'esketamine', 'glutamate', 'obesity', 'overweight']\", 'text': 'Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.^\\nBACKGROUND: Higher body mass index (BMI) has been found to predict greater antidepressant response to intravenous (IV) ketamine treatment. We evaluated the association between BMI and response to repeat-dose IV ketamine in patients with treatment-resistant depression (TRD). METHODS: Adults (N\\xa0=\\xa0230) with TRD received four infusions of IV ketamine at a community-based clinic. Changes in symptoms of depression (ie, Quick Inventory for Depressive Symptomatology-Self-Report 16; QIDS-SR16), suicidal ideation (SI; ie, QIDS-SR16 SI item), anxiety (ie, Generalized Anxiety Disorder-7 Scale), anhedonic severity (ie, Snaith-Hamilton Pleasure Scale), and functioning (ie, Sheehan Disability Scale) following infusions were evaluated. Participants were stratified by BMI as normal (18.0-24.9\\xa0kg/m2; n\\xa0=\\xa072), overweight (25-29.9\\xa0kg/m2; n\\xa0=\\xa076), obese I (30-34.9\\xa0kg/m2; n\\xa0=\\xa047), or obese II (≥35.0\\xa0kg/m2; n\\xa0=\\xa035). RESULTS: Similar antidepressant effects with repeat-dose ketamine were reported between BMI groups (P\\xa0=\\xa0.261). In addition, categorical partial response (P\\xa0=\\xa0.149), response (P\\xa0=\\xa0.526), and remission (P\\xa0=\\xa0.232) rates were similar between the four BMI groups. CONCLUSIONS: The findings are limited by the observational, open-label design of this retrospective analysis. Pretreatment BMI did not predict response to IV ketamine, which was effective regardless of BMI.', 'doi': '10.1017/s1092852920002102', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33267928/', 'secondary_title': 'CNS Spectr', '_input_hash': -1528535297, '_task_hash': -1647470593, 'spans': [{'text': 'ketamine', 'start': 53, 'end': 61, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 310, 'end': 318, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 402, 'end': 410, 'pattern': -1436149968}, {'text': '230', 'start': 487, 'end': 490, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 531, 'end': 539, 'pattern': -1436149968}, {'text': '16', 'start': 666, 'end': 668, 'pattern': 2095658839}, {'text': 'SR16', 'start': 675, 'end': 679, 'pattern': 2095658839}, {'text': 'SR16', 'start': 714, 'end': 718, 'pattern': 2095658839}, {'text': '18.0', 'start': 968, 'end': 972, 'pattern': 2095658839}, {'text': '24.9', 'start': 973, 'end': 977, 'pattern': 2095658839}, {'text': '72', 'start': 989, 'end': 991, 'pattern': 2095658839}, {'text': '25', 'start': 1006, 'end': 1008, 'pattern': 2095658839}, {'text': '29.9', 'start': 1009, 'end': 1013, 'pattern': 2095658839}, {'text': '76', 'start': 1025, 'end': 1027, 'pattern': 2095658839}, {'text': '30', 'start': 1039, 'end': 1041, 'pattern': 2095658839}, {'text': '34.9', 'start': 1042, 'end': 1046, 'pattern': 2095658839}, {'text': '47', 'start': 1058, 'end': 1060, 'pattern': 2095658839}, {'text': '≥35.0', 'start': 1076, 'end': 1081, 'pattern': 2095658839}, {'text': '35', 'start': 1093, 'end': 1095, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1155, 'end': 1163, 'pattern': -1436149968}, {'text': '.261', 'start': 1202, 'end': 1206, 'pattern': 2095658839}, {'text': '.149', 'start': 1256, 'end': 1260, 'pattern': 2095658839}, {'text': '.526', 'start': 1277, 'end': 1281, 'pattern': 2095658839}, {'text': '.232', 'start': 1303, 'end': 1307, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1515, 'end': 1523, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 9, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 9, 14, 14, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 9470, 'keywords': \"['midomafetamine', 'amnesia', 'aptitude test', 'article', 'clinical article', 'controlled study', 'disease association', 'disease course', 'human', 'memory', 'neurotoxicity', 'priority journal', 'recall', 'task performance']\", 'text': 'Memory impairment in abstinent MDMA (\"Ecstasy\") users: A longitudinal investigation.^\\nTo examine the neurotoxic potential of continued MDMA (\"Ecstasy\") use in humans and its functional consequences over the course of 1 year, 15 DMA users participated in a longitudinal study in which they completed a brief neuropsychological test battery composed mainly of retrospective and prospective memory tasks. Subjects were abstinent for 2 weeks on initial and 1-year testing. Continued use of MDMA was associated with progressive decline in terms of immediate and delayed recall.', 'doi': '10.1212/WNL.56.7.966', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/11294938/', 'secondary_title': 'Neurology', '_input_hash': -827864197, '_task_hash': -721330656, 'spans': [{'text': 'MDMA', 'start': 31, 'end': 35, 'pattern': -495411397}, {'text': 'Ecstasy', 'start': 38, 'end': 45, 'pattern': 611274830}, {'text': 'MDMA', 'start': 135, 'end': 139, 'pattern': -495411397}, {'text': 'Ecstasy', 'start': 142, 'end': 149, 'pattern': 611274830}, {'text': '15', 'start': 225, 'end': 227, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 486, 'end': 490, 'pattern': -495411397}], 'meta': {'pattern': '7, 8, 7, 8, 14, 7'}}\n",
      "0.5\n",
      "{'record_id': 9000, 'keywords': \"['Adult', 'Antidepressive Agents/administration & dosage/pharmacology', 'Bipolar Disorder/*drug therapy', 'Brain-Derived Neurotrophic Factor/blood', 'Depressive Disorder, Major/*drug therapy', 'Excitatory Amino Acid Antagonists/administration & dosage/pharmacology', 'Female', 'Humans', 'Infusions, Intravenous', 'Ketamine/administration & dosage/*pharmacology', 'Male', 'Psychiatric Status Rating Scales', 'Sleep Wake Disorders/*drug therapy', 'Time Factors', 'Treatment Outcome', 'Young Adult', 'Antidepressant efficacy', 'Bipolar disorder', 'Brain-derived neurotrophic factor', 'Early prediction', 'Hamd-17', 'Ketamine', 'Major depressive disorder', 'Sleep disturbance', 'Sleep improvement']\", 'text': \"Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.^\\nRATIONALE: Recently, the effects of ketamine on the circadian rhythm have suggested that ketamine's rapid antidepressant effects are associated with and without sleep disturbance improvement. OBJECTIVES: Here, we evaluated the antidepressant efficacy of repeated ketamine infusions in patients with sleep disturbances. METHODS: This study included 127 patients with major depressive disorder or bipolar disorder who received ketamine treatments during a 12-day period. Sleep quality was assessed by the 17-item Hamilton Depression Rating Scale sleep disturbance factor (SDF) (items 4, 5 and 6). Serum brain-derived neurotrophic factor (BDNF) was measured at baseline, day 13 and day 26. This study was a post-hoc analysis. RESULTS: Significant differences were found in the HAMD-17 score at 13 post-infusion time points compared to baseline, as well as the scores in SDF score at each of the 7 post-infusion (4\\xa0h after each infusion excluded) time points among all patients. Logistic regression and linear correlation analyses revealed that a greater reduction in the SDF after 24\\xa0h of the first ketamine infusion resulted in a better antidepressant effect in the last two follow-up visits. Moreover, BDNF levels were significantly higher in sleep responders than in non-responders. CONCLUSIONS: In the 127 patients, six ketamine infusions induced better therapeutic effects in sleep responders than in sleep non-responders and patients without sleep disturbances. The sleep response after repeated ketamine infusions was positively associated with high serum BDNF levels. Early sleep disturbance improvement (as early as 24\\xa0h after the first ketamine injection) may predict the antidepressant effect of repeated-dose ketamine.\", 'doi': '10.1007/s43440-020-00203-1', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33387333/', 'secondary_title': 'Pharmacol Rep', '_input_hash': 1396112558, '_task_hash': 2115115194, 'spans': [{'text': 'ketamine', 'start': 82, 'end': 90, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 172, 'end': 180, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 225, 'end': 233, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 399, 'end': 407, 'pattern': -1436149968}, {'text': '127', 'start': 484, 'end': 487, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 561, 'end': 569, 'pattern': -1436149968}, {'text': '12', 'start': 590, 'end': 592, 'pattern': 2095658839}, {'text': '17', 'start': 639, 'end': 641, 'pattern': 2095658839}, {'text': '13', 'start': 808, 'end': 810, 'pattern': 2095658839}, {'text': '26', 'start': 819, 'end': 821, 'pattern': 2095658839}, {'text': 'HAMD-17', 'start': 910, 'end': 917, 'pattern': 2095658839}, {'text': '13', 'start': 927, 'end': 929, 'pattern': 2095658839}, {'text': '24', 'start': 1214, 'end': 1216, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1232, 'end': 1240, 'pattern': -1436149968}, {'text': '127', 'start': 1439, 'end': 1442, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1457, 'end': 1465, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1635, 'end': 1643, 'pattern': -1436149968}, {'text': '24', 'start': 1758, 'end': 1760, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1779, 'end': 1787, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1854, 'end': 1862, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 9, 14, 14, 14, 14, 14, 14, 14, 9, 14, 9, 9, 14, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 8782, 'keywords': \"['Animals', 'Brain/diagnostic imaging/*drug effects', 'Dopamine/metabolism', 'Functional Neuroimaging', 'Hallucinogens/*pharmacology', 'Humans', 'Magnetic Resonance Imaging', 'Molecular Imaging', 'N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology', 'Neurons/*drug effects/metabolism', 'Neurotoxicity Syndromes/metabolism', 'Neurotransmitter Agents/metabolism', 'Positron-Emission Tomography', 'Receptors, Dopamine/*drug effects/metabolism', 'Serotonin/metabolism', 'Serotonin Plasma Membrane Transport Proteins/*drug effects/metabolism', 'Tomography, Emission-Computed, Single-Photon', '*3,4-Methylenedioxymethamphetamine', '*Dopamine', '*Ecstasy', '*mdma', '*Neuroimaging', '*Neurotoxicity', '*pet', '*spect', '*Serotonin', '*fMRI']\", 'text': 'The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.^\\nRATIONALE: Ecstasy is a commonly used psychoactive drug with 3,4-methylenedioxymethamphetamine (MDMA) as the main content. Importantly, it has been suggested that use of MDMA may be neurotoxic particularly for serotonergic (5-hydroxytryptamine (5-HT)) neurons. In the past decades, several molecular imaging studies examined directly in vivo the effects of ecstasy/MDMA on neurotransmitter systems. OBJECTIVES: The objective of the present study is to review the effects of ecstasy/MDMA on neurotransmitter systems as assessed by molecular imaging studies in small animals, non-human primates and humans. METHODS: A search in PubMed was performed. Eighty-eight articles were found on which inclusion and exclusion criteria were applied. RESULTS: Thirty-three studies met the inclusion criteria; all were focused on the 5-HT or dopamine (DA) system. Importantly, 9 out of 11 of the animal studies that examined the effects of MDMA on 5-HT transporter (SERT) availability showed a significant loss of binding potential. In human studies, this was the case for 14 out of 16 studies, particularly in heavy users. In abstinent users, significant recovery of SERT binding was found over time. Most imaging studies in humans that focused on the DA system did not find any significant effect of ecstasy/MDMA use. CONCLUSIONS: Preclinical and clinical molecular imaging studies on the effects of ecstasy/MDMA use/administration on neurotransmitter systems show quite consistent alterations of the 5-HT system. Particularly, in human studies, loss of SERT binding was observed in heavy ecstasy users, which might reflect 5-HT neurotoxicity, although alternative explanations (e.g. down-regulation of the SERT) cannot be excluded.', 'doi': '10.1007/s00213-016-4396-5', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/27568200/', 'secondary_title': 'Psychopharmacology (Berl)', '_input_hash': 2088857546, '_task_hash': 670784184, 'spans': [{'text': 'ecstasy', 'start': 15, 'end': 22, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 119, 'end': 126, 'pattern': 611274830}, {'text': 'MDMA', 'start': 204, 'end': 208, 'pattern': -495411397}, {'text': 'MDMA', 'start': 278, 'end': 282, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 465, 'end': 472, 'pattern': 611274830}, {'text': 'MDMA', 'start': 473, 'end': 477, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 582, 'end': 589, 'pattern': 611274830}, {'text': 'MDMA', 'start': 590, 'end': 594, 'pattern': -495411397}, {'text': '11', 'start': 979, 'end': 981, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1033, 'end': 1037, 'pattern': -495411397}, {'text': '14', 'start': 1166, 'end': 1168, 'pattern': 2095658839}, {'text': '16', 'start': 1176, 'end': 1178, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1395, 'end': 1402, 'pattern': 611274830}, {'text': 'MDMA', 'start': 1403, 'end': 1407, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 1495, 'end': 1502, 'pattern': 611274830}, {'text': 'MDMA', 'start': 1503, 'end': 1507, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 1684, 'end': 1691, 'pattern': 611274830}], 'meta': {'pattern': '8, 8, 7, 7, 8, 7, 8, 7, 14, 7, 14, 14, 8, 7, 8, 7, 8'}}\n",
      "0.5\n",
      "{'record_id': 3597, 'keywords': \"['Humans', 'Anxiety', '*Hallucinogens/adverse effects', 'Lysergic Acid Diethylamide', '*Mental Disorders/drug therapy/psychology', 'Psilocybin/adverse effects', 'Psychedelic', 'depression', 'hallucinogen', 'microdosing']\", 'text': 'The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.^\\nThere has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the \"Psychedelic Renaissance.\" This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain species of fungi. Pubmed was searched by one doctoral-level researcher using specific Boolean operator terms. The results were filtered by title and abstract and 76 articles were screened and analyzed in full detail. Oral psilocybin is showing itself to be clinically efficacious by producing statistically significant reductions in depression and anxiety symptoms over time versus control in multiple clinical trials. It has also been shown to reduce cigarettes per day and drinks per day in patients with substance use disorders. Thus far, there have been no significant adverse clinical events from psilocybin and there also have been no verifiable recorded deaths reported. Larger studies need to be performed before the drug can potentially become approved for use in the general population.', 'doi': '10.1080/02791072.2022.2044096', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/35225726/', 'secondary_title': 'J Psychoactive Drugs', '_input_hash': 791125959, '_task_hash': 1506797652, 'spans': [{'text': 'Psilocybin', 'start': 11, 'end': 21, 'pattern': 1563408733}, {'text': 'LSD', 'start': 205, 'end': 208, 'pattern': -496918669}, {'text': 'MDMA', 'start': 210, 'end': 214, 'pattern': -495411397}, {'text': 'psilocybin', 'start': 220, 'end': 230, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 450, 'end': 460, 'pattern': 1563408733}, {'text': '76', 'start': 687, 'end': 689, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 747, 'end': 757, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 1127, 'end': 1137, 'pattern': 1563408733}], 'meta': {'pattern': '1, 0, 7, 1, 1, 14, 1, 1'}}\n",
      "0.5\n",
      "{'record_id': 3640, 'keywords': \"['Adult', 'Affect/drug effects/physiology', 'Central Nervous System Stimulants/*administration & dosage', 'Consciousness/*drug effects/physiology', 'Cross-Over Studies', 'Dextroamphetamine/*administration & dosage', 'Double-Blind Method', 'Female', 'Hallucinogens/*administration & dosage', 'Healthy Volunteers', 'Humans', 'Lysergic Acid Diethylamide/*administration & dosage', 'Male', 'Middle Aged', 'N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage', 'Retrospective Studies', 'Time Factors']\", 'text': 'Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.^\\nLysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and D-amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and D-amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three substances induce distinct acute subjective effects. However, differences in acute responses to these prototypical psychoactive substances have not been characterized in a controlled study. We investigated the acute autonomic, subjective, and endocrine effects of single doses of LSD (0.1\\u2009mg), MDMA (125\\u2009mg), D-amphetamine (40\\u2009mg), and placebo in a randomized, double-blind, cross-over study in 28 healthy subjects. All of the substances produced comparable increases in hemodynamic effects, body temperature, and pupil size, indicating equivalent autonomic responses at the doses used. LSD and MDMA increased heart rate more than D-amphetamine, and D-amphetamine increased blood pressure more than LSD and MDMA. LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine. LSD also produced greater subjective drug effects, ego dissolution, introversion, emotional excitation, anxiety, and inactivity than MDMA and D-amphetamine. LSD also induced greater impairments in subjective ratings of concentration, sense of time, and speed of thinking compared with MDMA and D-amphetamine. MDMA produced greater ratings of good drug effects, liking, high, and ego dissolution compared with D-amphetamine. D-Amphetamine increased ratings of activity and concentration compared with LSD. MDMA but not LSD or D-amphetamine increased plasma concentrations of oxytocin. None of the substances altered plasma concentrations of brain-derived neurotrophic factor. These results indicate clearly distinct acute effects of LSD, MDMA, and D-amphetamine and may assist the dose-finding in substance-assisted psychotherapy research.', 'doi': '10.1038/s41386-019-0569-3', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/31733631/', 'secondary_title': 'Neuropsychopharmacology', '_input_hash': 893239006, '_task_hash': -1109172992, 'spans': [{'text': 'LSD', 'start': 26, 'end': 29, 'pattern': -496918669}, {'text': 'MDMA', 'start': 31, 'end': 35, 'pattern': -495411397}, {'text': 'LSD', 'start': 105, 'end': 108, 'pattern': -496918669}, {'text': 'MDMA', 'start': 171, 'end': 175, 'pattern': -495411397}, {'text': 'LSD', 'start': 283, 'end': 286, 'pattern': -496918669}, {'text': 'MDMA', 'start': 291, 'end': 295, 'pattern': -495411397}, {'text': 'LSD', 'start': 738, 'end': 741, 'pattern': -496918669}, {'text': 'MDMA', 'start': 752, 'end': 756, 'pattern': -495411397}, {'text': '125', 'start': 758, 'end': 761, 'pattern': 2095658839}, {'text': '40', 'start': 782, 'end': 784, 'pattern': 2095658839}, {'text': '28', 'start': 853, 'end': 855, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1045, 'end': 1048, 'pattern': -496918669}, {'text': 'MDMA', 'start': 1053, 'end': 1057, 'pattern': -495411397}, {'text': 'LSD', 'start': 1157, 'end': 1160, 'pattern': -496918669}, {'text': 'MDMA', 'start': 1165, 'end': 1169, 'pattern': -495411397}, {'text': 'LSD', 'start': 1171, 'end': 1174, 'pattern': -496918669}, {'text': 'MDMA', 'start': 1316, 'end': 1320, 'pattern': -495411397}, {'text': 'LSD', 'start': 1340, 'end': 1343, 'pattern': -496918669}, {'text': 'MDMA', 'start': 1473, 'end': 1477, 'pattern': -495411397}, {'text': 'LSD', 'start': 1497, 'end': 1500, 'pattern': -496918669}, {'text': 'MDMA', 'start': 1625, 'end': 1629, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1649, 'end': 1653, 'pattern': -495411397}, {'text': 'LSD', 'start': 1840, 'end': 1843, 'pattern': -496918669}, {'text': 'MDMA', 'start': 1845, 'end': 1849, 'pattern': -495411397}, {'text': 'LSD', 'start': 1858, 'end': 1861, 'pattern': -496918669}, {'text': 'LSD', 'start': 2072, 'end': 2075, 'pattern': -496918669}, {'text': 'MDMA', 'start': 2077, 'end': 2081, 'pattern': -495411397}], 'meta': {'pattern': '0, 7, 0, 7, 0, 7, 0, 7, 14, 14, 14, 0, 7, 0, 7, 0, 7, 0, 7, 0, 7, 7, 0, 7, 0, 0, 7'}}\n",
      "0.5\n",
      "{'record_id': 5370, 'keywords': \"['craving', 'detoxification', 'ibogaine', 'noribogaine', 'opioid dependence', 'withdrawal']\", 'text': \"Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.^\\nIbogaine may be effective for transitioning opioid and cocaine dependent individuals to sobriety. American and European self-help groups provided public testimonials that ibogaine alleviated drug craving and opioid withdrawal symptoms after only a single dose administration. Preclinical studies in animal models of addiction have provided proof-of-concept evidence in support of these claims. However, the purported therapeutic benefits of ibogaine are based on anecdotal reports from a small series of case reports that used retrospective recruitment procedures. We reviewed clinical results from an open label case series (N = 191) of human volunteers seeking to detoxify from opioids or cocaine with medical monitoring during inpatient treatment. Whole blood was assayed to obtain pharmacokinetic measures to determine the metabolism and clearance of ibogaine. Clinical safety data and adverse events (AEs) were studied in male and female subjects. There were no significant adverse events following administration of ibogaine in a dose range that was shown to be effective for blocking opioid withdrawal symptoms in this study. We used multi-dimensional craving questionnaires during inpatient detoxification to test if ibogaine was effective in diminishing heroin and cocaine cravings. Participants also completed standardized questionnaires about their health and mood before and after ibogaine treatment, and at program discharge. One-month follow-up data were reviewed where available to determine if ibogaine's effects on drug craving would persist outside of an inpatient setting. We report here that ibogaine therapy administered in a safe dose range diminishes opioid withdrawal symptoms and reduces drug cravings. Pharmacological treatments for opioid dependence include detoxification, narcotic antagonists and long-term opioid maintenance therapy. Our results support product development of single oral dose administration of ibogaine for the treatment of opioid withdrawal during medically supervised detoxification to transition drug dependent individuals to abstinence.\", 'doi': '10.3389/fphar.2018.00529', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/29922156/', 'secondary_title': 'Front Pharmacol', '_input_hash': -1672850650, '_task_hash': 1649308699, 'spans': [{'text': 'Ibogaine', 'start': 0, 'end': 8, 'pattern': -1497125929}, {'text': 'Ibogaine', 'start': 145, 'end': 153, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 316, 'end': 324, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 586, 'end': 594, 'pattern': -1497125929}, {'text': '191', 'start': 775, 'end': 778, 'pattern': 2095658839}, {'text': 'ibogaine', 'start': 1000, 'end': 1008, 'pattern': -1497125929}, {'text': 'male', 'start': 1072, 'end': 1076, 'pattern': -757571895}, {'text': 'female', 'start': 1081, 'end': 1087, 'pattern': 1547013372}, {'text': 'ibogaine', 'start': 1167, 'end': 1175, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 1370, 'end': 1378, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 1538, 'end': 1546, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 1655, 'end': 1663, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 1757, 'end': 1765, 'pattern': -1497125929}, {'text': 'ibogaine', 'start': 2087, 'end': 2095, 'pattern': -1497125929}], 'meta': {'pattern': '10, 10, 10, 10, 14, 10, 12, 13, 10, 10, 10, 10, 10, 10'}}\n",
      "0.5\n",
      "{'record_id': 6496, 'keywords': \"['Aged', 'Anesthetics, Dissociative/administration & dosage/*pharmacology', 'Electroencephalography', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Injections, Intravenous', 'Ketamine/administration & dosage/*pharmacology', 'Male', 'Middle Aged', 'Nervous System Diseases/*complications', 'Pain/*drug therapy/physiopathology', 'Psychotic Disorders/etiology', 'Sleep, REM/drug effects']\", 'text': 'Effects of low-dose ketamine on neuropathic pain: An electroencephalogram-electrooculogram/behavioral study.^\\nThe aim of the present study was to clarify the neurophysiological changes associated with analgesic and behavioral effects of low-dose ketamine HCl in patients suffering from chronic neuropathic pain. Ten in-patients with neuropathic pain participated in this single-blind, placebo-controlled study after giving written informed consent. Following intravenous injections of a saline solution (placebo), three bolus injections of 5 mg ketamine HCl were administered at 5 min intervals. Changes in pain perception were assessed using a numerical rating scale for pain. Behavioral changes, including psychotomimetic effects, were assessed using the Brief Psychiatric Rating Scale (BPRS). Electroencephalograms (EEG) and electrooculograms (EOG) were recorded continuously throughout the testing period. One minute EEG and closed-eye eye movements were quantified. The effects of ketamine were evaluated by comparing the neurophysiological and behavioral parameters obtained from the placebo and ketamine trials. Pain reduction was significantly correlated with ketamine-induced changes in hallucinatory behavior and excitement as measured by the BPRS. Ketamine injections caused a significant decrease in the EEGalpha amplitude without an accompanying reduction in EEG frequency. The EEGalpha amplitude reduction at the right central electrode was significantly related to subjective pain relief. Subanesthetic doses of ketamine significantly decreased rapid eye movements, but did not initiate slow eye movements. In conclusion, the present EEG-EOG/behavioral results indicate that ketamine-induced failure of neural integration between cortical-subcortical regions induces psychotic symptoms and alters pain perception on neuropathic pain.', 'doi': '10.1046/j.1440-1819.2002.01023.x', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/12109952/', 'secondary_title': 'Psychiatry Clin Neurosci', '_input_hash': -245195381, '_task_hash': 236366788, 'spans': [{'text': 'ketamine', 'start': 20, 'end': 28, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 246, 'end': 254, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 545, 'end': 553, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 986, 'end': 994, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1102, 'end': 1110, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1168, 'end': 1176, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1259, 'end': 1267, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1527, 'end': 1535, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1690, 'end': 1698, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 4404, 'keywords': \"['midomafetamine', 'iodine 123', 'serotonin transporter', 'adolescent', 'adult', 'age distribution', 'amygdala', 'animal cell', 'animal experiment', 'article', 'brain development', 'controlled study', 'corpus striatum', 'female', 'frontal cortex', 'hippocampus', 'human', 'hypothalamus', 'male', 'mesencephalon', 'neurotoxicity', 'neurotransmission', 'neurotropism', 'nonhuman', 'occipital cortex', 'perinatal drug exposure', 'prefrontal cortex', 'protein binding', 'rat', 'single photon emission computed tomography', 'temporal cortex']\", 'text': \"The Effects of Ecstasy (MDMA) on Brain Serotonin Transporters Are Dependent on Age-of-First Exposure in Recreational Users and Animals.^\\nRationale and Objective: Little is known on the effects of ecstasy (MDMA, a potent 5-HT-releaser and neurotoxin) exposure on brain development in teenagers. The objective of this study was to investigate whether in humans, like previous observations made in animals, the effects of MDMA on the 5-HT system are dependent on age-of-first exposure. Methods: 5-HT transporter (SERT) densities in the frontal cortex and midbrain were assessed with [123I]β-CIT single photon emission computed tomography in 33 users of ecstasy. Subjects were stratified for early-exposed users (age-at-first exposure 14-18 years; developing brain), and late-exposed users (age-at-first exposure 18-36 years; mature brain). In parallel, we investigated the effects of age experimentally with MDMA in early-exposed (adolescent) rats and late-exposed (adult) rats using the same radioligand. Results: On average, five years after first exposure, we found a strong inverse relationship, wherein age-at-first exposure predicted 79% of the midbrain SERT variability in early (developing brain) exposed ecstasy users, whereas this was only 0.3% in late (mature brain) exposed users (p = 0.007). No such effect was observed in the frontal cortex. In rats, a significant age-BY-treatment effect (p<0.01) was observed as well, however only in the frontal cortex. Conclusions: These age-related effects most likely reflect differences in the maturational stage of the 5-HT projection fields at age-at-first exposure and enhanced outgrowth of the 5-HT system due to 5-HT's neurotrophic effects. Ultimately, our findings stress the need for more knowledge on the effects of pharmacotherapies that alter brain 5-HT levels in the pediatric population. © 2012 Klomp et al.\", 'doi': '10.1371/journal.pone.0047524', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/23115651/', 'secondary_title': 'PLoS ONE', '_input_hash': 1571437269, '_task_hash': -1042148777, 'spans': [{'text': 'Ecstasy', 'start': 15, 'end': 22, 'pattern': 611274830}, {'text': 'MDMA', 'start': 24, 'end': 28, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 196, 'end': 203, 'pattern': 611274830}, {'text': 'MDMA', 'start': 205, 'end': 209, 'pattern': -495411397}, {'text': 'MDMA', 'start': 419, 'end': 423, 'pattern': -495411397}, {'text': '123I]β', 'start': 581, 'end': 587, 'pattern': 2095658839}, {'text': '33', 'start': 638, 'end': 640, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 650, 'end': 657, 'pattern': 611274830}, {'text': '14', 'start': 731, 'end': 733, 'pattern': 2095658839}, {'text': '18', 'start': 734, 'end': 736, 'pattern': 2095658839}, {'text': '18', 'start': 809, 'end': 811, 'pattern': 2095658839}, {'text': '36', 'start': 812, 'end': 814, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 905, 'end': 909, 'pattern': -495411397}, {'text': '79', 'start': 1137, 'end': 1139, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1210, 'end': 1217, 'pattern': 611274830}, {'text': '0.007', 'start': 1294, 'end': 1299, 'pattern': 2095658839}, {'text': 'p<0.01', 'start': 1401, 'end': 1407, 'pattern': 2095658839}, {'text': '2012', 'start': 1853, 'end': 1857, 'pattern': 2095658839}], 'meta': {'pattern': '8, 7, 8, 7, 7, 14, 14, 8, 14, 14, 14, 14, 7, 14, 8, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 9171, 'keywords': \"['Adult', 'Antidepressive Agents/*therapeutic use', 'Bipolar Disorder/*drug therapy', 'Clinical Trials as Topic', 'Depressive Disorder, Major/*drug therapy', 'Female', 'Humans', 'Ketamine/*therapeutic use', 'Male', 'Midazolam/*therapeutic use', 'Middle Aged', 'Saline Solution/administration & dosage', 'Treatment Outcome']\", 'text': 'Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.^\\nThe goal of this study was to infer the effectiveness of midazolam as a comparator in preserving the blind in ketamine studies for mood disorders through patient-level analyses of efficacy trial outcomes. In this integrative data analysis (k\\u2009=\\u20099, N\\u2009=\\u2009367 patients with mood disorders), clinical outcomes were compared across four groups: ketamine (midazolam-controlled), ketamine (saline-controlled), midazolam, and saline. Ketamine doses ranged from 0.5 to 0.54\\u2009mg/kg and midazolam doses ranged from 0.02 to 0.045\\u2009mg/kg. The baseline-to-Day 1 effect size was d\\u2009=\\u20090.7 (95% CI: 0.4-0.9) for ketamine (midazolam) versus midazolam and d\\u2009=\\u20091.8 (95% CI: 1.4-2.2) for ketamine (saline) versus saline. The effect of ketamine relative to control was larger in saline-controlled studies than in midazolam-controlled studies (t(276)\\u2009=\\u20092.32, p\\u2009=\\u20090.02). This was driven by a comparatively larger effect under midazolam than saline (t(111)\\u2009=\\u20095.40, p\\u2009<\\u20090.0001), whereas there was no difference between ketamine (midazolam) versus ketamine (saline) (t(177)\\u2009=\\u20090.65, p\\u2009=\\u20090.51). Model-estimated rates of response (with 95% CI) yielded similar results: ketamine (midazolam), 45% (34-56%); ketamine (saline), 46% (34-58%); midazolam, 18% (6-30%); saline, 1% (0-11%). The response rate for ketamine was higher than the control condition for both saline (t(353)\\u2009=\\u20097.41, p\\u2009<\\u20090.0001) and midazolam (t(353)\\u2009=\\u20094.59, p\\u2009<\\u20090.0001). Studies that used midazolam as a comparator yielded smaller effects of ketamine than those which used saline, which was accounted for by greater improvement following midazolam compared to saline.', 'doi': '10.1038/s41386-019-0317-8', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/30653192/', 'secondary_title': 'Neuropsychopharmacology', '_input_hash': 1101857305, '_task_hash': -852319436, 'spans': [{'text': 'ketamine', 'start': 80, 'end': 88, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 234, 'end': 242, 'pattern': -1436149968}, {'text': '367', 'start': 375, 'end': 378, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 462, 'end': 470, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 495, 'end': 503, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 548, 'end': 556, 'pattern': -1436149968}, {'text': '0.54', 'start': 582, 'end': 586, 'pattern': 2095658839}, {'text': '0.02', 'start': 625, 'end': 629, 'pattern': 2095658839}, {'text': '0.045', 'start': 633, 'end': 638, 'pattern': 2095658839}, {'text': '95', 'start': 693, 'end': 695, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 714, 'end': 722, 'pattern': -1436149968}, {'text': '95', 'start': 765, 'end': 767, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 786, 'end': 794, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 833, 'end': 841, 'pattern': -1436149968}, {'text': 't(276', 'start': 940, 'end': 945, 'pattern': 2095658839}, {'text': '2.32', 'start': 949, 'end': 953, 'pattern': 2095658839}, {'text': '0.02', 'start': 959, 'end': 963, 'pattern': 2095658839}, {'text': 't(111', 'start': 1044, 'end': 1049, 'pattern': 2095658839}, {'text': '5.40', 'start': 1053, 'end': 1057, 'pattern': 2095658839}, {'text': '0.0001', 'start': 1063, 'end': 1069, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1112, 'end': 1120, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1140, 'end': 1148, 'pattern': -1436149968}, {'text': 't(177', 'start': 1159, 'end': 1164, 'pattern': 2095658839}, {'text': '0.65', 'start': 1168, 'end': 1172, 'pattern': 2095658839}, {'text': '0.51', 'start': 1178, 'end': 1182, 'pattern': 2095658839}, {'text': '95', 'start': 1225, 'end': 1227, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1258, 'end': 1266, 'pattern': -1436149968}, {'text': '45', 'start': 1280, 'end': 1282, 'pattern': 2095658839}, {'text': '34', 'start': 1285, 'end': 1287, 'pattern': 2095658839}, {'text': '56', 'start': 1288, 'end': 1290, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1294, 'end': 1302, 'pattern': -1436149968}, {'text': '46', 'start': 1313, 'end': 1315, 'pattern': 2095658839}, {'text': '34', 'start': 1318, 'end': 1320, 'pattern': 2095658839}, {'text': '58', 'start': 1321, 'end': 1323, 'pattern': 2095658839}, {'text': '18', 'start': 1338, 'end': 1340, 'pattern': 2095658839}, {'text': '30', 'start': 1345, 'end': 1347, 'pattern': 2095658839}, {'text': '11', 'start': 1365, 'end': 1367, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1393, 'end': 1401, 'pattern': -1436149968}, {'text': 't(353', 'start': 1457, 'end': 1462, 'pattern': 2095658839}, {'text': '7.41', 'start': 1466, 'end': 1470, 'pattern': 2095658839}, {'text': '0.0001', 'start': 1476, 'end': 1482, 'pattern': 2095658839}, {'text': 't(353', 'start': 1499, 'end': 1504, 'pattern': 2095658839}, {'text': '4.59', 'start': 1508, 'end': 1512, 'pattern': 2095658839}, {'text': '0.0001', 'start': 1518, 'end': 1524, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1598, 'end': 1606, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 9, 9, 9, 14, 14, 14, 14, 9, 14, 9, 9, 14, 14, 14, 14, 14, 14, 9, 9, 14, 14, 14, 14, 9, 14, 14, 14, 9, 14, 14, 14, 14, 14, 14, 9, 14, 14, 14, 14, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 7904, 'keywords': \"['Brain imaging', 'MRI', 'Drug', 'Patterning', 'Modulation', 'Mapping', 'Schizophrenia', 'Recognition', 'Adult', 'Brain', 'Dopamine Antagonists', 'Double-Blind Method', 'Excitatory Amino Acid Antagonists', 'Glutamic Acid', 'Healthy Volunteers', 'Humans', 'Ketamine', 'Male', 'Receptors, N-Methyl-D-Aspartate', 'Risperidone', 'Triazines', 'Young Adult', 'Magnetic Resonance Imaging', 'Psychopharmacology']\", 'text': 'Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.^\\nRationale: Resting brain perfusion, measured using the MRI-based arterial spin labelling (ASL) technique, is sensitive to detect central effects of single, clinically effective, doses of pharmacological compounds. However, pharmacological interaction experiments, such as the modulation of one drug response in the presence of another, have not been widely investigated using a task-free ASL approach. Objectives: We assessed the effects of three psychoactive compounds (ketamine, risperidone and lamotrigine), and their interaction, on resting brain perfusion in healthy human volunteers. Methods: A multivariate Gaussian process classification (GPC) and more conventional univariate analyses were applied. The four pre-infusion conditions for each subject comprised risperidone, lamotrigine and two placebo sessions. The two placebo conditions enabled us to evaluate the classification performance in a test-retest setting, in addition to its performance in distinguishing the active oral drugs from placebo (direct effect on brain perfusion). The post ketamine- or saline-infusion scans allowed the effect of ketamine, and its interaction with risperidone and lamotrigine, on brain perfusion to be characterised. Results: The pseudo-continuous ASL measurements of perfusion were sensitive to the effects of ketamine infusion and risperidone. The GPC captured consistent changes in perfusion across the group and contextualised the univariate changes with a larger pattern of regions contributing to accurate discrimination of ketamine from placebo. Conclusions: The findings argue against perfusion changes confounding in the previously described evoked BOLD response to ketamine and emphasise the blockade of the NMDA receptor over neuronal glutamate release in determining the perfusion changes induced by ketamine. (PsycINFO Database Record (c) 2016 APA, all rights reserved)', 'doi': '10.1007/s00213-015-4021-z', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/26223493/', 'secondary_title': 'Psychopharmacology', '_input_hash': 1931339989, '_task_hash': -1095411902, 'spans': [{'text': 'ketamine', 'start': 22, 'end': 30, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 586, 'end': 594, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1227, 'end': 1235, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1425, 'end': 1433, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1644, 'end': 1652, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1789, 'end': 1797, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1926, 'end': 1934, 'pattern': -1436149968}, {'text': '2016', 'start': 1966, 'end': 1970, 'pattern': 2095658839}], 'meta': {'pattern': '9, 9, 9, 9, 9, 9, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 5525, 'keywords': \"['Adult', 'Antidepressive Agents/therapeutic use', 'Depression', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Humans', '*Ketamine/therapeutic use', 'Psychotherapy', 'Anxiety', 'Bipolar disorder', 'Esketamine', 'Ketamine', 'Major depressive disorder', 'Suicidality', 'Treatment-resistant depression']\", 'text': \"Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.^\\nINTRODUCTION: Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD). A limitation of ketamine treatment in TRD is the relatively short duration of time to relapse (e.g., median 2-4\\xa0weeks). The objective of the systematic review herein is to identify strategies capable of prolonging the acute efficacy of ketamine in adults with TRD. METHODS: PubMed/MEDLINE databases were searched from inception to December 2020 for clinical studies written in English using the following key terms: ketamine, prolong, and depression. A total of 454 articles were identified from the literature search which included all clinical studies regarding prolonging the antidepressant effects of ketamine. Twenty-two articles were included: ten randomized controlled trials (RCTs), eight prospective open-label trials, one retrospective chart review, and three case reports. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for data extraction. The primary outcome was prolonged effect, defined as statistically significant antidepressant effects following acute ketamine treatment. RESULTS: A total of 454 articles were identified, and 22 articles were included. Different treatment modalites including pharmacological interventions, manualized-based psychotherapies, electroconvulsive therapy, transcranial magnetic stimulation, and intravenous monotherapy were examined to determine their impact on the prolongation of antidepressant effects following acute ketamine treatment. No treatment modality, other than repeat-dose IV ketamine, has demonstrated ability to significantly prolong the acute efficacy of IV ketamine in TRD. CONCLUSION: Hitherto, available open-label data and controlled trial data support repeat administration of IV ketamine as an effective strategy to prolong the efficacy of ketamine's antidepressant effects (although not the focus of the study herein, maintenance repeat-dose esketamine treatment is proven effective in esketamine responders). There is a need to identify multimodality strategies that are safe and capable of prolonging the efficacy of ketamine in adults with TRD.\", 'doi': '10.1007/s12325-021-01732-8', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33929660/', 'secondary_title': 'Adv Ther', '_input_hash': 538316612, '_task_hash': -1160332038, 'spans': [{'text': 'Ketamine', 'start': 22, 'end': 30, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 104, 'end': 112, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 248, 'end': 256, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 468, 'end': 476, 'pattern': -1436149968}, {'text': '2020', 'start': 572, 'end': 576, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 648, 'end': 656, 'pattern': -1436149968}, {'text': '454', 'start': 694, 'end': 697, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 837, 'end': 845, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1256, 'end': 1264, 'pattern': -1436149968}, {'text': '454', 'start': 1296, 'end': 1299, 'pattern': 2095658839}, {'text': '22', 'start': 1330, 'end': 1332, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1654, 'end': 1662, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1723, 'end': 1731, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1808, 'end': 1816, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1935, 'end': 1943, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1996, 'end': 2004, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2276, 'end': 2284, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 9, 14, 9, 9, 14, 14, 9, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 2112, 'keywords': \"['Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Administration Schedule', 'Excitatory Amino Acid Antagonists/administration & dosage/*therapeutic use', 'Humans', 'Ketamine/administration & dosage/*therapeutic use', 'Outpatients', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Depressive disorders', 'antidepressants', 'ketamine', 'randomized controlled trial', 'treatment resistant depression']\", 'text': 'Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.^\\nBACKGROUND: Ketamine has been demonstrated to improve depressive symptoms.AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients with treatment-resistant depression (TRD). METHOD: In a randomised, double-blind, placebo-controlled, proof-of-concept trial, 41 participants received either 1 mg/kg oral ketamine or placebo thrice weekly for 21 days (ClinicalTrials.gov Identifier: NCT02037503). Evaluation was performed at baseline, 40 and 240 min post administration and on days 3, 7, 14 and 21. The main outcome measure was change in Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS: Twenty-two participants were randomised to the ketamine group, and 19 to the control, with 82.5% (n = 33) completing the study. In the ketamine group, a decrease in depressive symptoms was evident at all time points, whereas in the control group a decrease was evident only 40 min post administration. The reduction in MADRS score on day 21 was 12.75 in the ketamine group versus 2.49 points with placebo (P &lt; 0.001). Six participants in the ketamine group (27.3%) achieved remission compared with none of the controls (P &lt; 0.05). The number needed to treat for remission was 3.7. Side-effects were mild and transient. CONCLUSIONS: Repeated oral ketamine produced rapid and persistent amelioration of depressive symptoms in out-patients with TRD, and was well tolerated. These results suggest that add-on oral ketamine may hold significant promise in the care of patients suffering from TRD in the community.Declaration of interestNone.', 'doi': '10.1192/bjp.2018.196', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/30246667/', 'secondary_title': 'Br J Psychiatry', '_input_hash': 1012137387, '_task_hash': 2075444602, 'spans': [{'text': 'ketamine', 'start': 14, 'end': 22, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 157, 'end': 165, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 287, 'end': 295, 'pattern': -1436149968}, {'text': '41', 'start': 439, 'end': 441, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 484, 'end': 492, 'pattern': -1436149968}, {'text': '21', 'start': 522, 'end': 524, 'pattern': 2095658839}, {'text': 'NCT02037503', 'start': 562, 'end': 573, 'pattern': 2095658839}, {'text': '40', 'start': 614, 'end': 616, 'pattern': 2095658839}, {'text': '240', 'start': 621, 'end': 624, 'pattern': 2095658839}, {'text': '14', 'start': 667, 'end': 669, 'pattern': 2095658839}, {'text': '21', 'start': 674, 'end': 676, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 824, 'end': 832, 'pattern': -1436149968}, {'text': '19', 'start': 844, 'end': 846, 'pattern': 2095658839}, {'text': '82.5', 'start': 868, 'end': 872, 'pattern': 2095658839}, {'text': '33', 'start': 879, 'end': 881, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 912, 'end': 920, 'pattern': -1436149968}, {'text': '40', 'start': 1051, 'end': 1053, 'pattern': 2095658839}, {'text': '21', 'start': 1115, 'end': 1117, 'pattern': 2095658839}, {'text': '12.75', 'start': 1122, 'end': 1127, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1135, 'end': 1143, 'pattern': -1436149968}, {'text': '2.49', 'start': 1157, 'end': 1161, 'pattern': 2095658839}, {'text': '0.001', 'start': 1190, 'end': 1195, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1222, 'end': 1230, 'pattern': -1436149968}, {'text': '27.3', 'start': 1238, 'end': 1242, 'pattern': 2095658839}, {'text': '0.05', 'start': 1307, 'end': 1311, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1429, 'end': 1437, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1593, 'end': 1601, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 9, 14, 14, 14, 14, 14, 14, 9, 14, 14, 14, 9, 14, 14, 14, 9, 14, 14, 9, 14, 14, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 2820, 'keywords': \"['Administration, Intranasal', 'Administration, Intravenous', 'Adult', 'Analgesics/*administration & dosage', 'Antidepressive Agents/administration & dosage', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Ketamine/*administration & dosage/analogs & derivatives', 'Male', 'Midazolam/administration & dosage', 'Middle Aged', 'Pilot Projects', 'Treatment Outcome', 'Ketamine', 'adverse effects', 'efficacy', 'intranasal spray', 'randomised controlled trial', 'treatment-resistant depression']\", 'text': 'Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.^\\nBACKGROUND: Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. METHODS: This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due to poor tolerability after five treatment-resistant depressed participants were included. Feasibility, safety (acute and cumulative), cognitive and efficacy outcomes were assessed. Plasma ketamine and norketamine concentrations were assayed after the first treatment. RESULTS: Significant acute cardiovascular, psychotomimetic and neurological side effects occurred at doses < 100 mg ketamine. No participants were able to self-administer all 10 ketamine sprays due to incoordination; treatment time occasionally had to be extended (>45 min) due to acute side effects. No hepatic, cognitive or urinary changes were observed after the treatment course in either group. There was an approximately two-fold variation in ketamine and norketamine plasma concentrations between ketamine participants. At course end, one participant had remitted in each of the ketamine and midazolam groups. CONCLUSIONS: IN ketamine, with the drug formulation and delivery device used, was not a useful treatment approach in this study. Absorption was variable between individuals and acute tolerability was poor, requiring prolonged treatment administration time in some individuals. The drug formulation, the delivery device, the insufflation technique and individual patient factors play an important role in tolerability and efficacy when using IN ketamine for TRD.', 'doi': '10.1177/0269881118760660', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/29542371/', 'secondary_title': 'J Psychopharmacol', '_input_hash': 645249071, '_task_hash': -566824516, 'spans': [{'text': 'ketamine', 'start': 20, 'end': 28, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 144, 'end': 152, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 291, 'end': 299, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 434, 'end': 442, 'pattern': -1436149968}, {'text': '100', 'start': 574, 'end': 577, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 581, 'end': 589, 'pattern': -1436149968}, {'text': '10', 'start': 639, 'end': 641, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 913, 'end': 921, 'pattern': -1436149968}, {'text': '100', 'start': 1102, 'end': 1105, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1109, 'end': 1117, 'pattern': -1436149968}, {'text': '10', 'start': 1168, 'end': 1170, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1171, 'end': 1179, 'pattern': -1436149968}, {'text': '45', 'start': 1259, 'end': 1261, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1442, 'end': 1450, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1497, 'end': 1505, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1579, 'end': 1587, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1626, 'end': 1634, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2054, 'end': 2062, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 9, 14, 9, 14, 9, 14, 9, 14, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 8913, 'keywords': \"['Adult', 'Antipsychotic Agents/*pharmacokinetics', 'Basal Ganglia/drug effects/*metabolism', 'Dopamine/*metabolism', 'Dopamine Antagonists/*pharmacokinetics', 'Hallucinogens/*pharmacology', 'Humans', 'Male', 'Psilocybin/*pharmacology', 'Psychometrics', 'Psychoses, Substance-Induced/*metabolism/psychology', 'Raclopride', 'Salicylamides/*pharmacokinetics', 'Serotonin/*physiology', 'Tomography, Emission-Computed']\", 'text': '5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.^\\nThe modulating effects of serotonin on dopamine neurotransmission are not well understood, particularly in acute psychotic states. Positron emission tomography was used to examine the effect of psilocybin on the in vivo binding of [11C]raclopride to D2-dopamine receptors in the striatum in healthy volunteers after placebo and a psychotomimetic dose of psilocybin (n = 7). Psilocybin is a potent indoleamine hallucinogen and a mixed 5-HT2A and 5-HT1A receptor agonist. Psilocybin administration (0.25 mg/kg p.o.) produced changes in mood, disturbances in thinking, illusions, elementary and complex visual hallucinations and impaired ego-functioning. Psilocybin significantly decreased [11C]raclopride receptor binding potential (BP) bilaterally in the caudate nucleus (19%) and putamen (20%) consistent with an increase in endogenous dopamine. Changes in [11C]raclopride BP in the ventral striatum correlated with depersonalization associated with euphoria. Together with previous reports of 5-HT receptor involvement in striatal dopamine release, it is concluded that stimulation of both 5-HT2A and 5-HT1A receptors may be important for the modulation of striatal dopamine release in acute psychoses. The present results indirectly support the hypothesis of a serotonin-dopamine dysbalance in schizophrenia and suggest that psilocybin is a valuable tool in the analysis of serotonin-dopamine interactions in acute psychotic states.', 'doi': '10.1016/s0893-133x(98)00108-0', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/10192823/', 'secondary_title': 'Neuropsychopharmacology', '_input_hash': 326437839, '_task_hash': 1010301418, 'spans': [{'text': 'psilocybin', 'start': 56, 'end': 66, 'pattern': 1563408733}, {'text': '11C]raclopride.^', 'start': 111, 'end': 127, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 322, 'end': 332, 'pattern': 1563408733}, {'text': '11C]raclopride', 'start': 360, 'end': 374, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 482, 'end': 492, 'pattern': 1563408733}, {'text': 'Psilocybin', 'start': 502, 'end': 512, 'pattern': 1563408733}, {'text': 'Psilocybin', 'start': 598, 'end': 608, 'pattern': 1563408733}, {'text': '0.25', 'start': 625, 'end': 629, 'pattern': 2095658839}, {'text': 'Psilocybin', 'start': 780, 'end': 790, 'pattern': 1563408733}, {'text': '11C]raclopride', 'start': 816, 'end': 830, 'pattern': 2095658839}, {'text': '19', 'start': 899, 'end': 901, 'pattern': 2095658839}, {'text': '20', 'start': 917, 'end': 919, 'pattern': 2095658839}, {'text': '11C]raclopride', 'start': 986, 'end': 1000, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1455, 'end': 1465, 'pattern': 1563408733}], 'meta': {'pattern': '1, 14, 1, 14, 1, 1, 1, 14, 1, 14, 14, 14, 14, 1'}}\n",
      "0.5\n",
      "{'record_id': 9007, 'keywords': \"['Anesthetics, Combined', '*Anesthetics, Dissociative/adverse effects', '*Anesthetics, Intravenous/adverse effects', 'Depressive Disorder, Major/psychology/*therapy', 'Electroconvulsive Therapy/adverse effects/*methods', 'Electroencephalography/drug effects', 'Female', 'Humans', '*Ketamine/adverse effects', 'Male', 'Middle Aged', '*Propofol/adverse effects', 'Psychiatric Status Rating Scales', 'Treatment Outcome']\", 'text': 'Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder.^\\nBACKGROUND: Electroconvulsive therapy (ECT) is a preferred therapy for major depressive disorder. Intravenous propofol, a sedative and hypnotic agent, is one of the choices of anesthetic for ECT. Ketamine, another anesthetic agent, providing sedation, amnesia, and analgesia, can also be used in patients undergoing ECT owing to its rapid action and persistent antidepressive effect. One adverse effect of ketamine is cardiovascular excitement, which may be reduced by propofol. Currently, the effects of combined anesthesia (propofol and ketamine) for patients with depressive disorder who have undergone ECT are unclear. The purpose of this study was to investigate the effects of the combined agents for patients undergoing ECT. METHODS: Forty-eight patients with Hamilton Depression Rating Scale (HDRS) scores greater than 20 were randomly divided into 3 groups (n=16 each): propofol group (group P), ketamine group (group K), and propofol plus ketamine group (group PK). Propofol (1.5 mg/kg), ketamine (0.8 mg/kg), and propofol (1.5 mg/kg) plus ketamine (0.8 mg/kg) were infused to each group of patients, respectively, before ECT by an anesthesiologist with no knowledge of the HDRS score. For the purpose of this study, the patients received a single ECT treatment and were assessed for depression using the HDRS scores (1 day before ECT and days 1, 2, 3, and 7 after the ECT treatment) by a psychiatrist with no knowledge of the randomization group. After the final assessment, the patients received further treatment as needed up to 3 treatments per week. Seizure energy index, seizure duration, and adverse effects were observed during anesthesia by a nurse with no knowledge of the study group. RESULTS: The HDRS scores improved earlier in group K and group PK. Decreases in HDRS scores were significantly greater in group K and group PK compared with those in group P. The adverse effects in group PK were fewer than those in group K. Seizure energy index and seizure duration in group K and group PK were higher and longer than those in group P during ECT. CONCLUSION: The results suggested that propofol combined with ketamine anesthesia might be the first-choice anesthesia in patients with depressive disorder undergoing ECT.', 'doi': '10.1097/YCT.0b013e31824d1d02', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/22622291/', 'secondary_title': 'J ect', '_input_hash': -222085271, '_task_hash': -805975067, 'spans': [{'text': 'ketamine', 'start': 24, 'end': 32, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 321, 'end': 329, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 531, 'end': 539, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 664, 'end': 672, 'pattern': -1436149968}, {'text': '20', 'start': 952, 'end': 954, 'pattern': 2095658839}, {'text': 'n=16', 'start': 992, 'end': 996, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1030, 'end': 1038, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1074, 'end': 1082, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1123, 'end': 1131, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1175, 'end': 1183, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2257, 'end': 2265, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 14, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 170, 'keywords': \"['midomafetamine', 'alcohol', 'amphetamine', 'analgesic agent', 'cannabis', 'cocaine', 'diamorphine', 'opiate', 'psychedelic agent', 'sedative agent', 'adult', 'alpha rhythm', 'article', 'attention disturbance', 'beta rhythm', 'controlled study', 'drug misuse', 'electroencephalogram', 'female', 'human', 'major clinical study', 'male', 'memory disorder', 'methodology', 'multiple drug abuse', 'neurotoxicity', 'pathophysiology', 'quantitative analysis', 'serotoninergic system', 'statistical analysis', 'theta rhythm']\", 'text': 'Evidence of neurotoxicity of ecstasy: Sustained effects on electroencephalographic activity in polydrug users.^\\nObjective: According to previous EEG reports of indicative disturbances in Alpha and Beta activities, a systematic search for distinct EEG abnormalities in a broader population of Ecstasy users may especially corroborate the presumed specific neurotoxicity of Ecstasy in humans. Methods: 105 poly-drug consumers with former Ecstasy use and 41 persons with comparable drug history without Ecstasy use, and 11 drug naives were investigated for EEG features. Conventional EEG derivations of 19 electrodes according to the 10-20-system were conducted. Besides standard EEG bands, quantitative EEG analyses of 1-Hz-subdivided power ranges of Alpha, Theta and Beta bands have been considered. Results: Ecstasy users with medium and high cumulative Ecstasy doses revealed an increase in Theta and lower Alpha activities, significant increases in Beta activities, and a reduction of background activity. Ecstasy users with low cumulative Ecstasy doses showed a significant Alpha activity at 11 Hz. Interestingly, the spectral power of low frequencies in medium and high Ecstasy users was already significantly increased in the early phase of EEG recording. Statistical analyses suggested the main effect of Ecstasy to EEG results. Conclusions: Our data from a major sample of Ecstasy users support previous data revealing alterations of EEG frequency spectrum due rather to neurotoxic effects of Ecstasy on serotonergic systems in more detail. Accordingly, our data may be in line with the observation of attentional and memory impairments in Ecstasy users with moderate to high misuse. Despite the methodological problem of polydrug use also in our approach, our EEG results may be indicative of the neuropathophysiological background of the reported memory and attentional deficits in Ecstasy abusers. Overall, our findings may suggest the usefulness of EEG in diagnostic approaches in assessing neurotoxic sequela of this common drug abuse. © 2010 Adamaszek et al.', 'doi': '10.1371/journal.pone.0014097', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/21124854/', 'secondary_title': 'PLoS ONE', '_input_hash': 1877350900, '_task_hash': 669689746, 'spans': [{'text': 'ecstasy', 'start': 29, 'end': 36, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 292, 'end': 299, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 372, 'end': 379, 'pattern': 611274830}, {'text': '105', 'start': 400, 'end': 403, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 436, 'end': 443, 'pattern': 611274830}, {'text': '41', 'start': 452, 'end': 454, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 500, 'end': 507, 'pattern': 611274830}, {'text': '11', 'start': 517, 'end': 519, 'pattern': 2095658839}, {'text': '19', 'start': 600, 'end': 602, 'pattern': 2095658839}, {'text': '10', 'start': 631, 'end': 633, 'pattern': 2095658839}, {'text': '20', 'start': 634, 'end': 636, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 808, 'end': 815, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 854, 'end': 861, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1008, 'end': 1015, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1042, 'end': 1049, 'pattern': 611274830}, {'text': '11', 'start': 1095, 'end': 1097, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 1174, 'end': 1181, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1311, 'end': 1318, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1380, 'end': 1387, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1500, 'end': 1507, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1647, 'end': 1654, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1891, 'end': 1898, 'pattern': 611274830}, {'text': '2010', 'start': 2050, 'end': 2054, 'pattern': 2095658839}], 'meta': {'pattern': '8, 8, 8, 14, 8, 14, 8, 14, 14, 14, 14, 8, 8, 8, 8, 14, 8, 8, 8, 8, 8, 8, 14'}}\n",
      "0.5\n",
      "{'record_id': 7474, 'keywords': \"['Adult', 'Cross-Over Studies', 'Double-Blind Method', 'Evoked Potentials, Auditory', 'Excitatory Amino Acid Antagonists/pharmacology', 'Humans', 'Ketamine/*pharmacology', 'Male', 'Piperidines/*pharmacology', 'Prospective Studies', 'Pyrazoles/*pharmacology', 'Receptor, Cannabinoid, CB1/*antagonists & inhibitors', 'Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors', 'Rimonabant', 'Schizophrenia/chemically induced/*physiopathology', 'Young Adult']\", 'text': 'Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.^\\nRATIONALE: Preclinical and clinical research suggests that the endogenous cannabinoid system is involved in cognitive impairments related to schizophrenia. In particular, the deficient generation of mismatch negativity (MMN) indicating auditory sensory memory is a characteristic finding in schizophrenic patients. Experimental studies implicate deficient N-methyl-D: -aspartate (NMDA) receptor functioning in such abnormalities. OBJECTIVES: The primary aim of this study was to investigate the effects of the cannabinoid CB(1) receptor antagonist rimonabant on MMN deficits in the NMDA receptor antagonist model of schizophrenia by using ketamine. METHODS: Twenty-four healthy male subjects participated in a randomized, double-blind, placebo-controlled cross-over study with subanesthetic doses of intravenous ketamine. The MMNs to frequency and duration deviants were elicited within an auditory oddball paradigm and recorded by a 32-channel EEG. Psychopathology was assessed using the Psychotomimetic States Inventory. RESULTS: Twenty subjects completed both experimental sessions. Ketamine infusion had no significant effect on MMN amplitudes in both deviance conditions. In contrast to placebo, co-administration of rimonabant produced significant deficits in MMN amplitudes to duration deviants at electrode position Fz. CONCLUSIONS: The results point to the involvement of the endogenous cannabinoid system in auditory sensory memory as a cognitive key feature in schizophrenia. They particularly suggest that CB(1) receptor antagonism may impair cognitive performance by a disturbed interaction between endocannabinergic activity and glutamatergic neurotransmission implied in schizophrenia.', 'doi': '10.1007/s00213-011-2352-y', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/21590281/', 'secondary_title': 'Psychopharmacology (Berl)', '_input_hash': 930444896, '_task_hash': 1279174190, 'spans': [{'text': 'ketamine', 'start': 127, 'end': 135, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 800, 'end': 808, 'pattern': -1436149968}, {'text': 'male', 'start': 839, 'end': 843, 'pattern': -757571895}, {'text': 'ketamine', 'start': 973, 'end': 981, 'pattern': -1436149968}, {'text': '32', 'start': 1095, 'end': 1097, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 1247, 'end': 1255, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 12, 9, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 1148, 'keywords': \"['Adolescent', 'Adult', 'Analysis of Variance', 'Chi-Square Distribution', 'Female', 'Humans', '*Illicit Drugs', 'Impulsive Behavior/*epidemiology', 'Male', '*N-Methyl-3,4-methylenedioxyamphetamine', '*Risk-Taking', 'Statistics, Nonparametric', 'Substance-Related Disorders/*epidemiology', 'Surveys and Questionnaires/standards']\", 'text': \"Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use.^\\nThe present study investigated characteristics of recreational drug users, especially 'ecstasy' (MDMA) users, in 254 undergraduates. All participants completed a drug history questionnaire (DHQ), the impulsiveness venturesomeness and empathy questionnaire, a novel risk-taking task (Bets16), and 59 also completed the tri-dimensional personality questionnaire (TPQ). DHQ responses allocated participants to five groups: non-drug controls, cannabis users, polydrug (no ecstasy) users, low (<20 occasions) ecstasy users and high (>20 occasions) ecstasy users. Eighteen percent of the sample had used ecstasy and of the ecstasy users, only one had not used other substances. A larger proportion of high ecstasy users had also used amphetamines, cocaine and LSD in comparison to the low ecstasy and non-ecstasy polydrug users. High ecstasy users typically took significantly more ecstasy tablets compared with low ecstasy users. Impulsiveness, venturesomeness and novelty seeking behaviour increased from the non-drug users to high ecstasy users. Ecstasy users (low and high) and polydrug (non-ecstasy) users had higher levels of impulsivity, venturesomeness and novelty seeking behaviour compared with non-drug users. Furthermore, high ecstasy users scored higher on the Bets16 risk-taking measure than non-drug users, cannabis users and low ecstasy users. The findings are discussed in relation to: (i) the possibility that increased impulsivity pre-dated drug use; and (ii) the possible link between impulsivity and the putative serotonergic neurotoxicity of ecstasy.\", 'doi': '10.1016/j.drugalcdep.2004.04.003', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/15380289/', 'secondary_title': 'Drug Alcohol Depend', '_input_hash': 997014547, '_task_hash': 468859622, 'spans': [{'text': 'ecstasy', 'start': 43, 'end': 50, 'pattern': 611274830}, {'text': 'MDMA', 'start': 53, 'end': 57, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 152, 'end': 159, 'pattern': 611274830}, {'text': 'MDMA', 'start': 162, 'end': 166, 'pattern': -495411397}, {'text': '254', 'start': 178, 'end': 181, 'pattern': 2095658839}, {'text': 'Bets16', 'start': 348, 'end': 354, 'pattern': 2095658839}, {'text': '59', 'start': 361, 'end': 363, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 533, 'end': 540, 'pattern': 611274830}, {'text': '20', 'start': 555, 'end': 557, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 569, 'end': 576, 'pattern': 611274830}, {'text': '20', 'start': 594, 'end': 596, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 608, 'end': 615, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 663, 'end': 670, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 682, 'end': 689, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 765, 'end': 772, 'pattern': 611274830}, {'text': 'LSD', 'start': 819, 'end': 822, 'pattern': -496918669}, {'text': 'ecstasy', 'start': 848, 'end': 855, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 864, 'end': 871, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 893, 'end': 900, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 941, 'end': 948, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 975, 'end': 982, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1093, 'end': 1100, 'pattern': 611274830}, {'text': 'Ecstasy', 'start': 1108, 'end': 1115, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1155, 'end': 1162, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1298, 'end': 1305, 'pattern': 611274830}, {'text': 'Bets16', 'start': 1333, 'end': 1339, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1404, 'end': 1411, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1623, 'end': 1630, 'pattern': 611274830}], 'meta': {'pattern': '8, 7, 8, 7, 14, 14, 14, 8, 14, 8, 14, 8, 8, 8, 8, 0, 8, 8, 8, 8, 8, 8, 8, 8, 8, 14, 8, 8'}}\n",
      "0.5\n",
      "{'record_id': 5177, 'keywords': \"['Adult', 'Depression/*chemically induced/psychology', 'Female', 'Humans', 'Internal-External Control', 'Life Change Events', 'Male', 'Motivation', 'N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects', 'Personality Inventory', 'Substance Withdrawal Syndrome/*diagnosis/psychology', 'Substance-Related Disorders/psychology/*rehabilitation']\", 'text': \"Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms.^\\nPrevious work has indicated recreational use of methylenedioxymethamphetamine (MDMA or ecstasy) is associated with elevated scores on self-report measures of depression. We sought to examine the long-term effects of consumption on depression in a group of individuals who had consumed large quantities of the drug in the past, but were now leading relatively drug free lives. Respondents to this study (n = 29) had consumed an average of 1.5 ecstasy tablets in the last month, 8.4 in the last 6 months and 23.3 in the last 12 months. The estimated total consumed was 527 tablets, indicating that these respondents were indeed former chronic users of the drug. None of the respondents had consumed ecstasy in the last 14 days. Levels of depression (Beck's Depression Inventory) were significantly (p < 0.01) elevated compared to a matched non-drug using control group. Within the group of former chronic users, these levels of depression were not significantly affected by current use of alcohol, cannabis or amphetamine, but were positively correlated with an external locus of control (p < 0.05), infrequent but severe- (p < 0.05) and frequent but mild- (p < 0.005) self-report measures of life stress. Multiple regression indicated that levels of frequent but mild life stress (p < 0.005) and the quantity of ecstasy tablets respondents consumed over a 12-h period (p < 0.05) were the only variables that were significant predictors of self-reported levels of depression. The results of this study indicate that former chronic ecstasy users report higher levels of depression than their matched controls.\", 'doi': '10.1177/026988110101500310', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/11565625/', 'secondary_title': 'J Psychopharmacol', '_input_hash': -844339938, '_task_hash': 917834677, 'spans': [{'text': 'MDMA', 'start': 46, 'end': 50, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 54, 'end': 61, 'pattern': 611274830}, {'text': 'MDMA', 'start': 182, 'end': 186, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 190, 'end': 197, 'pattern': 611274830}, {'text': '29', 'start': 510, 'end': 512, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 545, 'end': 552, 'pattern': 611274830}, {'text': '23.3', 'start': 609, 'end': 613, 'pattern': 2095658839}, {'text': '12', 'start': 626, 'end': 628, 'pattern': 2095658839}, {'text': '527', 'start': 670, 'end': 673, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 800, 'end': 807, 'pattern': 611274830}, {'text': '14', 'start': 820, 'end': 822, 'pattern': 2095658839}, {'text': '0.01', 'start': 904, 'end': 908, 'pattern': 2095658839}, {'text': '0.05', 'start': 1194, 'end': 1198, 'pattern': 2095658839}, {'text': '0.05', 'start': 1229, 'end': 1233, 'pattern': 2095658839}, {'text': '0.005', 'start': 1263, 'end': 1268, 'pattern': 2095658839}, {'text': '0.005', 'start': 1387, 'end': 1392, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1414, 'end': 1421, 'pattern': 611274830}, {'text': '12', 'start': 1458, 'end': 1460, 'pattern': 2095658839}, {'text': '0.05', 'start': 1475, 'end': 1479, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1632, 'end': 1639, 'pattern': 611274830}], 'meta': {'pattern': '7, 8, 7, 8, 14, 8, 14, 14, 14, 8, 14, 14, 14, 14, 14, 14, 8, 14, 14, 8'}}\n",
      "0.5\n",
      "{'record_id': 8030, 'keywords': \"['ayahuasca', 'haloperidol', 'Hypericum perforatum extract', 'lithium', 'lysergide', 'mescaline', 'monoamine oxidase inhibitor', 'mood stabilizer', 'n,n dimethyltryptamine', 'phenethylamine derivative', 'psilocybine', 'psychedelic agent', 'serotonin noradrenalin reuptake inhibitor', 'serotonin uptake inhibitor', 'tricyclic antidepressant agent', 'tryptamine derivative', 'unclassified drug', 'adult', 'article', 'challenging difficult or distressing experience', 'controlled study', 'disease association', 'disease duration', 'female', 'functional disease', 'human', 'major clinical study', 'male', 'mental disease', 'middle aged', 'patient harm', 'prevalence', 'risk']\", 'text': 'Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.^\\nPrevious studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day as a result of such experiences. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing classic psychedelic experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.', 'doi': '10.1016/j.jad.2023.01.073', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36720405/', 'secondary_title': 'Journal of Affective Disorders', '_input_hash': 277077556, '_task_hash': 1684844613, 'spans': [{'text': '2822', 'start': 365, 'end': 369, 'pattern': 2095658839}, {'text': '613', 'start': 587, 'end': 590, 'pattern': 2095658839}, {'text': '613', 'start': 600, 'end': 603, 'pattern': 2095658839}, {'text': '59.1', 'start': 685, 'end': 689, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 9055, 'keywords': \"['psilocybin', 'psychedelic therapy', 'depression', 'treatment-resistant depression', 'Client Attitudes', 'Drug Therapy', 'Psychedelic Drugs', 'Psychotherapeutic Outcomes', 'Treatment Resistant Depression', 'Test Construction']\", 'text': \"Patients’ accounts of increased 'connectedness' and 'acceptance' after psilocybin for treatment-resistant depression.^\\nObjective: To identify patients’ perceptions of the value of psilocybin as a treatment for depression. Method: Twenty patients enrolled in an open-label trial of psilocybin for treatment-resistant depression participated in a semistructured interview at 6-month follow-up. Thematic analysis was used to identify patients’ experiences of the treatment and how it compared with previous treatments. Results: Two main change processes were identified in relation to the treatment. The first concerned change from disconnection (from self, others, and world) to connection, and the second concerned change from avoidance (of emotion) to acceptance. A third theme concerned comparison between psilocybin and conventional treatments. Patients reported that medications and some short-term talking therapies tended to reinforce their sense of disconnection and avoidance, whereas treatment with psilocybin encouraged connection and acceptance. Conclusions: These results suggest that psilocybin treatment for depression may work via paradigmatically novel means, antithetical to antidepressant medications, and some short-term talking therapies. (PsycInfo Database Record (c) 2022 APA, all rights reserved)\", 'doi': '10.1177/0022167817709585', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/38545534/', 'secondary_title': 'Journal of Humanistic Psychology', '_input_hash': 26929849, '_task_hash': -1506840084, 'spans': [{'text': 'psilocybin', 'start': 71, 'end': 81, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 180, 'end': 190, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 281, 'end': 291, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 807, 'end': 817, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 1007, 'end': 1017, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 1096, 'end': 1106, 'pattern': 1563408733}, {'text': '2022', 'start': 1288, 'end': 1292, 'pattern': 2095658839}], 'meta': {'pattern': '1, 1, 1, 1, 1, 1, 14'}}\n",
      "0.5\n",
      "{'record_id': 1513, 'keywords': \"['ketamine', 'article', 'chronic drug administration', 'controlled study', 'drug effect', 'drug reexposure', 'drug sensitization', 'human', 'human characteristic', 'normal human', 'Positive and Negative Syndrome Scale', 'priority journal', 'psychologic assessment', 'psychopharmacology', 'rating scale', 'visual analog scale']\", 'text': 'Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine.^\\nRationale: Sensitization to the effects of N-methyl-d-aspartate (NMDA) glutamate receptor antagonists is robust in animals. However, the applicability of this model to humans is unclear because it currently rests on highly confounded retrospective studies of individuals who experienced protracted psychoses following repeated binges with NMDA receptor antagonists. Objectives: The purpose of the current study was to determine whether there was evidence of sensitization to the behavioral effects of ketamine in healthy human subjects with repeated exposure to this drug. Methods: Data were studied from 295 healthy human subjects who participated in one or more of 11 separate studies that involved ketamine administration over 14 years. Positive and negative symptoms (Brief Psychiatric Rating Scale: BPRS), perceptual alterations (Clinician-Administered Dissociative States Scale: CADSS), and \"high\" and \"anxiety\" states (Visual Analog Scale: VAS) that were measured in all studies were included as outcome measures. Results: After including the number of previous exposures, number of previous studies, and time since first exposure as variables, repeated exposure to ketamine did not result in increased behavioral responses, suggestive of behavioral sensitization. Conclusions: The current data do not provide evidence that repeated exposure to ketamine, albeit limited, is associated with sensitization to the behavioral effects of ketamine. © Springer-Verlag 2005.', 'doi': '10.1007/s00213-004-2066-5', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/15682309/', 'secondary_title': 'Psychopharmacology', '_input_hash': 1293574738, '_task_hash': 437914394, 'spans': [{'text': 'ketamine', 'start': 605, 'end': 613, 'pattern': -1436149968}, {'text': '295', 'start': 709, 'end': 712, 'pattern': 2095658839}, {'text': '11', 'start': 771, 'end': 773, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 805, 'end': 813, 'pattern': -1436149968}, {'text': '14', 'start': 834, 'end': 836, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1277, 'end': 1285, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1456, 'end': 1464, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1544, 'end': 1552, 'pattern': -1436149968}, {'text': '2005', 'start': 1572, 'end': 1576, 'pattern': 2095658839}], 'meta': {'pattern': '9, 14, 14, 9, 14, 9, 9, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 4658, 'keywords': \"['Mdma', 'MDMA-assisted therapy', 'clinical trial', 'depression', 'major depressive disorder', 'study protocol']\", 'text': 'Study protocol for \"MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study\".^\\nBACKGROUND: Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the proof of principle and safety of MDMA-AT in participants with MDD and provides an initial impression of treatment effectiveness. METHODS: A total of 12 participants [>18 years] with DSM-5 diagnosis of MDD will receive a flexible dose of MDMA in a therapeutic setting on two dosing days over a 4 week period preceded by three preparatory sessions. Each MDMA dosing session will be followed by three integration sessions. The primary outcome is change in MDD symptom severity, as measured by the mean change in MADRS scores from Baseline to 8 weeks after the second MDMA session. The secondary outcome is change in functional impairment, as evaluated by the mean change in Sheehan Disability Scale scores from Baseline to 8 weeks after the second MDMA session. Safety measures include vital signs, the incidence of Adverse Events and suicidality as measured by the Colombia-Suicide Severity Rating Scale. DISCUSSION: This proof of principle trial will inform the development of fully powered clinical trials, optimize the protocol for the administration of MDMA-AT in participants with MDD and explore uncertainties including barriers to recruitment, retention and acceptability of MDMA-AT as a treatment for MDD. CLINICAL TRIAL IDENTIFICATION: EudraCT number 2021-000805-26.', 'doi': '10.3389/fpsyt.2022.954388', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36386973/', 'secondary_title': 'Front Psychiatry', '_input_hash': -1092062290, '_task_hash': -490892070, 'spans': [{'text': 'MDMA', 'start': 20, 'end': 24, 'pattern': -495411397}, {'text': 'MDMA', 'start': 420, 'end': 424, 'pattern': -495411397}, {'text': 'MDMA', 'start': 443, 'end': 447, 'pattern': -495411397}, {'text': 'MDMA', 'start': 546, 'end': 550, 'pattern': -495411397}, {'text': '12', 'start': 662, 'end': 664, 'pattern': 2095658839}, {'text': '18', 'start': 680, 'end': 682, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 750, 'end': 754, 'pattern': -495411397}, {'text': 'MDMA', 'start': 865, 'end': 869, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1077, 'end': 1081, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1258, 'end': 1262, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1568, 'end': 1572, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1693, 'end': 1697, 'pattern': -495411397}, {'text': '2021', 'start': 1771, 'end': 1775, 'pattern': 2095658839}, {'text': '000805', 'start': 1776, 'end': 1782, 'pattern': 2095658839}, {'text': '26', 'start': 1783, 'end': 1785, 'pattern': 2095658839}], 'meta': {'pattern': '7, 7, 7, 7, 14, 14, 7, 7, 7, 7, 7, 7, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 8552, 'keywords': \"['Humans', '*N,N-Dimethyltryptamine/pharmacology', '*Hallucinogens/pharmacology', 'Magnetic Resonance Imaging', 'Brain', 'Electroencephalography', 'ayahuasca', 'consciousness', 'dimethyltryptamine', 'psychedelics', 'serotonin']\", 'text': \"Human brain effects of DMT assessed via EEG-fMRI.^\\nPsychedelics have attracted medical interest, but their effects on human brain function are incompletely understood. In a comprehensive, within-subjects, placebo-controlled design, we acquired multimodal neuroimaging [i.e., EEG-fMRI\\xa0(electroencephalography-functional MRI)] data to assess the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT) on brain function in 20 healthy volunteers. Simultaneous EEG-fMRI was acquired prior to, during, and after a bolus IV administration of 20 mg DMT, and, separately, placebo. At dosages consistent with the present study, DMT, a serotonin 2A receptor (5-HT2AR) agonist, induces a deeply immersive and radically altered state of consciousness. DMT is thus a useful research tool for probing the neural correlates of conscious experience. Here, fMRI results revealed robust increases in global functional connectivity (GFC), network disintegration and desegregation, and a compression of the principal cortical gradient under DMT. GFC × subjective intensity maps correlated with independent positron emission tomography (PET)-derived 5-HT2AR maps, and both overlapped with meta-analytical data implying human-specific psychological functions. Changes in major EEG-measured neurophysiological properties correlated with specific changes in various fMRI metrics, enriching our understanding of the neural basis of DMT's effects. The present findings advance on previous work by confirming a predominant action of DMT-and likely other 5-HT2AR agonist psychedelics-on the brain's transmodal association pole, i.e., the neurodevelopmentally and evolutionarily recent cortex that is associated with species-specific psychological advancements, and high expression of 5-HT2A receptors.\", 'doi': '10.1073/pnas.2218949120', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36940333/', 'secondary_title': 'Proc Natl Acad Sci U S A', '_input_hash': 308249553, '_task_hash': 357666213, 'spans': [{'text': 'DMT', 'start': 23, 'end': 26, 'pattern': -394200700}, {'text': 'DMT', 'start': 396, 'end': 399, 'pattern': -394200700}, {'text': '20', 'start': 422, 'end': 424, 'pattern': 2095658839}, {'text': '20', 'start': 537, 'end': 539, 'pattern': 2095658839}, {'text': 'DMT', 'start': 543, 'end': 546, 'pattern': -394200700}, {'text': 'DMT', 'start': 620, 'end': 623, 'pattern': -394200700}, {'text': 'DMT', 'start': 741, 'end': 744, 'pattern': -394200700}, {'text': 'DMT', 'start': 1022, 'end': 1025, 'pattern': -394200700}, {'text': 'DMT', 'start': 1408, 'end': 1411, 'pattern': -394200700}, {'text': 'DMT', 'start': 1507, 'end': 1510, 'pattern': -394200700}], 'meta': {'pattern': '4, 4, 14, 14, 4, 4, 4, 4, 4, 4'}}\n",
      "0.5\n",
      "{'record_id': 3818, 'keywords': \"['*major depression', '*risk assessment', '*suicidal ideation', 'Adult', 'Argentina', 'Austria', 'Behavior assessment', 'Belgium', 'Brazil', 'Canada', 'Clinical Global Impression scale', 'Clinical assessment', 'Comparative effectiveness', 'Conference abstract', 'Controlled study', 'Czech Republic', 'DSM‐5', 'Dissociation', 'Double blind procedure', 'Drug efficacy', 'Drug safety', 'Drug therapy', 'Employee', 'Female', 'Food and Drug Administration', 'France', 'Health care quality', 'Hospitalization', 'Human', 'Lithuania', 'Major clinical study', 'Male', 'Mini international neuropsychiatric interview', 'Montgomery Asberg Depression Rating Scale', 'Pharmacokinetics', 'Phase 2 clinical trial', 'Phase 3 clinical trial', 'Poland', 'Randomized controlled trial', 'Spain', 'Turkey (republic)']\", 'text': 'P.607 Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: ASPIRE-2 study.^\\nIntroduction: Major depressive disorder (MDD) greatly increases the likelihood of suicide [1]. Available antidepressants often fail to provide rapid relief of depressive symptoms including suicidal ideation (SI) in acutely suicidal patients with MDD and there are currently no approved treatments for this population. In 2016, esketamine (ESK) was granted breakthrough therapy designation by the US Food and Drug Administration for MDD patients at imminent risk for suicide based on data suggesting rapid reduction in depressive symptoms, including SI observed at 4 hours after an initial dose of ESK nasal spray in a phase 2 study [2]. The efficacy and safety of ESK nasal spray is being further evaluated in ASPIRE‐2, one of two phase 3 studies in the first global registration program in an understudied population of MDD patients, assessed to be at imminent risk for suicide. Methods: ASPIRE‐2 (NCT03097133) is an ongoing double‐blind (DB), randomised, placebo‐controlled study being conducted in Argentina, Austria, Belgium, Brazil, Canada, Czech Republic, France, Lithuania, Poland, Spain, Turkey and the United States. Adult patients (18 to 64 years) with MDD (DSM‐5 criteria, confirmed by Mini‐International Neuropsychiatric Interview [MINI]), with active SI and intent and in need of psychiatric hospitalisation were eligible. All patients received optimized standard‐of‐care (SoC hospitalisation and initiation/optimisation of antidepressant treatment). Patients were randomised (1:1) to ESK (84 mg) or placebo nasal spray twice‐weekly for 4 weeks, in addition to SoC. Change from baseline (day 1, predose) to 24 hours after first dose in Montgomery‐Ǻsberg Depression Rating Scale (MADRS) total score (primary endpoint) and Clinical Global Impression – Severity of Suicidality – Revised (CGI‐SS‐R) from the Suicide Ideation and Behaviour Assessment Tool (SIBAT) were assessed for efficacy. Treatment‐emergent adverse events (TEAEs), potential suicidal events from the SIBAT and dissociative effects (Clinician‐Administered Dissociative States Scale [CADSS]) were monitored for safety. Results: In total, 230 patients have been randomised to ESK+SoC or placebo+SoC; 184 (80%) patients completed the DB treatment (Table 1). Conclusions: MDD patients with active suicidal ideation and intent represent a vulnerable group in need of rapid treatment of their symptoms. ASPIRE‐2, along with ASPIRE‐1, comprise a novel program that focuses on addressing depressive symptoms including SI in MDD patients, assessed to be at imminent risk for suicide who are typically excluded from clinical studies of antidepressants. Key efficacy and safety results from ASPIRE‐2 will be presented at the ECNP 2019 along with results from ASPIRE‐1. Disclosure statement: All authors are employees of Janssen Research & Development, LLC and hold company stocks.', 'doi': '10.1016/j.euroneuro.2019.09.591', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/38591002/', 'secondary_title': 'European neuropsychopharmacology', '_input_hash': 2118859310, '_task_hash': 1926530350, 'spans': [{'text': 'P.607', 'start': 0, 'end': 5, 'pattern': 2095658839}, {'text': '2016', 'start': 467, 'end': 471, 'pattern': 2095658839}, {'text': 'NCT03097133', 'start': 1045, 'end': 1056, 'pattern': 2095658839}, {'text': '18', 'start': 1288, 'end': 1290, 'pattern': 2095658839}, {'text': '64', 'start': 1294, 'end': 1296, 'pattern': 2095658839}, {'text': '84', 'start': 1649, 'end': 1651, 'pattern': 2095658839}, {'text': '24', 'start': 1766, 'end': 1768, 'pattern': 2095658839}, {'text': '230', 'start': 2260, 'end': 2263, 'pattern': 2095658839}, {'text': '184', 'start': 2321, 'end': 2324, 'pattern': 2095658839}, {'text': '80', 'start': 2326, 'end': 2328, 'pattern': 2095658839}, {'text': '2019', 'start': 2842, 'end': 2846, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 3340, 'keywords': \"['midomafetamine', 'abdominal pain', 'adolescent', 'adult', 'agitation', 'anxiety', 'article', 'association', 'blood clotting disorder', 'blurred vision', 'brain edema', 'cognitive defect', 'coma', 'cyanosis', 'dehydration', 'depression', 'disorientation', 'distress syndrome', 'dizziness', 'drug abuse', 'drug use', 'emergency ward', 'empathy', 'facial expression', 'faintness', 'female', 'headache', 'health survey', 'hospital admission', 'hospitalization', 'human', 'hypertension', 'hyperthermia', 'hyponatremia', 'illusion', 'intensive care unit', 'logorrhea', 'major clinical study', 'male', 'memory disorder', 'mood change', 'morbidity', 'muscle cramp', 'mydriasis', 'nausea', 'panic', 'paranoia', 'paresthesia', 'pneumonia', 'poison center', 'priority journal', 'prospective study', 'respiratory arrest', 'restlessness', 'rhabdomyolysis', 'seizure', 'speech disorder', 'cerebrovascular accident', 'suicidal ideation', 'sweating', 'tachycardia', 'unconsciousness', 'violence']\", 'text': \"Morbidity associated with MDMA (ecstasy) abuse: A survey of emergency department admissions.^\\nMethods: We conducted a prospective, representative-sample nationwide study on morbidity related to 3,4, methylenedioxymethamphetamine (MDMA; 'ecstasy') as determined from admissions to 5 geographically representative emergency departments (EDs) and from data from the poison information center (PIC). MDMArelated ED admissions were analyzed over a 7-month period and the records of all PIC calls were reviewed. Results: There were 52 (age 15-44 years, 32 males) ecstasy-related ED admissions during the study period. Most (68%) admissions presented to the ED at night, 52% on weekends and 44% consumed the drug at clubs and parties. Forty-six percent of the patients took between 1/2 to 3 tablets and 29 patients (56%) had taken ecstasy before. Twenty-two subjects (42%) reported poly-drug use. Fifteen subjects (29%) required hospitalization, six of them (11%) to the intensive care unit. The most common manifestations were restlessness, agitation, disorientation, shaking, high blood pressure, headache and loss of consciousness. More serious complications were hyperthermia, hyponatremia, rhabdomyolysis, brain edema and coma. Conclusion: The image of ecstasy as a safe party drug is spurious. The results of this study confirm that the drug bears real danger of physical harm and of behavioral, psychological and psychiatric disturbances. © The Author(s) 2010.\", 'doi': '10.1177/0960327110370984', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/20488845/', 'secondary_title': 'Human and Experimental Toxicology', '_input_hash': 1464447561, '_task_hash': 2077424278, 'spans': [{'text': 'MDMA', 'start': 26, 'end': 30, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 32, 'end': 39, 'pattern': 611274830}, {'text': 'MDMA', 'start': 230, 'end': 234, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 237, 'end': 244, 'pattern': 611274830}, {'text': '52', 'start': 526, 'end': 528, 'pattern': 2095658839}, {'text': '15', 'start': 534, 'end': 536, 'pattern': 2095658839}, {'text': '44', 'start': 537, 'end': 539, 'pattern': 2095658839}, {'text': '32', 'start': 547, 'end': 549, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 557, 'end': 564, 'pattern': 611274830}, {'text': '68', 'start': 618, 'end': 620, 'pattern': 2095658839}, {'text': '52', 'start': 664, 'end': 666, 'pattern': 2095658839}, {'text': '44', 'start': 684, 'end': 686, 'pattern': 2095658839}, {'text': '29', 'start': 796, 'end': 798, 'pattern': 2095658839}, {'text': '56', 'start': 809, 'end': 811, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 824, 'end': 831, 'pattern': 611274830}, {'text': '42', 'start': 861, 'end': 863, 'pattern': 2095658839}, {'text': '29', 'start': 908, 'end': 910, 'pattern': 2095658839}, {'text': '11', 'start': 952, 'end': 954, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1251, 'end': 1258, 'pattern': 611274830}, {'text': '2010', 'start': 1455, 'end': 1459, 'pattern': 2095658839}], 'meta': {'pattern': '7, 8, 7, 8, 14, 14, 14, 14, 8, 14, 14, 14, 14, 14, 8, 14, 14, 14, 8, 14'}}\n",
      "0.5\n",
      "{'record_id': 5625, 'keywords': \"['Adult', 'Anesthetics, Dissociative/*pharmacology', 'Behavior/*drug effects', 'Cognition/drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Emotions/*drug effects', 'Excitatory Amino Acid Antagonists/*pharmacology', 'Humans', 'Ketamine/*pharmacology', 'Male', 'Memory Disorders/chemically induced', 'Psychiatric Status Rating Scales', 'Psychometrics', 'Schizophrenic Psychology', 'Substance-Related Disorders/psychology']\", 'text': \"[Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].^\\nSchizophrenic patients suffer from positive (delusions, hallucinations) and negative signs (social withdrawal) as well as emotional disturbance that included quantitative (blunted affect) and qualitative impairments (discordance of emotional level). Ketamine, a phencyclidine derivative, is a non competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist. In healthy subjects its administration induces some positive symptoms (perceptual distortions.), negative symptoms (emotional deficit, apathy, social withdrawal) and cognitive changes (memory impairments and perseverations) that resemble some aspects of the symptoms of schizophrenia. A double blind cross over, placebo controlled was performed in 12 normal subjects with 2 sessions separated by one week of wash-out to determine ketamine-induced effects on behavioral and emotional responses. During each session, subjects received either ketamine or placebo (saline) infusion. A subanesthetic dose of ketamine (0,5 mg/kg) was administered by constant perfusion over 60 min. Behavioral and cognitive responses were assessed using positive and negative symptoms scales (BPRS, items from SAPS and SANS), vigilance and mood visual analog scale, subjective feelings using the Addiction Research Center Inventory (ARCI) and the Profile of Mood States (POMS). Using Philippot's method, emotions were elicited by films segments which induce a diversity of predictable emotions (fear, anger, sadness, joy, disgust and neutral state) and emotional responses were assessed by the Differential Emotions Scale (DES Izard). Low dose of ketamine induced significant effects on 7-items BPRS score (positive and negative items) and significant effects on positive and negative symptoms from SANS and SAPS. This was associated with emotional blunting of visually-induced responses that resemble aspects of schizophrenic emotional impairments. Ketamine impaired ARCI subscales (benzedrine subscale, pentobarbital-chlorpromazine subscale and LSD subscale). The recent findings of ketamine's pharmacology and imaging studies allow to draw several hypothesis related to neurotransmitter systems (glutamate, dopamine, serotonin interactions) and cerebral areas (particularly prefrontal cortex, anterior cingulate cortex, hippocampus) underlying some of these ketamine-induced effects.\", 'doi': '10.1016/s0987-7053(03)00028-5', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/12909392/', 'secondary_title': 'Neurophysiol Clin', '_input_hash': -1172130972, '_task_hash': 566288833, 'spans': [{'text': 'ketamine', 'start': 37, 'end': 45, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 353, 'end': 361, 'pattern': -1436149968}, {'text': '12', 'start': 819, 'end': 821, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 901, 'end': 909, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1011, 'end': 1019, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1074, 'end': 1082, 'pattern': -1436149968}, {'text': '60', 'start': 1139, 'end': 1141, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1695, 'end': 1703, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1998, 'end': 2006, 'pattern': -1436149968}, {'text': 'LSD', 'start': 2095, 'end': 2098, 'pattern': -496918669}, {'text': 'ketamine', 'start': 2133, 'end': 2141, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2409, 'end': 2417, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 9, 9, 9, 14, 9, 9, 0, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 8987, 'keywords': \"['*bariatric surgery', '*gastrectomy', '*laparoscopic surgery', '*mood', '*pain', 'Adult', 'Article', 'Beck Depression Inventory', 'Controlled study', 'Dizziness /side effect', 'Double blind procedure', 'Dysphoria /side effect', 'Euphoria', 'Female', 'Headache /side effect', 'Human', 'Low drug dose', 'Major clinical study', 'Male', 'McGill Pain Questionnaire', 'Montgomery Asberg Depression Rating Scale', 'Nausea /side effect', 'Postoperative period', 'Psychiatry', 'Quality of recovery', 'Randomized controlled trial', 'Scoring system', 'Single drug dose', 'Visual analog scale', 'Visual hallucination /side effect']\", 'text': 'Effects of a single subanaesthetic dose of ketamine on pain and mood after laparoscopic bariatric surgery A randomised double-blind placebo controlled study.^\\nBACKGROUND When administered as a continuous infusion, ketamine is known to be a potent analgesic and general anaesthetic. Recent studies suggest that a single low‐dose administration of ketamine can provide a long‐lasting effect on mood, but its effects when given in the postoperative period have not been studied. OBJECTIVE We hypothesised that a single low‐dose administration of ketamine after bariatric surgery can improve pain and mood scores in the immediate postoperative period. DESIGN We performed a randomised, double‐blind, placebo‐controlled study to compare a single subanaesthetic dose of ketamine (0.4 mg kg‐1) with a normal saline placebo in the postanaesthesia care unit after laparoscopic gastric bypass and gastrectomy. SETTING Single‐centre, tertiary care hospital, October 2014 to January 2018. PATIENTS A total of 100 patients were randomised into the ketamine and saline groups. INTERVENTION Patients in the ketamine group received a single dose of ketamine infusion (0.4 mg kg‐1) in the postanaesthesia care unit. Patients in the placebo groups received 0.9% saline. OUTCOME MEASURES The primary outcome was the visual analogue pain score. A secondary outcome was performance on the short‐form McGill’s Pain Questionnaire (SF‐MPQ). RESULTS There were no significant differences in visual analogue pain scores between groups (group‐by‐time interaction P ¼ 0.966; marginal group effect P ¼ 0.137). However, scores on the affective scale of SF‐MPQ (secondary outcome) significantly decreased in the ketamine group as early as postoperative day (POD) 2 [mean difference ¼ ‐2.2 (95% bootstrap CI ‐2.9 to 1.6), Bonferroni adjusted P < 0.001], compared with placebo group in which the scores decreased only by POD 7. Scores on the total scale of SF‐MPQ for the ketamine group were smaller compared with the placebo group (P ¼ 0.034). CONCLUSION Although there was no significant difference between ketamine and placebo for the primary outcome measure, patients who received ketamine experienced statistically and clinically significant improvement in their comprehensive evaluation of pain, particularly the affective component of pain, on POD 2. However, future studies are needed to confirm the enduring effects of ketamine on the affective response to postoperative pain.', 'doi': '10.1097/EJA.0000000000000860', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/30095550/', 'secondary_title': 'European journal of anaesthesiology', '_input_hash': 521205460, '_task_hash': -1534874462, 'spans': [{'text': 'ketamine', 'start': 43, 'end': 51, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 214, 'end': 222, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 346, 'end': 354, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 543, 'end': 551, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 764, 'end': 772, 'pattern': -1436149968}, {'text': '2014', 'start': 955, 'end': 959, 'pattern': 2095658839}, {'text': '2018', 'start': 971, 'end': 975, 'pattern': 2095658839}, {'text': '100', 'start': 997, 'end': 1000, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1035, 'end': 1043, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1092, 'end': 1100, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1133, 'end': 1141, 'pattern': -1436149968}, {'text': '0.966', 'start': 1540, 'end': 1545, 'pattern': 2095658839}, {'text': '0.137', 'start': 1573, 'end': 1578, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1681, 'end': 1689, 'pattern': -1436149968}, {'text': '95', 'start': 1759, 'end': 1761, 'pattern': 2095658839}, {'text': '0.001', 'start': 1814, 'end': 1819, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1939, 'end': 1947, 'pattern': -1436149968}, {'text': '0.034', 'start': 2004, 'end': 2009, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 2076, 'end': 2084, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2152, 'end': 2160, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2395, 'end': 2403, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 9, 14, 14, 14, 9, 9, 9, 14, 14, 9, 14, 14, 9, 14, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 2864, 'keywords': \"['Adult', 'Cognitive Behavioral Therapy/methods', 'Female', 'Follow-Up Studies', 'Hallucinogens/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Pilot Projects', 'Psilocybin/administration & dosage/pharmacology/*therapeutic use', 'Smoking/epidemiology/psychology', 'Smoking Cessation/*methods/psychology', 'Smoking Prevention', 'Tobacco Use Disorder/psychology/*rehabilitation']\", 'text': 'Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.^\\nPsilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy (CBT) for smoking cessation. Twelve of 15 participants (80%) demonstrated biologically verified smoking abstinence at 6-month follow-up. Participants who were abstinent at 6 months (n=12) were compared to participants still smoking at 6 months (n=3) on measures of subjective effects of psilocybin. Abstainers scored significantly higher on a measure of psilocybin-occasioned mystical experience. No significant differences in general intensity of drug effects were found between groups, suggesting that mystical-type subjective effects, rather than overall intensity of drug effects, were responsible for smoking cessation. Nine of 15 participants (60%) met criteria for \"complete\" mystical experience. Smoking cessation outcomes were significantly correlated with measures of mystical experience on session days, as well as retrospective ratings of personal meaning and spiritual significance of psilocybin sessions. These results suggest a mediating role of mystical experience in psychedelic-facilitated addiction treatment.', 'doi': '10.2174/1874473708666150107121331', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/25563443/', 'secondary_title': 'Curr Drug Abuse Rev', '_input_hash': 2094066971, '_task_hash': 1052319301, 'spans': [{'text': 'Psilocybin', 'start': 0, 'end': 10, 'pattern': 1563408733}, {'text': 'Psilocybin', 'start': 83, 'end': 93, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 335, 'end': 345, 'pattern': 1563408733}, {'text': '15', 'start': 387, 'end': 389, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 423, 'end': 433, 'pattern': 1563408733}, {'text': '15', 'start': 520, 'end': 522, 'pattern': 2095658839}, {'text': '80', 'start': 537, 'end': 539, 'pattern': 2095658839}, {'text': 'n=12', 'start': 663, 'end': 667, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 768, 'end': 778, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 835, 'end': 845, 'pattern': 1563408733}, {'text': '15', 'start': 1114, 'end': 1116, 'pattern': 2095658839}, {'text': '60', 'start': 1131, 'end': 1133, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1379, 'end': 1389, 'pattern': 1563408733}], 'meta': {'pattern': '1, 1, 1, 14, 1, 14, 14, 14, 1, 1, 14, 14, 1'}}\n",
      "0.5\n",
      "{'record_id': 8847, 'keywords': \"['Adult', 'Antidepressive Agents/pharmacology/therapeutic use', 'Biomarkers, Pharmacological/blood', 'Bipolar Disorder/*blood', 'Cross-Over Studies', 'Depressive Disorder, Treatment-Resistant/*blood/drug therapy', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ketamine/pharmacology/*therapeutic use', 'Lithium/therapeutic use', 'Lysophosphatidylcholines/*blood', 'Lysophospholipids/*blood', 'Male', 'Metabolome/*drug effects', 'Middle Aged', 'Pilot Projects', 'Valproic Acid/therapeutic use', 'Young Adult', 'fatty acid metabolism', 'lithium', 'mitochondrial function', 'pharmacometabolomics', 'valproate']\", 'text': 'A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.^\\nBACKGROUND AND PURPOSE: (R,S)-ketamine produces rapid and significant antidepressant effects in approximately 65% of patients suffering from treatment-resistant bipolar depression (BD). The genetic, pharmacological and biochemical differences between ketamine responders and non-responders have not been identified. The purpose of this study was to employ a metabolomics approach, a global, non-targeted determination of endogenous metabolic patterns, to identify potential markers of ketamine response and non-response. EXPERIMENTAL APPROACH: Plasma samples from 22 BD patients were analyzed to produce metabolomic patterns. The patients had received ketamine in a placebo-controlled crossover study and the samples were obtained 230\\u2009min post-administration at which time the patients were categorized as responders or non-responders. Matching plasma samples from the placebo arm of the study were also analysed. During the study, the patients were maintained on either lithium or valproate. KEY RESULTS: The metabolomic patterns were significantly different between the patients maintained on lithium and those maintained on valproate, irrespective of response to ketamine. In the patients maintained on lithium, 18 biomarkers were identified. In responders, lysophosphatidylethanolamines (4) and lysophosphatidylcholines (9) were increased relative to non-responders. CONCLUSIONS AND IMPLICATIONS: The results indicate that the differences between patients who respond to ketamine and those who do not are due to alterations in the mitochondrial β-oxidation of fatty acids. These differences were not produced by ketamine administration. The data indicate that pretreatment metabolomics screening may be a guide to the prediction of response and a potential approach to the individualization of ketamine therapy.', 'doi': '10.1111/bph.12494', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/24684390/', 'secondary_title': 'Br J Pharmacol', '_input_hash': 2120694398, '_task_hash': -588500266, 'spans': [{'text': 'ketamine', 'start': 72, 'end': 80, 'pattern': -1436149968}, {'text': '65', 'start': 286, 'end': 288, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 427, 'end': 435, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 661, 'end': 669, 'pattern': -1436149968}, {'text': '22', 'start': 740, 'end': 742, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 828, 'end': 836, 'pattern': -1436149968}, {'text': '230', 'start': 907, 'end': 910, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1342, 'end': 1350, 'pattern': -1436149968}, {'text': '18', 'start': 1391, 'end': 1393, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1651, 'end': 1659, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1792, 'end': 1800, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1974, 'end': 1982, 'pattern': -1436149968}], 'meta': {'pattern': '9, 14, 9, 9, 14, 9, 14, 9, 14, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 8414, 'keywords': \"['*amygdaloid nucleus', '*antidepressant activity', '*emotion', '*ketamine', '*processing', '*psychiatry', '*society', 'Antidepressant agent', 'BOLD signal', 'Biological marker', 'Crossover procedure', 'Depression', 'Functional magnetic resonance imaging', 'Gender', 'Hemodynamics', 'Human', 'Infusion', 'Major depression', 'Male', 'Montgomery Asberg Depression Rating Scale', 'N methyl dextro aspartic acid', 'N methyl dextro aspartic acid receptor blocking agent', 'Patient', 'Placebo', 'Radius', 'Stimulus', 'Treatment response', 'amygdala', 'antidepressant activity', 'emotion', 'processing', 'psychiatry', 'society']\", 'text': 'Amygdala response to processing emotion at baseline predicts antidepressant effect of ketamine.^\\nBackground: The amygdala is implicated in the processing of emotional stimuli, and is affected in major depressive disorder (MDD). Here we evaluate the potential for baseline amygdala response, during the processing of emotional faces, to predict subsequent treatment response to the NMDA antagonist ketamine. Methods: Sixteen unmedicated depressed MDD patients (7 males) participated in an fMRI study. Emotional faces were presented under 2 conditions: 1) judge emotion as positive (happy/neutral) or negative (sad/angry) and 2) judge gender, each with two difficulty levels, faces presented straight up or upside‐down. Subjects subsequently participated in a placebo‐controlled, crossover trial with i.v. ketamine (.5mg/kg). Depressive symptoms were assessed using the Montgomery‐Asberg Depression Rating Scale (MADRS). A 5mm radius sphere was placed in the left and right amygdala based on previously defined peak voxels showing differential hemodynamic responses to emotional faces before and after antidepressant treatment. BOLD signal estimates were averaged across voxels for each subject/ task condition, and correlated with percent change on MADRS (from baseline to 230 minutes post‐infusion). Significance was defined as p< 0.0125 (= 0.05/4 task conditions, judging gender/emotion, positive/negative emotion). Results: BOLD response in right amygdala correlated ( r>+0.6, p< 0.0125) with treatment response when judging positive and negative emotion presented straight up, and when judging positive emotion presented upside‐down. Conclusions: Neural activity in the right amygdala prior to treatment, during an overt emotional processing task, correlated with subsequent treatment response to ketamine. Thus, pre‐treatment amygdala activity measured in currently depressed MDD patients during emotion processing may provide a biomarker of subsequent treatment response.', 'doi': '10.1016/j.biopsych.2014.03.014', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/38591002/', 'secondary_title': 'Biological psychiatry', '_input_hash': -1488441988, '_task_hash': -584758996, 'spans': [{'text': 'ketamine', 'start': 397, 'end': 405, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 804, 'end': 812, 'pattern': -1436149968}, {'text': '230', 'start': 1272, 'end': 1275, 'pattern': 2095658839}, {'text': '0.0125', 'start': 1331, 'end': 1337, 'pattern': 2095658839}, {'text': '0.05/4', 'start': 1341, 'end': 1347, 'pattern': 2095658839}, {'text': '0.0125', 'start': 1482, 'end': 1488, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1800, 'end': 1808, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 14, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 1887, 'keywords': \"['midomafetamine', 'cannabis', 'lysergide', 'psychedelic agent', 'psychostimulant agent', 'psychotropic agent', 'adolescent', 'adult', 'article', 'Brazil', 'cannabis addiction', 'cigarette smoking', 'drug abuse', 'drug dependence', 'female', 'human', 'interview', 'major clinical study', 'male', 'questionnaire', 'self report', 'social behavior', 'tobacco']\", 'text': \"Ecstasy (MDMA): Effects and patterns of use reported by users in São Paulo.^\\nObjective: As there are no studies about the use of ecstasy in Brazil, our aim was to identify the effects and patterns of use of this substance among users in the city of São Paulo. Methods: Subjects were recruited through the snowball technique. Fifty-two subjects of both genders who had been using ecstasy frequently and recently were interviewed. The instrument was a self-reported and anonymous questionnaire. Results: The sample's mean age was 24 years, mostly composed by single, college graduated middle-class subjects. Among the interviewed users, 61.6% used ecstasy at least once per week and 50% of them took one pill per episode of use and 46% more than one. Drug taking was usually performed in company of several people (63%) in contexts related to night leisure, such as rave parties (78.8%), dancing clubs (69.2%) and parties (53.8%). Ecstasy pills were mainly purchased from friends or acquaintances in order to favor a dancing mood in those places. Most subjects used ecstasy associated to other psychoactive drugs (93.3%), mainly Cannabis, followed by tobacco and LSD. The effects attributed to ecstasy were mainly positive. Discussion: The use of ecstasy in São Paulo has had a recreational pattern quite similar to those described in previous studies. The assessment of the use of ecstasy as positive also agrees with the findings of the literature.\", 'doi': '10.1590/s1516-44462003000100004', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/12975674/', 'secondary_title': 'Revista Brasileira de Psiquiatria', '_input_hash': 96128882, '_task_hash': -1754660054, 'spans': [{'text': 'Ecstasy', 'start': 0, 'end': 7, 'pattern': 611274830}, {'text': 'MDMA', 'start': 9, 'end': 13, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 129, 'end': 136, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 379, 'end': 386, 'pattern': 611274830}, {'text': '24', 'start': 528, 'end': 530, 'pattern': 2095658839}, {'text': '61.6', 'start': 635, 'end': 639, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 646, 'end': 653, 'pattern': 611274830}, {'text': '50', 'start': 681, 'end': 683, 'pattern': 2095658839}, {'text': '46', 'start': 730, 'end': 732, 'pattern': 2095658839}, {'text': '63', 'start': 813, 'end': 815, 'pattern': 2095658839}, {'text': '78.8', 'start': 878, 'end': 882, 'pattern': 2095658839}, {'text': '69.2', 'start': 901, 'end': 905, 'pattern': 2095658839}, {'text': '53.8', 'start': 921, 'end': 925, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 929, 'end': 936, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1064, 'end': 1071, 'pattern': 611274830}, {'text': '93.3', 'start': 1112, 'end': 1116, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1161, 'end': 1164, 'pattern': -496918669}, {'text': 'ecstasy', 'start': 1192, 'end': 1199, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1245, 'end': 1252, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1380, 'end': 1387, 'pattern': 611274830}], 'meta': {'pattern': '8, 7, 8, 8, 14, 14, 8, 14, 14, 14, 14, 14, 14, 8, 8, 14, 0, 8, 8, 8'}}\n",
      "0.5\n",
      "{'record_id': 4728, 'keywords': \"['Adult', 'Humans', 'Antidepressive Agents/therapeutic use', 'Depression/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', '*Hallucinogens/therapeutic use', 'Infusions, Intravenous', '*Ketamine/therapeutic use', 'Treatment Outcome', 'Intravenous ketamine', 'Qualitative methods', 'Recovery', 'Remission', 'Treatment-resistant depression']\", 'text': \"Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.^\\nBACKGROUND: Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression. A large data base is confirmatory and steadily expanding. Qualitative studies can inform best practices and suggest new research directions. As part of a clinical trial designed to identify biomarkers of ketamine response, a qualitative study was conducted to characterize experiences with: receiving infusions; recovering or not recovering from depression; and beliefs about why ketamine worked or did not work. METHODS: Adults with treatment-resistant depression received three IV ketamine infusions in a two-week period and were characterized as remitters or non-remitters via symptom reduction 24\\xa0h after the third infusion. Qualitative interviews of a subset of participants were audio recorded, transcribed verbatim, and coded using deductive and inductive methods. Themes were derived and compared across a broader construct of recovery status. RESULTS: Of the 21 participants, nine (43\\xa0%) were characterized as having experienced remission and 12 (57\\xa0%) non-remission. Of the 12 non-remitters, five were characterized as having experienced partial recovery based on their subjective experiences, reporting substantial benefit from ketamine infusions despite non-remission status based on scale measurements. Attributions for ketamine's effects included biological and experiential mechanisms. Among non-remitters there was risk of disappointment when adding another failed treatment. LIMITATIONS: A more diverse sample may have yielded different themes. Different patients had different amounts of time elapsed between ketamine infusions and qualitative interview. CONCLUSIONS: Qualitative methods may enhance researchers' characterization of IV ketamine's impact on treatment-resistant depression. While requiring confirmation, patients may benefit from a preparatory milieu that prepares them for multiple recovery pathways; decouples the psychedelic experience from clinical outcomes; and addresses potential risks of another failed treatment.\", 'doi': '10.1016/j.jad.2022.11.090', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36481228/', 'secondary_title': 'J Affect Disord', '_input_hash': -1269433222, '_task_hash': 2134430764, 'spans': [{'text': 'ketamine', 'start': 65, 'end': 73, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 140, 'end': 148, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 413, 'end': 421, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 589, 'end': 597, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 692, 'end': 700, 'pattern': -1436149968}, {'text': '24', 'start': 807, 'end': 809, 'pattern': 2095658839}, {'text': '21', 'start': 1077, 'end': 1079, 'pattern': 2095658839}, {'text': '43', 'start': 1100, 'end': 1102, 'pattern': 2095658839}, {'text': '12', 'start': 1161, 'end': 1163, 'pattern': 2095658839}, {'text': '57', 'start': 1165, 'end': 1167, 'pattern': 2095658839}, {'text': '12', 'start': 1193, 'end': 1195, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1348, 'end': 1356, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1442, 'end': 1450, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1736, 'end': 1744, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1863, 'end': 1871, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 9, 14, 14, 14, 14, 14, 14, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 9113, 'keywords': \"['Adult', 'Affect/drug effects', 'Age Factors', 'Cannabis/chemistry', 'Female', 'Hallucinogens/*adverse effects', 'Humans', 'Male', 'Marijuana Abuse/*physiopathology/psychology', 'N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects', 'Neuropsychological Tests', 'Stress, Psychological/*etiology', 'Substance-Related Disorders/physiopathology', 'Workload/psychology', 'Young Adult']\", 'text': 'The effects of multitasking on psychological stress reactivity in recreational users of cannabis and MDMA.^\\nBACKGROUND: Cannabis and 3,4-methylenedioxymethamphetamine (MDMA) use is associated with psychobiological and neurocognitive deficits. Assessments of the latter typically include tests of memory and everyday cognitive functioning. However, to date, little attention has been paid to effects of drug use on psychological stress reactivity. We report three studies examining the effects of recreational use of cannabis and MDMA on mood and psychological responses to multitasking using a cognitively demanding laboratory stressor that provides an analogue for everyday situations involving responses to multiple stimuli. METHODS: The effects of the multitasking framework on mood and perceived workload were assessed in cannabis (N=25), younger (N=18) and older (N=20) MDMA users and compared with non-target drug controls. RESULTS: Compared with respective control groups, cannabis users became less alert and content, and both MDMA groups became less calm following acute stress. Unexpectedly, the stressor increased ratings of calm in cannabis users. Users also scored higher than their controls with respect to ratings of resources needed to complete the multitasking framework. CONCLUSIONS: These findings show, for the first time, that recreational use of cannabis and MDMA, beyond the period of intoxication, can negatively influence psychological responses to a multitasking stressor, and this may have implications for real-life situations which place high demands on cognitive resources.', 'doi': '10.1002/hup.1261', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/22389081/', 'secondary_title': 'Hum Psychopharmacol', '_input_hash': -1187854787, '_task_hash': 940514397, 'spans': [{'text': 'MDMA', 'start': 168, 'end': 172, 'pattern': -495411397}, {'text': 'MDMA', 'start': 529, 'end': 533, 'pattern': -495411397}, {'text': 'N=25', 'start': 836, 'end': 840, 'pattern': 2095658839}, {'text': 'N=18', 'start': 852, 'end': 856, 'pattern': 2095658839}, {'text': 'N=20', 'start': 869, 'end': 873, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 875, 'end': 879, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1035, 'end': 1039, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1381, 'end': 1385, 'pattern': -495411397}], 'meta': {'pattern': '7, 7, 14, 14, 14, 7, 7, 7'}}\n",
      "0.5\n",
      "{'record_id': 7946, 'keywords': \"['Humans', 'Adolescent', 'Young Adult', 'Adult', 'Middle Aged', 'Aged', '*Ketamine/therapeutic use', 'Suicidal Ideation', 'Suicide, Attempted', 'Pilot Projects', '*Suicide', 'consultation-liaison psychiatry', 'intravenous ketamine', 'medical toxicology', 'suicide', 'suicide attempt', 'tertiary care']\", 'text': \"A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting.^\\nKetamine, in research settings, rapidly reduces suicidal thoughts 2-24 h after a single infusion in patients with high suicidal ideation. In this study, the authors investigate ketamine's effects on suicidality in a real-world sample of recent suicide attempters on a tertiary-care Consultation-Liaison (CL) psychiatry service. Using an open-label design, 16 transdiagnostic CL patients were recruited, 18-65 years old, to receive a single dose of intravenous ketamine (0.5 mg/kg) in the acute medical setting. All were psychiatrically hospitalized post-infusion. Baseline suicidality and depression measures were compared to ratings taken at 24 h, 5 days, 12 days, and 1, 3 and 6 months post-infusion using paired t-tests. Across all measures, rapid, statistically significant decreases (p's < 0.001) were observed with large to very large effect sizes (Cohen's d's: 1.7-8.8) at acute timepoints (24 h; 5 days). These gains were uniformly maintained to 6 months post-infusion. Open-label ketamine appeared to rapidly and robustly reduced suicidal symptoms in an ultra-high-risk, heterogeneous, real-world sample. Ketamine infusion may therefore be a safe, feasible, viable method to rapidly reduce suicidality among medically hospitalized patients after a suicide attempt, with potentially enduring benefits. The current pilot findings suggest ketamine could be readily integrated into the settings where high-risk CL patients already receive healthcare, with the potential to become an important and novel tool in the treatment of suicidality.\", 'doi': '10.3390/ijerph192113792', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36360672/', 'secondary_title': 'Int J Environ Res Public Health', '_input_hash': 283854253, '_task_hash': -688596514, 'spans': [{'text': 'Ketamine', 'start': 17, 'end': 25, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 136, 'end': 144, 'pattern': -1436149968}, {'text': '24', 'start': 204, 'end': 206, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 313, 'end': 321, 'pattern': -1436149968}, {'text': '16', 'start': 492, 'end': 494, 'pattern': 2095658839}, {'text': '18', 'start': 539, 'end': 541, 'pattern': 2095658839}, {'text': '65', 'start': 542, 'end': 544, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 596, 'end': 604, 'pattern': -1436149968}, {'text': '24', 'start': 779, 'end': 781, 'pattern': 2095658839}, {'text': '12', 'start': 793, 'end': 795, 'pattern': 2095658839}, {'text': '0.001', 'start': 931, 'end': 936, 'pattern': 2095658839}, {'text': '24', 'start': 1034, 'end': 1036, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1125, 'end': 1133, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1250, 'end': 1258, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1481, 'end': 1489, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 9, 14, 14, 14, 9, 14, 14, 14, 14, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 2816, 'keywords': \"['awakening salivary cortisol', 'ayahuasca', 'hypocortisolemia', 'plasma cortisol', 'treatment-resistant depression']\", 'text': \"Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls.^\\nMajor depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial (RCT) supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients (MD) and in healthy volunteers (C). Subjects received a single dose of ayahuasca or placebo (dosing session), and both plasma and awakening salivary cortisol response were measured at baseline (before dosing session) and 48 h after the dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients, with respect to healthy controls. Salivary cortisol was also measured during dosing session, and we observed higher increases for both C and MD that ingested ayahuasca than placebo. After 48 h from the dosing session with ayahuasca, patients' awakening salivary cortisol response is similar to the ones detected in controls. No significant changes in plasma cortisol levels were observed 48 h after the sessions. Therefore, these findings point to new evidence on the modulation of salivary cortisol levels as a result of an ayahuasca session, both in healthy and depressive volunteers. Considering that cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes, it is assumed to be critically involved to the etiology of depression and its regulation seems to be important for the treatment and remission of major depression, ayahuasca use as antidepressant should be further investigated. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.\", 'doi': '10.3389/fpsyt.2018.00185', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/29867608/', 'secondary_title': 'Front Psychiatry', '_input_hash': 844538648, '_task_hash': 1503444166, 'spans': [{'text': 'Ayahuasca', 'start': 23, 'end': 32, 'pattern': -1438173035}, {'text': '350', 'start': 174, 'end': 177, 'pattern': 2095658839}, {'text': '30', 'start': 205, 'end': 207, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 408, 'end': 417, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 504, 'end': 513, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 696, 'end': 705, 'pattern': -1438173035}, {'text': '48', 'start': 846, 'end': 848, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1146, 'end': 1155, 'pattern': -1438173035}, {'text': '48', 'start': 1176, 'end': 1178, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1210, 'end': 1219, 'pattern': -1438173035}, {'text': '48', 'start': 1376, 'end': 1378, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1513, 'end': 1522, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 1855, 'end': 1864, 'pattern': -1438173035}], 'meta': {'pattern': '5, 14, 14, 5, 5, 5, 14, 5, 14, 5, 14, 5, 5'}}\n",
      "0.5\n",
      "{'record_id': 4035, 'keywords': \"['Adult', 'Aged', 'Banisteriopsis/*chemistry', 'Cross-Sectional Studies', 'Female', 'Hallucinogens/*adverse effects', 'Humans', 'Interview, Psychological', 'Longitudinal Studies', 'Male', 'Mental Disorders/*chemically induced/pathology', '*Mental Health', 'Middle Aged', 'Personality/*drug effects', 'Psychopathology', '*Quality of Life', 'Surveys and Questionnaires', 'Young Adult']\", 'text': 'Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination.^\\nAyahuasca is a hallucinogenic decoction used as a traditional medicine in several Amazonian regions. The ritualistic use of ayahuasca has spread throughout many countries, making it necessary to study its risks and benefits. Two sub-studies were designed for this investigation. In sub-study 1, a psychiatric interview and a battery of questionnaires were administered to subjects (n\\u2009=\\u200940) before their first ayahuasca use. Two follow-ups were conducted at 1 and 6 months. In sub-study 2, the same interview and battery of questionnaires were administered to long-term ayahuasca users (n\\u2009=\\u200923) and their scores were compared with those of the ayahuasca-naïve group. In the first assessment, nearly half (45%) of the naïve users were found to meet the diagnostic criteria for a psychiatric disorder. After the ayahuasca use, more than 80% of those subjects showed clinical improvements that persisted at 6 months. The questionnaires showed significant reductions in depression and psychopathology. Regarding sub-study 2, long-term users showed lower depression scores, and higher scores for self-transcendence and quality of life, as compared to their peers in sub-study 1. Further controlled and observational naturalistic studies assessing the eventual risks and potential benefits of ayahuasca are warranted.', 'doi': '10.1038/s41598-020-61169-x', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/32139811/', 'secondary_title': 'Sci Rep', '_input_hash': 1984653936, '_task_hash': 1718391217, 'spans': [{'text': 'ayahuasca', 'start': 11, 'end': 20, 'pattern': -1438173035}, {'text': 'Ayahuasca', 'start': 129, 'end': 138, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 253, 'end': 262, 'pattern': -1438173035}, {'text': '40', 'start': 515, 'end': 517, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 538, 'end': 547, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 698, 'end': 707, 'pattern': -1438173035}, {'text': '23', 'start': 719, 'end': 721, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 772, 'end': 781, 'pattern': -1438173035}, {'text': '45', 'start': 833, 'end': 835, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 938, 'end': 947, 'pattern': -1438173035}, {'text': '80', 'start': 963, 'end': 965, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1415, 'end': 1424, 'pattern': -1438173035}], 'meta': {'pattern': '5, 5, 5, 14, 5, 5, 14, 5, 14, 5, 14, 5'}}\n",
      "0.5\n",
      "{'record_id': 5041, 'keywords': \"['Humans', 'Female', 'Pregnancy', 'Cesarean Section/adverse effects', '*Ketamine/therapeutic use', '*Depression, Postpartum/diagnosis/epidemiology/prevention & control', 'Sufentanil/therapeutic use', 'Biomarkers', 'Cesarean section', 'Depression', 'Esketamine', 'Pain', 'Postoperative', 'Postpartum']\", 'text': 'Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: A randomized controlled trial.^\\nBACKGROUND: Postpartum depression (PPD) is a prevalent public health issue. Although ketamine has prophylactic effects on PPD in women undergoing cesarean section, the effects of esketamine on PPD remain unclear. This trial aimed to evaluate the efficacy of perioperative esketamine infusion on PPD risk by assessing Edinburgh Postnatal Depression Scale (EPDS) scores and blood biomarkers. METHODS: A total of 150 participants undergoing elective cesarean section were randomly allocated to receive either esketamine or normal saline. Since 27 participants were excluded due to consent withdrawal or loss to follow-up, 123 patients were included. The primary outcome was the prevalence of PPD risk. Secondary outcomes included the prevalence of postpartum anxiety (PPA) risk, levels of biomarkers, postoperative pain intensity, and cumulative sufentanil consumption. RESULTS: The prevalence of PPD and PPA risk at 3\\xa0days, 42\\xa0days, 3\\xa0months, and 6\\xa0months postpartum did not differ between the two groups. Furthermore, EPDS scores, pain intensity at rest, and during coughing on postoperative days (POD) 1 and 2 did not differ between the two groups. Sufentanil consumption during 0-12 h, 12-24\\xa0h, 0-24\\xa0h, and 0-48\\xa0h postoperatively were significantly lower in the esketamine group compared to the control group. Blood biomarkers did not differ between the two groups on POD 3. LIMITATIONS: The sample size was small. PPD risk was simply screened, not diagnosed. CONCLUSIONS: Perioperative administration of esketamine did not decrease the incidence of PPD risk in women after elective cesarean section. However, esketamine reduced opioid consumption.', 'doi': '10.1016/j.jad.2023.07.103', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/37482224/', 'secondary_title': 'J Affect Disord', '_input_hash': 1574227254, '_task_hash': 2145968110, 'spans': [{'text': 'ketamine', 'start': 231, 'end': 239, 'pattern': -1436149968}, {'text': '150', 'start': 556, 'end': 559, 'pattern': 2095658839}, {'text': '27', 'start': 687, 'end': 689, 'pattern': 2095658839}, {'text': '123', 'start': 765, 'end': 768, 'pattern': 2095658839}, {'text': '42', 'start': 1068, 'end': 1070, 'pattern': 2095658839}, {'text': '12', 'start': 1327, 'end': 1329, 'pattern': 2095658839}, {'text': '12', 'start': 1333, 'end': 1335, 'pattern': 2095658839}, {'text': '24', 'start': 1336, 'end': 1338, 'pattern': 2095658839}, {'text': '24', 'start': 1344, 'end': 1346, 'pattern': 2095658839}, {'text': '48', 'start': 1356, 'end': 1358, 'pattern': 2095658839}], 'meta': {'pattern': '9, 14, 14, 14, 14, 14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 2861, 'keywords': \"['psilocybine', 'psychedelic agent', 'serotonin', 'adult', 'article', 'body weight', 'controlled study', 'dose response', 'drug cost', 'drug dose comparison', 'female', 'human', 'major clinical study', 'major depression', 'male', 'priority journal', 'sex factor']\", 'text': 'Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.^\\nBackground: Growing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as part of a structured intervention. In most trials to date, psilocybin dose has been administered on a weight-adjusted basis rather than the more convenient procedure of administering a fixed dose. Aims: The present post hoc analyses sought to determine whether the subjective effects of psilocybin are affected by body weight when psilocybin is administered on a weight-adjusted basis and when psilocybin is administered as a fixed dose. Methods: We analyzed acute subjective drug effects (mystical, challenging, and intensity) associated with therapeutic outcomes from ten previous studies (total N = 288) in which psilocybin was administered in the range 20 to 30 mg/70 kg (inclusive). Separate multivariate regression analyses examined the relationships between demographic variables including body weight and subjective effects in participants receiving 20 mg/70 kg (n = 120), participants receiving 30 mg/70 kg (n = 182), and participants whose weight-adjusted dose was about 25 mg (to approximate the fixed dose that is currently being evaluated in registration trials for major depressive disorder) (n = 103). Results: In the 20 mg/70 kg and 30 mg/70 kg weight-adjusted groups, and in the fixed dose group, no significant associations were found between subjective effects and demographic variables including body weight or sex. Across a wide range of body weights (49 to 113 kg) the present results showed no evidence that body weight affected subjective effects of psilocybin. Conclusions: These results suggest that the convenience and lower cost of administering psilocybin as a fixed dose outweigh any potential advantage of weight-adjusted dosing.', 'doi': '10.1177/0269881121991822', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33611977/', 'secondary_title': 'Journal of Psychopharmacology', '_input_hash': -2045296631, '_task_hash': -1978944705, 'spans': [{'text': 'psilocybin', 'start': 19, 'end': 29, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 143, 'end': 153, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 360, 'end': 370, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 588, 'end': 598, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 632, 'end': 642, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 695, 'end': 705, 'pattern': 1563408733}, {'text': '288', 'start': 903, 'end': 906, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 917, 'end': 927, 'pattern': 1563408733}, {'text': '20', 'start': 958, 'end': 960, 'pattern': 2095658839}, {'text': '30', 'start': 964, 'end': 966, 'pattern': 2095658839}, {'text': 'mg/70', 'start': 967, 'end': 972, 'pattern': 2095658839}, {'text': '20', 'start': 1159, 'end': 1161, 'pattern': 2095658839}, {'text': 'mg/70', 'start': 1162, 'end': 1167, 'pattern': 2095658839}, {'text': '120', 'start': 1176, 'end': 1179, 'pattern': 2095658839}, {'text': '30', 'start': 1205, 'end': 1207, 'pattern': 2095658839}, {'text': 'mg/70', 'start': 1208, 'end': 1213, 'pattern': 2095658839}, {'text': '182', 'start': 1222, 'end': 1225, 'pattern': 2095658839}, {'text': '25', 'start': 1282, 'end': 1284, 'pattern': 2095658839}, {'text': '103', 'start': 1412, 'end': 1415, 'pattern': 2095658839}, {'text': '20', 'start': 1434, 'end': 1436, 'pattern': 2095658839}, {'text': 'mg/70', 'start': 1437, 'end': 1442, 'pattern': 2095658839}, {'text': '30', 'start': 1450, 'end': 1452, 'pattern': 2095658839}, {'text': 'mg/70', 'start': 1453, 'end': 1458, 'pattern': 2095658839}, {'text': '49', 'start': 1674, 'end': 1676, 'pattern': 2095658839}, {'text': '113', 'start': 1680, 'end': 1683, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1775, 'end': 1785, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 1875, 'end': 1885, 'pattern': 1563408733}], 'meta': {'pattern': '1, 1, 1, 1, 1, 1, 14, 1, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 1, 1'}}\n",
      "0.5\n",
      "{'record_id': 3215, 'keywords': \"['ketamine', 'metabolite', 'major depressive disorder', 'suicidal ideation', 'clinical trial', 'Drug Therapy', 'Major Depression', 'Metabolites', 'Midazolam', 'Treatment Withholding']\", 'text': \"'Ketamine metabolite pilot study in a suicidal depression trial': Corrigendum.^\\nReports an error in 'Ketamine metabolite pilot study in a suicidal depression trial' by Michael F. Grunebaum, Hanga C. Galfalvy, Tse-Hwei Choo, Michelle S. Parris, Ainsley K. Burke, Raymond F. Suckow, Thomas B. Cooper and J. John Mann (Journal of Psychiatric Research, 2019[Oct], Vol 117, 129-134). In the original article, there was an error in Figure 1 which shows the amine and aryl group moved one carbon over on the cyclohexanone structure whereas they should be next to the ketone. A corrected Figure 1 can be found in the NIHMS manuscript, but was too late for the journal publication. (The following abstract of the original article appeared in record [rid]2019-49924-018[/rid]). Ketamine shows promise as a rapidly-acting treatment for depression and suicidal ideation, but side effects and abuse potential limit its use. Understanding its mechanism of action could help develop analogous but safer drugs. This post hoc study explored relationships of ketamine and metabolites, including hydroxynorketamine enantiomers, (2S,6S)- and (2R,6R)-HNK, to clinical response in a subgroup from a published trial in suicidal depression. Depressed adults with clinically significant suicidal ideation were randomized to double-blind infusion of sub-anesthetic ketamine or midazolam. Ketamine and metabolites were measured after infusion (N = 53). Plasma (2R,6R)-HNK was associated with change (higher levels correlated with less clinical improvement) from baseline to 24 h post-infusion of depression (HDRS-24: Spearman r = 0.37, p = 0.009) and suicidal thoughts (SSI: Spearman r = 0.29, p = 0.041). There were similar correlations with weekly follow-up clinical rating scores for both HNK enantiomers and dehydronorketamine (DHNK). Ketamine and norketamine were not associated with change in depression or suicidal ideation (unadjusted p > 0.28). (PsycINFO Database Record (c) 2019 APA, all rights reserved)\", 'doi': '10.1016/j.jpsychires.2019.09.008', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/31550622/', 'secondary_title': 'Journal of Psychiatric Research', '_input_hash': -385504338, '_task_hash': -861022696, 'spans': [{'text': 'Ketamine', 'start': 1, 'end': 9, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 101, 'end': 109, 'pattern': -1436149968}, {'text': '2019[Oct', 'start': 349, 'end': 357, 'pattern': 2095658839}, {'text': '117', 'start': 364, 'end': 367, 'pattern': 2095658839}, {'text': '129', 'start': 369, 'end': 372, 'pattern': 2095658839}, {'text': '134', 'start': 373, 'end': 376, 'pattern': 2095658839}, {'text': 'rid]2019', 'start': 741, 'end': 749, 'pattern': 2095658839}, {'text': '49924', 'start': 750, 'end': 755, 'pattern': 2095658839}, {'text': '018[/rid', 'start': 756, 'end': 764, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 768, 'end': 776, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1041, 'end': 1049, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1339, 'end': 1347, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1362, 'end': 1370, 'pattern': -1436149968}, {'text': '53', 'start': 1421, 'end': 1423, 'pattern': 2095658839}, {'text': '24', 'start': 1547, 'end': 1549, 'pattern': 2095658839}, {'text': 'HDRS-24', 'start': 1581, 'end': 1588, 'pattern': 2095658839}, {'text': '0.37', 'start': 1603, 'end': 1607, 'pattern': 2095658839}, {'text': '0.009', 'start': 1613, 'end': 1618, 'pattern': 2095658839}, {'text': '0.29', 'start': 1661, 'end': 1665, 'pattern': 2095658839}, {'text': '0.041', 'start': 1671, 'end': 1676, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 1812, 'end': 1820, 'pattern': -1436149968}, {'text': '0.28', 'start': 1920, 'end': 1924, 'pattern': 2095658839}, {'text': '2019', 'start': 1957, 'end': 1961, 'pattern': 2095658839}], 'meta': {'pattern': '9, 9, 14, 14, 14, 14, 14, 14, 14, 9, 9, 9, 9, 14, 14, 14, 14, 14, 14, 14, 9, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 5545, 'keywords': \"['midomafetamine', 'cannabis', 'adult', 'anxiety', 'article', 'Beck Depression Inventory', 'behavior', 'clinical article', 'controlled study', 'depression', 'drug exposure', 'ethnicity', 'female', 'human', 'male', 'mental disease', 'multiple drug abuse', 'priority journal', 'rating scale', 'self report', 'sex difference', 'State Trait Anxiety Inventory', 'symptom']\", 'text': \"Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use.^\\nBackground: Given ecstasy's (MDMA) potential serotonergic neurotoxicity, it is plausible that regular ecstasy users would have an elevated prevalence of behavioral executive dysfunction or mood symptoms. However, recent studies have found that the relationship between ecstasy use and psychological symptoms was no longer significant after controlling for marijuana use (e.g., Morgan et al., 2002). The goal of the present study was to examine the relationship between ecstasy exposure and self-reported executive functioning and psychological symptoms after controlling for gender, ethnicity, and other drug use. Methods: Data were collected from 65 men and women with a wide range of ecstasy use (including 17 marijuana-using controls). Participants were administered the Frontal Systems Behavioral Scale, State-Trait Anxiety Inventory for adults, and the Beck Depression Inventory-2nd edition. Results: Although 19-63% of the ecstasy users demonstrated clinically elevated psychological symptoms, frequency of ecstasy use did not predict the psychological symptoms. No gender differences or interactions were observed. Conclusions: These results revealed that, although ecstasy users demonstrate elevated levels of psychological symptoms and executive dysfunction, these symptoms are not statistically associated with their ecstasy consumption. Instead, other drug use (alcohol, marijuana, opioids, and inhalants) significantly predict psychological symptoms in this sample of polydrug users. © 2006 Elsevier Ireland Ltd. All rights reserved.\", 'doi': '10.1016/j.drugalcdep.2006.09.003', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/17074449/', 'secondary_title': 'Drug and Alcohol Dependence', '_input_hash': 156816689, '_task_hash': 308451837, 'spans': [{'text': 'ecstasy', 'start': 73, 'end': 80, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 138, 'end': 145, 'pattern': 611274830}, {'text': 'MDMA', 'start': 149, 'end': 153, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 222, 'end': 229, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 389, 'end': 396, 'pattern': 611274830}, {'text': '2002', 'start': 512, 'end': 516, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 589, 'end': 596, 'pattern': 611274830}, {'text': '65', 'start': 768, 'end': 770, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 806, 'end': 813, 'pattern': 611274830}, {'text': '17', 'start': 829, 'end': 831, 'pattern': 2095658839}, {'text': '19', 'start': 1035, 'end': 1037, 'pattern': 2095658839}, {'text': '63', 'start': 1038, 'end': 1040, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1049, 'end': 1056, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1133, 'end': 1140, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1293, 'end': 1300, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1447, 'end': 1454, 'pattern': 611274830}, {'text': '2006', 'start': 1618, 'end': 1622, 'pattern': 2095658839}], 'meta': {'pattern': '8, 8, 7, 8, 8, 14, 8, 14, 8, 14, 14, 14, 8, 8, 8, 8, 14'}}\n",
      "0.5\n",
      "{'record_id': 1811, 'keywords': \"['psychedelic agent', 'tobacco smoke', 'adolescent', 'adolescent smoking', 'adult', 'article', 'awareness', 'Banisteriopsis caapi', 'Brazil', 'confidence interval', 'controlled study', 'cross-sectional study', 'drinking', 'female', 'frequency', 'health survey', 'human', 'male', 'mood', 'motivation', 'multivariate logistic regression analysis', 'odds ratio', 'online system', 'outcome assessment', 'people by smoking status', 'personal experience', 'prediction', 'qualitative analysis', 'quantitative analysis', 'questionnaire', 'retrospective study', 'risk factor', 'self report', 'smoking cessation', 'smoking reduction', 'sociodemographics', 'spiritual care', 'thematic analysis']\", 'text': 'Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.^\\nRationale: Smoking-related disease is a major problem globally. Effective smoking cessation treatments are however limited. Increasing evidence suggests that psychedelics have potential as treatments for substance use disorders and may therefore prove an option in aiding smoking cessation. Objectives: To establish which factors predict smoking cessation in people who reported quitting or reducing smoking following ayahuasca consumption. Methods: A retrospective cross-sectional mixed-method study (quantitative and qualitative design) was undertaken using data from an online survey evaluating peoples’ experiences before and after drinking ayahuasca. Multivariate logistic regression was performed with smoking condition (cessation or reduction/relapse) as a dependent variable and demographics, smoking, ayahuasca-related variables and the mystical experience (MEQ30) as predicting factors. Results: A total of 441 responses were grouped according to self-reported smoking status: cessation (n = 305) or reduction/relapse (n = 136) smoking. Logistic regression showed that mystical experience (OR: 1.03; 95% CI [1.00–1.05]) and frequency of ayahuasca intake (OR: 2.16[1.00–4.70]) were protective factors, while positive mood (measured by the MEQ30) during the ayahuasca experience was a risk factor (OR: 0.91[0.85–0.97]). Qualitative thematic analysis identified eight themes (e.g. acquired awareness, spiritual experience, increased motivation) related to the ayahuasca experience and the process of smoking cessation/reduction. Conclusions: Our results suggest that ayahuasca could be used as a potential tool for smoking cessation, and that effects may be mediated by mystical experience. Given the current burden of smoking-related disease and the limited treatment options, studies are needed to investigate the efficacy of psychedelics in smoking cessation.', 'doi': '10.1007/s00213-022-06063-2', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/35179623/', 'secondary_title': 'Psychopharmacology', '_input_hash': -1075464217, '_task_hash': 520816030, 'spans': [{'text': 'Ayahuasca', 'start': 0, 'end': 9, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 501, 'end': 510, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 728, 'end': 737, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 893, 'end': 902, 'pattern': -1438173035}, {'text': 'MEQ30', 'start': 950, 'end': 955, 'pattern': 2095658839}, {'text': '441', 'start': 1000, 'end': 1003, 'pattern': 2095658839}, {'text': '305', 'start': 1085, 'end': 1088, 'pattern': 2095658839}, {'text': '136', 'start': 1116, 'end': 1119, 'pattern': 2095658839}, {'text': '1.03', 'start': 1187, 'end': 1191, 'pattern': 2095658839}, {'text': '95', 'start': 1193, 'end': 1195, 'pattern': 2095658839}, {'text': '1.00–1.05', 'start': 1201, 'end': 1210, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1230, 'end': 1239, 'pattern': -1438173035}, {'text': '2.16[1.00–4.70', 'start': 1252, 'end': 1266, 'pattern': 2095658839}, {'text': 'MEQ30', 'start': 1331, 'end': 1336, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1349, 'end': 1358, 'pattern': -1438173035}, {'text': '0.91[0.85–0.97', 'start': 1393, 'end': 1407, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1550, 'end': 1559, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 1657, 'end': 1666, 'pattern': -1438173035}], 'meta': {'pattern': '5, 5, 5, 5, 14, 14, 14, 14, 14, 14, 14, 5, 14, 14, 5, 14, 5, 5'}}\n",
      "0.5\n",
      "{'record_id': 2956, 'keywords': \"['Antidepressive Agents/pharmacology/therapeutic use', 'Biomarkers', 'Depression/psychology', '*Depressive Disorder, Major/drug therapy/psychology', 'Humans', '*Ketamine/pharmacology/therapeutic use', 'Magnetoencephalography', 'Suicidal Ideation', 'Suicide, Attempted/psychology', 'Ketamine', 'Suicide attempt', 'Treatment-resistant depression']\", 'text': 'Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.^\\nBACKGROUND: This study examined magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD) at baseline and following subanesthetic-dose ketamine infusion. METHODS: Twenty-nine drug-free TRD patients (12 suicide attempters/17 non-attempters) participated in a crossover randomized trial of ketamine. MEG data were collected during an attentional dot probe task with emotional face stimuli at baseline and several hours post-ketamine infusion. Synthetic aperture magnetometry was used to project source power in the theta, alpha, beta, and gamma frequencies for angry-neutral, happy-neutral, and neutral-neutral face pairings during a one-second peristimulus period. Mixed models were used to test for clinical, behavioral, and electrophysiological effects of group, emotion, session, and SI score. RESULTS: Ketamine significantly reduced SI and depression across the sample. Post-ketamine, attempters had improved accuracy and non-attempters had reduced accuracy on the task. SI was positively associated with gamma power in regions of the frontal and parietal cortices across groups. In an extended amygdala-hippocampal region, attempters differed significantly in their emotional reactivity to angry versus happy faces as indexed by theta power differences, irrespective of drug. Ketamine significantly reduced the association between alpha power and SI for angry compared with happy faces in a fronto-insular/anterior cingulate region important for regulating sensory attentiveness. LIMITATIONS: Limitations include a small sample size of attempters. CONCLUSIONS: The findings highlight key differences in band-limited power between attempters and non-attempters and reinforce previous findings that ketamine has distinct response properties in patients with a suicide history.', 'doi': '10.1016/j.jad.2022.06.025', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/35728680/', 'secondary_title': 'J Affect Disord', '_input_hash': -49971556, '_task_hash': -2017349589, 'spans': [{'text': 'ketamine', 'start': 92, 'end': 100, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 375, 'end': 383, 'pattern': -1436149968}, {'text': '12', 'start': 439, 'end': 441, 'pattern': 2095658839}, {'text': 'attempters/17', 'start': 450, 'end': 463, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 528, 'end': 536, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 662, 'end': 670, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1045, 'end': 1053, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1118, 'end': 1126, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1520, 'end': 1528, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1941, 'end': 1949, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 14, 9, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 793, 'keywords': \"['Adult', 'Altered state of consciousness', 'Anger', 'Anxiety', 'Clinical article', 'Conference abstract', 'Controlled study', 'Depression', 'Drug effect', 'Drug megadose', 'Drug therapy', 'Facial expression', 'Female', 'Happiness', 'Human', 'Low drug dose', 'Male', 'Mood', 'Perception', 'Profile of Mood States', 'Questionnaire', 'Randomized controlled trial', 'Simulation', 'Social rejection']\", 'text': 'Subjective and Behavioral Effects of Microdoses of LSD in Healthy Human Volunteers.^\\nBackground: There have been numerous anecdotal reports that very low doses of lysergic acid diethylamide (LSD) reduce depressed mood and improve positive outlook. Yet, the effects of such “microdoses” have not been tested under double‐blind, placebo‐controlled conditions. As a first step, we examined the subjective and behavioral effects of single low doses of LSD in healthy adults. Methods: Volunteers (N=20) attended four laboratory sessions during with they received placebo, 6.5μg, 13μg, or 26μg LSD in randomized order. During expected peak drug effect, they completed mood questionnaires and behavioral tasks assessing emotion processing, including i) recognition of emotional facial expressions and ii) responses to simulated social rejection. Results: LSD dose‐dependently increased ratings of “feeling” the drug, “liking” the drug, and “feeling high,” in addition to dose‐dependently increasing responses to the Altered States of Consciousness questionnaire. The highest dose of LSD increased vigor, elation, and anxiety on the Profile of Mood States. On the emotion recognition task, LSD enhanced participants’ ability to recognize both anger and happiness. During the simulated social rejection task, LSD increased participants’ desire to play again with the other players, but did not affect their perception of the degree to which they were included or excluded. Conclusions: These findings with non‐symptomatic volunteers suggest that “microdoses” of LSD have dose‐dependent effects on mood and emotional behavior. These results set the stage for measuring the clinical efficacy of the drug in the treatment of depressed mood, and help to understand the expanding use of low doses of LSD in the community. Supported By: NIDA DA02812 Keywords: Microdosing, LSD, Human Behavioral Pharmacology, Emotion Processing, Mood', 'doi': '10.1016/j.biopsych.2019.03.876', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/38591002/', 'secondary_title': 'Biological psychiatry', '_input_hash': -230530854, '_task_hash': -883536085, 'spans': [{'text': 'LSD', 'start': 51, 'end': 54, 'pattern': -496918669}, {'text': 'LSD', 'start': 191, 'end': 194, 'pattern': -496918669}, {'text': 'LSD', 'start': 448, 'end': 451, 'pattern': -496918669}, {'text': 'N=20', 'start': 492, 'end': 496, 'pattern': 2095658839}, {'text': '13μg', 'start': 574, 'end': 578, 'pattern': 2095658839}, {'text': '26μg', 'start': 583, 'end': 587, 'pattern': 2095658839}, {'text': 'LSD', 'start': 588, 'end': 591, 'pattern': -496918669}, {'text': 'LSD', 'start': 848, 'end': 851, 'pattern': -496918669}, {'text': 'LSD', 'start': 1076, 'end': 1079, 'pattern': -496918669}, {'text': 'LSD', 'start': 1182, 'end': 1185, 'pattern': -496918669}, {'text': 'LSD', 'start': 1300, 'end': 1303, 'pattern': -496918669}, {'text': 'LSD', 'start': 1553, 'end': 1556, 'pattern': -496918669}, {'text': 'LSD', 'start': 1786, 'end': 1789, 'pattern': -496918669}, {'text': 'DA02812', 'start': 1827, 'end': 1834, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1858, 'end': 1861, 'pattern': -496918669}], 'meta': {'pattern': '0, 0, 0, 14, 14, 14, 0, 0, 0, 0, 0, 0, 0, 14, 0'}}\n",
      "0.5\n",
      "{'record_id': 7786, 'keywords': \"['3,4-Methylenedioxyamphetamine/*analogs & derivatives/pharmacology', 'Adult', 'Cerebral Cortex/diagnostic imaging/*drug effects/metabolism', 'Double-Blind Method', 'Female', 'Fluorodeoxyglucose F18', 'Glucose/*metabolism', 'Humans', 'Male', 'Mental Disorders/*chemically induced/metabolism', 'Middle Aged', 'Psychological Tests', 'Radionuclide Imaging', 'Radiopharmaceuticals']\", 'text': '\"Ecstasy\"-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study.^\\nThe aim of this study was to determine the acute effects of the \"Ecstasy\" analogue MDE (3,4-methylene dioxyethamphetamine) on cerebral glucose metabolism (rMRGlu) of healthy volunteers and to correlate neurometabolism with acute psychopathology. In a randomized double-blind trial, 15 healthy volunteers without a history of drug abuse were examined with fluorine-18-deoxyglucose (18FDG) positron emission tomography (PET) 110-120 min after oral administration of 2 mg/kg MDE (n = 7) or placebo (n = 8). Two minutes prior to radiotracer injection, constant cognitive stimulation was started and maintained for 32 min using a word repetition paradigm to ensure constant and comparable mental conditions during cerebral glucose uptake. Individual brain anatomy was represented using Tl-weighted 3D flash magnetic resonance imaging (MRI), followed by manual regionalization into 108 regions of interest and PET/MRI overlay. After absolute quantification of rMRGlu and normalization to global metabolism, normalized rMRGlu under MDE was compared to placebo using the Mann-Whitney U-test. Acute psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and rMRGlu was correlated to PANSS scores according to Spearman. MDE subjects showed significantly decreased rMRGlu in the bilateral frontal cortex: left frontal posterior (-7.1%, P < 0.05) and right prefrontal superior (-4.6%, P < 0.05). On the other hand, rMRGlu was significantly increased in the bilateral cerebellum (right: +10.1%, P < 0.05; left: +7.6%, P < 0.05) and in the right putamen (+6.2%, P < 0.05). There were positive correlations between rMRGlu in the middle right cingulate and grandiosity (r = 0.87, P < 0.05), both the right amygdala (r = 0.90, P < 0.01) and the left posterior cingulate (r = 0.90, P < 0.01) to difficulties in abstract thinking, and the right frontal inferior (r = 0.85, P < 0.05), right anterior cingulate (r = 0.93, P < 0.01), and left anterior cingulate (r = 0.85, P < 0.05) to attentional deficits. A negative correlation was found between the left frontal operculum (Broca\\'s area) and attentional deficits (r = -0.85, P < 0.05). The present study revealed acute neurometabolic changes under the \"Ecstasy\" analogue MDE, indicating a frontostriatocerebellar imbalance paralleling other psychotropic substances or various psychiatric disorders.', 'doi': '10.1007/s002590050497', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/10638409/', 'secondary_title': 'Eur J Nucl Med', '_input_hash': -629238405, '_task_hash': 504183611, 'spans': [{'text': '18', 'start': 108, 'end': 110, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 192, 'end': 199, 'pattern': 611274830}, {'text': '15', 'start': 409, 'end': 411, 'pattern': 2095658839}, {'text': 'fluorine-18', 'start': 482, 'end': 493, 'pattern': 2095658839}, {'text': '18FDG', 'start': 508, 'end': 513, 'pattern': 2095658839}, {'text': '110', 'start': 550, 'end': 553, 'pattern': 2095658839}, {'text': '120', 'start': 554, 'end': 557, 'pattern': 2095658839}, {'text': '32', 'start': 737, 'end': 739, 'pattern': 2095658839}, {'text': '108', 'start': 1003, 'end': 1006, 'pattern': 2095658839}, {'text': '0.05', 'start': 1485, 'end': 1489, 'pattern': 2095658839}, {'text': '0.05', 'start': 1533, 'end': 1537, 'pattern': 2095658839}, {'text': '+10.1', 'start': 1630, 'end': 1635, 'pattern': 2095658839}, {'text': '0.05', 'start': 1642, 'end': 1646, 'pattern': 2095658839}, {'text': '0.05', 'start': 1665, 'end': 1669, 'pattern': 2095658839}, {'text': '0.05', 'start': 1708, 'end': 1712, 'pattern': 2095658839}, {'text': '0.87', 'start': 1814, 'end': 1818, 'pattern': 2095658839}, {'text': '0.05', 'start': 1824, 'end': 1828, 'pattern': 2095658839}, {'text': '0.90', 'start': 1860, 'end': 1864, 'pattern': 2095658839}, {'text': '0.01', 'start': 1870, 'end': 1874, 'pattern': 2095658839}, {'text': '0.90', 'start': 1914, 'end': 1918, 'pattern': 2095658839}, {'text': '0.01', 'start': 1924, 'end': 1928, 'pattern': 2095658839}, {'text': '0.85', 'start': 2004, 'end': 2008, 'pattern': 2095658839}, {'text': '0.05', 'start': 2014, 'end': 2018, 'pattern': 2095658839}, {'text': '0.93', 'start': 2051, 'end': 2055, 'pattern': 2095658839}, {'text': '0.01', 'start': 2061, 'end': 2065, 'pattern': 2095658839}, {'text': '0.85', 'start': 2101, 'end': 2105, 'pattern': 2095658839}, {'text': '0.05', 'start': 2111, 'end': 2115, 'pattern': 2095658839}, {'text': '-0.85', 'start': 2255, 'end': 2260, 'pattern': 2095658839}, {'text': '0.05', 'start': 2266, 'end': 2270, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 2340, 'end': 2347, 'pattern': 611274830}], 'meta': {'pattern': '14, 8, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 8'}}\n",
      "0.5\n",
      "{'record_id': 2301, 'keywords': \"['Activities of Daily Living/psychology', '*Chronic Pain/diagnosis/etiology', 'Duration of Therapy', 'Female', 'Functional Status', 'Humans', 'Injury Severity Score', '*Long Term Adverse Effects/chemically induced/diagnosis/epidemiology/prevention &', 'control', 'Male', 'Mental Health/*statistics & numerical data', 'Middle Aged', 'Prognosis', '*Psychotropic Drugs/administration & dosage/adverse effects/classification', '*Quality of Life', 'Social Interaction/*drug effects', 'Toxicity Tests/methods/statistics & numerical data', 'United States/epidemiology', '*Wounds and Injuries/complications/drug therapy/psychology/rehabilitation']\", 'text': \"Long-term outcomes of psychoactive drug use in trauma patients: A multicenter patient-reported outcomes study.^\\nINTRODUCTION: Psychoactive drug use (PDU) is reported in up to 40% of trauma patients and is associated with a higher rate of in-hospital complications. However, little is known about its long-term impact on trauma patients. We aimed to assess the long-term functional, mental, and psychosocial outcomes of PDU in trauma patients 6 to 12 months after injury. METHODS: Trauma patients with moderate to severe injuries (Injury Severity Score, >9) who had a toxicology screen upon admission to one of three level 1 trauma centers were contacted by phone 6 to 12 months postinjury. Psychoactive drug use was defined as the presence of a psychoactive, nonprescribed substance on toxicology screen including amphetamine, barbiturate, benzodiazepine, cannabinoid, methamphetamine, methadone, opioid, oxycodone, methylenedioxymethamphetamine (ecstasy), phencyclidine, tricyclic antidepressant, and cocaine. The interviews systematically evaluated functional limitations, social functioning, chronic pain, and mental health (posttraumatic stress disorder, depression, anxiety). Patients with a score of ≤47 on the Short-Form Health Survey version 2.0 social functioning subdomain were considered to have social dysfunction. Multivariable regression models were built to determine the independent association between PDU and long-term outcomes. RESULTS: Of the 1,699 eligible patients, 571 (34%) were included in the analysis, and 173 (30.3%) screened positive for PDU on admission. Patients with PDU were younger (median age [interquartile range], 43 [28-55] years vs. 66 [46-78] years, p < 0.001), had more penetrating injuries (8.7% vs. 4.3%, p = 0.036), and were less likely to have received a college education (41.3% vs. 54.5%, p = 0.004). After adjusting for patients' characteristics including the presence of a baseline psychiatric comorbidity, patients with PDU on admission were more likely to suffer from daily chronic pain, mental health disorders, and social dysfunction 6 to 12 months after injury. There was no difference in the functional limitations between patients with and without PDU. CONCLUSION: On the long term, PDU in trauma patients is strongly and independently associated with worse mental health, more chronic pain, and severe impairment in social functioning. A trauma hospitalization presents an opportunity to identify patients at risk and to mitigate the long-term impact of PDU on recovery. LEVEL OF EVIDENCE: Prognostic/epidemiologic, level III.\", 'doi': '10.1097/ta.0000000000003032', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33264267/', 'secondary_title': 'J Trauma Acute Care Surg', '_input_hash': 878450658, '_task_hash': -967815919, 'spans': [{'text': '40', 'start': 175, 'end': 177, 'pattern': 2095658839}, {'text': '12', 'start': 447, 'end': 449, 'pattern': 2095658839}, {'text': '12', 'start': 668, 'end': 670, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 947, 'end': 954, 'pattern': 611274830}, {'text': '≤47', 'start': 1206, 'end': 1209, 'pattern': 2095658839}, {'text': '1,699', 'start': 1463, 'end': 1468, 'pattern': 2095658839}, {'text': '571', 'start': 1488, 'end': 1491, 'pattern': 2095658839}, {'text': '34', 'start': 1493, 'end': 1495, 'pattern': 2095658839}, {'text': '173', 'start': 1533, 'end': 1536, 'pattern': 2095658839}, {'text': '30.3', 'start': 1538, 'end': 1542, 'pattern': 2095658839}, {'text': '43', 'start': 1651, 'end': 1653, 'pattern': 2095658839}, {'text': '28', 'start': 1655, 'end': 1657, 'pattern': 2095658839}, {'text': '55', 'start': 1658, 'end': 1660, 'pattern': 2095658839}, {'text': '66', 'start': 1672, 'end': 1674, 'pattern': 2095658839}, {'text': '46', 'start': 1676, 'end': 1678, 'pattern': 2095658839}, {'text': '78', 'start': 1679, 'end': 1681, 'pattern': 2095658839}, {'text': '0.001', 'start': 1694, 'end': 1699, 'pattern': 2095658839}, {'text': '0.036', 'start': 1752, 'end': 1757, 'pattern': 2095658839}, {'text': '41.3', 'start': 1819, 'end': 1823, 'pattern': 2095658839}, {'text': '54.5', 'start': 1829, 'end': 1833, 'pattern': 2095658839}, {'text': '0.004', 'start': 1840, 'end': 1845, 'pattern': 2095658839}, {'text': '12', 'start': 2092, 'end': 2094, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 8, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 531, 'keywords': \"['Antidepressive Agents/adverse effects', 'Depression/drug therapy', '*Depressive Disorder, Major/drug therapy', 'Female', 'Humans', '*Ketamine/adverse effects', 'Male', 'bipolar disorder', 'depression', 'depressive disorder', 'esketamine', 'ketamine', 'major', 'meta-analysis', 'randomized controlled trials']\", 'text': \"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.^\\nBACKGROUND: Racemic ketamine and esketamine have demonstrated rapid antidepressant effects. We aimed to review the efficacy and safety of racemic and esketamine for depression. RESEARCH DESIGN AND METHODS: We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021. We conducted random-effects meta-analyses using pooled rate ratios (RRs) and Cohen's standardized mean differences (d) with their 95% confidence intervals (CI). RESULTS: We found 36 studies (2903 participants, 57% female, 45.1 +/- 7.0 years). Nine trials used esketamine, while the rest used racemic ketamine. The overall study quality was high. Treatment with any form of ketamine was associated with improved response (RR=2.14; 95% CI, 1.72-2.66; I2=65%), remission (RR=1.64; 95% CI, 1.33-2.02; I2=39%), and depression severity (d=-0.63; 95% CI, -0.80 to -0.45; I2=78%) against placebo. Overall, there was no association between treatment with any form of ketamine and retention in treatment (RR=1.00; 95% CI, 0.99-1.01; I2<1%), dropouts due to adverse events (RR=1.56; 95% CI, 1.00-2.45; I2<1%), or the overall number of adverse events reported per participant (OR=2.14; 95% CI, 0.82-5.60; I2=62%) against placebo. CONCLUSIONS: Ketamine and esketamine are effective, safe, and acceptable treatments for individuals living with depression.\", 'doi': '10.1080/14740338.2022.2047928', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/35231204/', 'secondary_title': 'Expert Opin Drug Saf', '_input_hash': 765903723, '_task_hash': -2057999015, 'spans': [{'text': 'ketamine', 'start': 31, 'end': 39, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 131, 'end': 139, 'pattern': -1436149968}, {'text': '2021', 'start': 493, 'end': 497, 'pattern': 2095658839}, {'text': '95', 'start': 629, 'end': 631, 'pattern': 2095658839}, {'text': '36', 'start': 678, 'end': 680, 'pattern': 2095658839}, {'text': '2903', 'start': 690, 'end': 694, 'pattern': 2095658839}, {'text': '57', 'start': 709, 'end': 711, 'pattern': 2095658839}, {'text': 'female', 'start': 713, 'end': 719, 'pattern': 1547013372}, {'text': '45.1', 'start': 721, 'end': 725, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 799, 'end': 807, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 872, 'end': 880, 'pattern': -1436149968}, {'text': 'RR=2.14', 'start': 920, 'end': 927, 'pattern': 2095658839}, {'text': '95', 'start': 929, 'end': 931, 'pattern': 2095658839}, {'text': '1.72', 'start': 937, 'end': 941, 'pattern': 2095658839}, {'text': '2.66', 'start': 942, 'end': 946, 'pattern': 2095658839}, {'text': 'I2=65', 'start': 948, 'end': 953, 'pattern': 2095658839}, {'text': 'RR=1.64', 'start': 968, 'end': 975, 'pattern': 2095658839}, {'text': '95', 'start': 977, 'end': 979, 'pattern': 2095658839}, {'text': '1.33', 'start': 985, 'end': 989, 'pattern': 2095658839}, {'text': '2.02', 'start': 990, 'end': 994, 'pattern': 2095658839}, {'text': 'I2=39', 'start': 996, 'end': 1001, 'pattern': 2095658839}, {'text': 'd=-0.63', 'start': 1030, 'end': 1037, 'pattern': 2095658839}, {'text': '95', 'start': 1039, 'end': 1041, 'pattern': 2095658839}, {'text': '-0.80', 'start': 1047, 'end': 1052, 'pattern': 2095658839}, {'text': '-0.45', 'start': 1056, 'end': 1061, 'pattern': 2095658839}, {'text': 'I2=78', 'start': 1063, 'end': 1068, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1157, 'end': 1165, 'pattern': -1436149968}, {'text': 'RR=1.00', 'start': 1194, 'end': 1201, 'pattern': 2095658839}, {'text': '95', 'start': 1203, 'end': 1205, 'pattern': 2095658839}, {'text': '0.99', 'start': 1211, 'end': 1215, 'pattern': 2095658839}, {'text': '1.01', 'start': 1216, 'end': 1220, 'pattern': 2095658839}, {'text': 'RR=1.56', 'start': 1262, 'end': 1269, 'pattern': 2095658839}, {'text': '95', 'start': 1271, 'end': 1273, 'pattern': 2095658839}, {'text': '1.00', 'start': 1279, 'end': 1283, 'pattern': 2095658839}, {'text': '2.45', 'start': 1284, 'end': 1288, 'pattern': 2095658839}, {'text': 'OR=2.14', 'start': 1364, 'end': 1371, 'pattern': 2095658839}, {'text': '95', 'start': 1373, 'end': 1375, 'pattern': 2095658839}, {'text': '0.82', 'start': 1381, 'end': 1385, 'pattern': 2095658839}, {'text': '5.60', 'start': 1386, 'end': 1390, 'pattern': 2095658839}, {'text': 'I2=62', 'start': 1392, 'end': 1397, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 1430, 'end': 1438, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 14, 14, 14, 14, 13, 14, 9, 9, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 9, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 3637, 'keywords': \"['Double-Blind Method', 'Female', '*Hallucinogens', 'Healthy Volunteers', 'Humans', '*Lysergic Acid Diethylamide', 'Male', 'Psilocybin/pharmacology']\", 'text': 'Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.^\\nGrowing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25\\u2009h sessions and received placebo, LSD (100 and 200\\u2009µg), and psilocybin (15 and 30\\u2009mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200\\u2009µg LSD and 30\\u2009mg psilocybin produced comparable subjective effects. The 15\\u2009mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30\\u2009mg psilocybin. The 200\\u2009µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100\\u2009µg dose. The 200\\u2009µg dose of LSD increased only ratings of ineffability significantly more than 30\\u2009mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research.Trial registration: ClinicalTrials.gov identifier: NCT03604744.', 'doi': '10.1038/s41386-022-01297-2', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/35217796/', 'secondary_title': 'Neuropsychopharmacology', '_input_hash': 1861313115, '_task_hash': 2104170036, 'spans': [{'text': 'psilocybin', 'start': 73, 'end': 83, 'pattern': 1563408733}, {'text': 'LSD', 'start': 217, 'end': 220, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 226, 'end': 236, 'pattern': 1563408733}, {'text': 'LSD', 'start': 367, 'end': 370, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 375, 'end': 385, 'pattern': 1563408733}, {'text': '28', 'start': 506, 'end': 508, 'pattern': 2095658839}, {'text': '14', 'start': 527, 'end': 529, 'pattern': 2095658839}, {'text': '14', 'start': 537, 'end': 539, 'pattern': 2095658839}, {'text': '25', 'start': 564, 'end': 566, 'pattern': 2095658839}, {'text': 'LSD', 'start': 600, 'end': 603, 'pattern': -496918669}, {'text': '100', 'start': 605, 'end': 608, 'pattern': 2095658839}, {'text': '200', 'start': 613, 'end': 616, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 626, 'end': 636, 'pattern': 1563408733}, {'text': '15', 'start': 638, 'end': 640, 'pattern': 2095658839}, {'text': '30', 'start': 645, 'end': 647, 'pattern': 2095658839}, {'text': '10', 'start': 690, 'end': 692, 'pattern': 2095658839}, {'text': '100', 'start': 951, 'end': 954, 'pattern': 2095658839}, {'text': '200', 'start': 959, 'end': 962, 'pattern': 2095658839}, {'text': 'LSD', 'start': 966, 'end': 969, 'pattern': -496918669}, {'text': '30', 'start': 974, 'end': 976, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 980, 'end': 990, 'pattern': 1563408733}, {'text': '15', 'start': 1035, 'end': 1037, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1041, 'end': 1051, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1128, 'end': 1131, 'pattern': -496918669}, {'text': '30', 'start': 1136, 'end': 1138, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1142, 'end': 1152, 'pattern': 1563408733}, {'text': '200', 'start': 1158, 'end': 1161, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1173, 'end': 1176, 'pattern': -496918669}, {'text': '100', 'start': 1279, 'end': 1282, 'pattern': 2095658839}, {'text': '200', 'start': 1296, 'end': 1299, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1311, 'end': 1314, 'pattern': -496918669}, {'text': '30', 'start': 1378, 'end': 1380, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1384, 'end': 1394, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1396, 'end': 1399, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 1455, 'end': 1465, 'pattern': 1563408733}, {'text': 'Psilocybin', 'start': 1467, 'end': 1477, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1513, 'end': 1516, 'pattern': -496918669}, {'text': 'LSD', 'start': 1526, 'end': 1529, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 1561, 'end': 1571, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1587, 'end': 1590, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 1595, 'end': 1605, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1696, 'end': 1699, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 1704, 'end': 1714, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1797, 'end': 1800, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 1822, 'end': 1832, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1964, 'end': 1967, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 1972, 'end': 1982, 'pattern': 1563408733}, {'text': 'LSD', 'start': 2049, 'end': 2052, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 2057, 'end': 2067, 'pattern': 1563408733}, {'text': 'LSD', 'start': 2129, 'end': 2132, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 2137, 'end': 2147, 'pattern': 1563408733}, {'text': 'NCT03604744', 'start': 2330, 'end': 2341, 'pattern': 2095658839}], 'meta': {'pattern': '1, 0, 1, 0, 1, 14, 14, 14, 14, 0, 14, 14, 1, 14, 14, 14, 14, 14, 0, 14, 1, 14, 1, 0, 14, 1, 14, 0, 14, 14, 0, 14, 1, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 14'}}\n",
      "0.5\n",
      "{'record_id': 2480, 'keywords': \"['Adult', 'Cross-Over Studies', 'Double-Blind Method', '*Hallucinogens/pharmacology', 'Healthy Volunteers', 'Humans', '*Lysergic Acid Diethylamide/adverse effects', '*Hallucinogen', '*lsd', '*Lysergic acid diethylamide', '*implementation science', '*psychedelic']\", 'text': 'Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.^\\nBACKGROUND: Classic psychedelics hold promise as therapeutics for psychiatric disorders, but require scalable intervention protocols. This proof-of-concept study evaluated the safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100\\u2009µg lysergic acid diethylamide (LSD) in healthy adults within a novel intervention paradigm. METHODS: Up to three participants were administered LSD on the same day in separate rooms, each with a single attendant, after 1\\u2009day of preparation. An open-label design and a double-blind placebo-controlled design were used. RESULTS: Ninety-one percent of participants completed the study. Thirty-two adults (mean age\\u2009=\\u200928.8\\u2009years) received 50 (n\\u2009=\\u20093), 75 (n\\u2009=\\u20097), 100 (n\\u2009=\\u20093) LSD, 50\\u2009µg followed by 75\\u2009µg LSD (n\\u2009=\\u20099) 1\\u2009week apart, or placebo followed by a 75 µg LSD (n\\u2009=\\u200910) 1\\u2009week apart. There were no serious adverse events. Twenty-eight percent of participants experienced at least one expected mild adverse event, with one expected moderate adverse event. The maximum blood plasma levels occurred between 1.2 and 2\\u2009h post-administration, with an apparent half-life between 2.8 and 4.3\\u2009h. LSD largely induced greater subjective effects versus placebo. CONCLUSION: In the current novel intervention paradigm, 50, 75, and 100\\u2009µg LSD are tolerable with favourable safety profiles in healthy adults, only mild adverse events during the day of drug administration, and mystical-type subjective experiences. Future studies are needed to evaluate safety, tolerability, subjective effects, and cost-effectiveness in clinical populations.', 'doi': '10.1177/02698811211069103', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/35253516/', 'secondary_title': 'J Psychopharmacol', '_input_hash': -1710497161, '_task_hash': 250263921, 'spans': [{'text': '50', 'start': 66, 'end': 68, 'pattern': 2095658839}, {'text': '75', 'start': 70, 'end': 72, 'pattern': 2095658839}, {'text': '100', 'start': 78, 'end': 81, 'pattern': 2095658839}, {'text': 'LSD', 'start': 85, 'end': 88, 'pattern': -496918669}, {'text': '50', 'start': 420, 'end': 422, 'pattern': 2095658839}, {'text': '75', 'start': 424, 'end': 426, 'pattern': 2095658839}, {'text': '100', 'start': 432, 'end': 435, 'pattern': 2095658839}, {'text': 'LSD', 'start': 467, 'end': 470, 'pattern': -496918669}, {'text': 'LSD', 'start': 580, 'end': 583, 'pattern': -496918669}, {'text': '28.8', 'start': 849, 'end': 853, 'pattern': 2095658839}, {'text': '50', 'start': 870, 'end': 872, 'pattern': 2095658839}, {'text': '75', 'start': 882, 'end': 884, 'pattern': 2095658839}, {'text': '100', 'start': 894, 'end': 897, 'pattern': 2095658839}, {'text': 'LSD', 'start': 906, 'end': 909, 'pattern': -496918669}, {'text': '50', 'start': 911, 'end': 913, 'pattern': 2095658839}, {'text': '75', 'start': 929, 'end': 931, 'pattern': 2095658839}, {'text': 'LSD', 'start': 935, 'end': 938, 'pattern': -496918669}, {'text': '75', 'start': 986, 'end': 988, 'pattern': 2095658839}, {'text': 'LSD', 'start': 992, 'end': 995, 'pattern': -496918669}, {'text': '10', 'start': 1001, 'end': 1003, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1322, 'end': 1325, 'pattern': -496918669}, {'text': '50', 'start': 1441, 'end': 1443, 'pattern': 2095658839}, {'text': '75', 'start': 1445, 'end': 1447, 'pattern': 2095658839}, {'text': '100', 'start': 1453, 'end': 1456, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1460, 'end': 1463, 'pattern': -496918669}], 'meta': {'pattern': '14, 14, 14, 0, 14, 14, 14, 0, 0, 14, 14, 14, 14, 0, 14, 14, 0, 14, 0, 14, 0, 14, 14, 14, 0'}}\n",
      "0.5\n",
      "{'record_id': 7719, 'keywords': \"['*cluster headache', '*migraine', 'Adult', 'Clinical article', 'Clinical trial', 'Conference abstract', 'Controlled study', 'Double blind procedure', 'Drug effect', 'Drug safety', 'Drug therapy', 'Effect size', 'Exploratory research', 'Female', 'Follow up', 'Human', 'Low drug dose', 'Male', 'Oral drug administration', 'Pharmacokinetics', 'Randomized controlled trial', 'Therapy effect']\", 'text': 'Sustained reductions in headache burden after the limited administration of low dose psilocybin in migraine and cluster headache: results from two preliminary studies.^\\nBackground: Headache disorders maintain top worldwide disability ratings, urging the continued investigation of novel targets and mechanisms of treatment. Anecdotal evidence suggests that psilocybin, lysergic acid diethylamide (LSD), and other select indoleamine 5‐hydroxytryptamine 2A (5‐HT2A) receptor ligands confer sustained therapeutic benefit in cluster and migraine headache, though controlled studies are lacking. We sought to carry out the first controlled investigations of the effects and safety of psilocybin in these headache disorders. Methods: Two exploratory clinical trials were carried out in adult males and females with migraine or cluster headache (twelve each). The migraine design was a double‐blind, placebocontrolled, cross‐over study and the cluster design was a randomized, double‐blind, placebo‐controlled study. Migraine subjects received single administrations of oral placebo (microcrystalline cellulose) and psilocybin (0.143 mg/kg) two weeks apart. Cluster subjects were randomized to receive a pulse regimen of three administrations of either psilocybin (0.143 mg/ kg) or placebo, each administration separated by approximately 5 days. Headache diaries, in which subjects documented headache attacks, began two weeks before the first test day and ended two weeks after the second test day for migraine subjects and two months after the last test day for cluster subjects. Physiological and psychological drug effects were monitored during sessionsand several follow‐up contacts with subjects were carried out to assure safety of study procedures. Ten subjects in each the migraine and cluster studies were included in the final analysis. Results: Over the 2‐week period after single drug administration, the reduction in weekly migraine days from baseline was significantly greater after psilocybin [‐1.65 (95% CI: ‐2.53 to ‐0.77) days/week] than after placebo [‐0.15 (‐1.13 to 0.83) days/ week; p = 0.003, t(9) = 4.11; effect size ‐1.15]. Over the 3‐week period after initiating the pulse regimen, the reduction in weekly cluster attacks from baseline was greater with psilocybin [‐6.03 (‐9.96 to ‐2.10)] than with placebo [+1.17 (‐2.76 to 5.10); p = 0.017, t(8) = 2.99; effect size ‐1.89]. In neither study did the rating of psychedelic effects during acute psilocybin exposure correlate with the change in headache burden. Psilocybin was welltolerated in both studies and there were no unexpected or serious adverse events. Conclusions: These two exploratory controlled trials showed that limited administration of a low oral dose of psilocybin has sustained therapeutic effects in migraine and cluster headache. These findings validate the potential value of psilocybin in headache research and medicine. That the reductions in headache burden were not correlated with acute psychedelic effects in these studies urges the consideration of the several neurobiological functions common to both headache pathology and the known actions of select 5‐HT2A receptor ligands as potential sources of therapeutic effects in headache.', 'doi': '10.1038/s41386-020-00889-0', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/33279933/', 'secondary_title': 'Neuropsychopharmacology', '_input_hash': 2086621401, '_task_hash': 990768146, 'spans': [{'text': 'psilocybin', 'start': 85, 'end': 95, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 357, 'end': 367, 'pattern': 1563408733}, {'text': 'LSD', 'start': 397, 'end': 400, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 679, 'end': 689, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 1109, 'end': 1119, 'pattern': 1563408733}, {'text': '0.143', 'start': 1121, 'end': 1126, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1246, 'end': 1256, 'pattern': 1563408733}, {'text': '0.143', 'start': 1258, 'end': 1263, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1991, 'end': 2001, 'pattern': 1563408733}, {'text': '‐1.65', 'start': 2003, 'end': 2008, 'pattern': 2095658839}, {'text': '95', 'start': 2010, 'end': 2012, 'pattern': 2095658839}, {'text': '‐2.53', 'start': 2018, 'end': 2023, 'pattern': 2095658839}, {'text': '‐0.77', 'start': 2027, 'end': 2032, 'pattern': 2095658839}, {'text': '‐0.15', 'start': 2065, 'end': 2070, 'pattern': 2095658839}, {'text': '‐1.13', 'start': 2072, 'end': 2077, 'pattern': 2095658839}, {'text': '0.83', 'start': 2081, 'end': 2085, 'pattern': 2095658839}, {'text': '0.003', 'start': 2103, 'end': 2108, 'pattern': 2095658839}, {'text': '4.11', 'start': 2117, 'end': 2121, 'pattern': 2095658839}, {'text': '‐1.15', 'start': 2135, 'end': 2140, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 2273, 'end': 2283, 'pattern': 1563408733}, {'text': '‐6.03', 'start': 2285, 'end': 2290, 'pattern': 2095658839}, {'text': '‐9.96', 'start': 2292, 'end': 2297, 'pattern': 2095658839}, {'text': '‐2.10', 'start': 2301, 'end': 2306, 'pattern': 2095658839}, {'text': '+1.17', 'start': 2328, 'end': 2333, 'pattern': 2095658839}, {'text': '‐2.76', 'start': 2335, 'end': 2340, 'pattern': 2095658839}, {'text': '5.10', 'start': 2344, 'end': 2348, 'pattern': 2095658839}, {'text': '0.017', 'start': 2355, 'end': 2360, 'pattern': 2095658839}, {'text': '2.99', 'start': 2369, 'end': 2373, 'pattern': 2095658839}, {'text': '‐1.89', 'start': 2387, 'end': 2392, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 2463, 'end': 2473, 'pattern': 1563408733}, {'text': 'Psilocybin', 'start': 2529, 'end': 2539, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 2740, 'end': 2750, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 2866, 'end': 2876, 'pattern': 1563408733}], 'meta': {'pattern': '1, 1, 0, 1, 1, 14, 1, 14, 1, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 1, 14, 14, 14, 14, 14, 14, 14, 14, 14, 1, 1, 1, 1'}}\n",
      "0.5\n",
      "{'record_id': 3977, 'keywords': \"['Esketamine', 'major depressive disorder', 'patient-reported outcomes', 'pooled analysis', 'suicidal ideation', 'Antidepressant Drugs', 'Drug Therapy', 'Ketamine', 'Major Depression', 'Satisfaction', 'Treatment Effectiveness Evaluation', 'Health Related Quality of Life']\", 'text': 'Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: A pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).^\\nPurpose To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI). Methods Patient-level data from two phase 3 studies (ASPIRE I; ASPIRE II) of esketamine + standard of care (SOC) in patients (aged 18–64 years) with MDSI, were pooled. PROs were evaluated from baseline through end of the double-blind treatment phase (day 25). Outcome assessments included: Beck Hopelessness Scale (BHS), Quality of Life (QoL) in Depression Scale (QLDS), European QoL Group-5-Dimension-5-Level (EQ-5D-5L), and 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). Changes in BHS and QLDS scores (baseline to day 25) were analyzed using a mixed-effects model for repeated measures (MMRM). Results Pooled data for esketamine + SOC (n = 226; mean age: 40.5 years, 59.3% females) and placebo + SOC (n = 225; mean age: 39.6 years, 62.2% females) were analyzed. Mean ± SD change from baseline to day 25, esketamine + SOC vs placebo + SOC (least-square mean difference [95% CI] based on MMRM): BHS total score, − 7.4 ± 6.7 vs − 6.8 ± 6.5 [− 1.0 (− 2.23, 0.21)]; QLDS score, − 14.4 ± 11.5 vs − 12.2 ± 10.8 [− 3.1 (− 5.21, − 1.02)]. Relative risk (95% CI) of reporting perceived problems (slight to extreme) in EQ-5D-5L dimensions (day 25) in esketamine + SOC vs placebo + SOC: mobility [0.78 (0.50, 1.20)], self-care [0.83 (0.55, 1.27)], usual activities [0.87 (0.72, 1.05)], pain/discomfort [0.85 (0.69, 1.04)], and anxiety/depression [0.90 (0.80, 1.00)]. Mean ± SD changes from baseline in esketamine + SOC vs placebo + SOC for health status index: 0.23 ± 0.21 vs 0.19 ± 0.22; and for EQ-Visual Analogue Scale: 24.0 ± 27.2 vs 19.3 ± 24.4. At day 25, mean ± SD in domains of TSQM-9 scores in esketamine + SOC vs placebo + SOC were: effectiveness, 67.2 ± 25.3 vs 56.2 ± 26.8; global satisfaction, 69.9 ± 25.2 vs 56.3 ± 27.8; and convenience, 74.0 ± 19.4 vs 75.4 ± 18.7. Conclusion These PRO data support the patient perspective of the effect associated with esketamine + SOC in improving health-related QoL in patients with MDSI. (PsycInfo Database Record (c) 2023 APA, all rights reserved)', 'doi': '10.1007/s11136-023-03451-9', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/37439961/', 'secondary_title': 'Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation', '_input_hash': -1681804661, '_task_hash': -2046932847, 'spans': [{'text': '18–64', 'start': 517, 'end': 522, 'pattern': 2095658839}, {'text': '25', 'start': 641, 'end': 643, 'pattern': 2095658839}, {'text': '25', 'start': 929, 'end': 931, 'pattern': 2095658839}, {'text': '226', 'start': 1051, 'end': 1054, 'pattern': 2095658839}, {'text': '40.5', 'start': 1066, 'end': 1070, 'pattern': 2095658839}, {'text': '59.3', 'start': 1078, 'end': 1082, 'pattern': 2095658839}, {'text': '225', 'start': 1116, 'end': 1119, 'pattern': 2095658839}, {'text': '39.6', 'start': 1131, 'end': 1135, 'pattern': 2095658839}, {'text': '62.2', 'start': 1143, 'end': 1147, 'pattern': 2095658839}, {'text': '25', 'start': 1211, 'end': 1213, 'pattern': 2095658839}, {'text': '95', 'start': 1280, 'end': 1282, 'pattern': 2095658839}, {'text': '2.23', 'start': 1358, 'end': 1362, 'pattern': 2095658839}, {'text': '0.21', 'start': 1364, 'end': 1368, 'pattern': 2095658839}, {'text': '14.4', 'start': 1386, 'end': 1390, 'pattern': 2095658839}, {'text': '11.5', 'start': 1393, 'end': 1397, 'pattern': 2095658839}, {'text': '12.2', 'start': 1403, 'end': 1407, 'pattern': 2095658839}, {'text': '10.8', 'start': 1410, 'end': 1414, 'pattern': 2095658839}, {'text': '5.21', 'start': 1425, 'end': 1429, 'pattern': 2095658839}, {'text': '1.02', 'start': 1433, 'end': 1437, 'pattern': 2095658839}, {'text': '95', 'start': 1456, 'end': 1458, 'pattern': 2095658839}, {'text': '25', 'start': 1544, 'end': 1546, 'pattern': 2095658839}, {'text': '0.78', 'start': 1596, 'end': 1600, 'pattern': 2095658839}, {'text': '0.50', 'start': 1602, 'end': 1606, 'pattern': 2095658839}, {'text': '1.20', 'start': 1608, 'end': 1612, 'pattern': 2095658839}, {'text': '0.83', 'start': 1627, 'end': 1631, 'pattern': 2095658839}, {'text': '0.55', 'start': 1633, 'end': 1637, 'pattern': 2095658839}, {'text': '1.27', 'start': 1639, 'end': 1643, 'pattern': 2095658839}, {'text': '0.87', 'start': 1665, 'end': 1669, 'pattern': 2095658839}, {'text': '0.72', 'start': 1671, 'end': 1675, 'pattern': 2095658839}, {'text': '1.05', 'start': 1677, 'end': 1681, 'pattern': 2095658839}, {'text': '0.85', 'start': 1702, 'end': 1706, 'pattern': 2095658839}, {'text': '0.69', 'start': 1708, 'end': 1712, 'pattern': 2095658839}, {'text': '1.04', 'start': 1714, 'end': 1718, 'pattern': 2095658839}, {'text': '0.90', 'start': 1746, 'end': 1750, 'pattern': 2095658839}, {'text': '0.80', 'start': 1752, 'end': 1756, 'pattern': 2095658839}, {'text': '1.00', 'start': 1758, 'end': 1762, 'pattern': 2095658839}, {'text': '0.23', 'start': 1860, 'end': 1864, 'pattern': 2095658839}, {'text': '0.21', 'start': 1867, 'end': 1871, 'pattern': 2095658839}, {'text': '0.19', 'start': 1875, 'end': 1879, 'pattern': 2095658839}, {'text': '0.22', 'start': 1882, 'end': 1886, 'pattern': 2095658839}, {'text': '24.0', 'start': 1922, 'end': 1926, 'pattern': 2095658839}, {'text': '27.2', 'start': 1929, 'end': 1933, 'pattern': 2095658839}, {'text': '19.3', 'start': 1937, 'end': 1941, 'pattern': 2095658839}, {'text': '24.4', 'start': 1944, 'end': 1948, 'pattern': 2095658839}, {'text': '25', 'start': 1957, 'end': 1959, 'pattern': 2095658839}, {'text': '67.2', 'start': 2057, 'end': 2061, 'pattern': 2095658839}, {'text': '25.3', 'start': 2064, 'end': 2068, 'pattern': 2095658839}, {'text': '56.2', 'start': 2072, 'end': 2076, 'pattern': 2095658839}, {'text': '26.8', 'start': 2079, 'end': 2083, 'pattern': 2095658839}, {'text': '69.9', 'start': 2106, 'end': 2110, 'pattern': 2095658839}, {'text': '25.2', 'start': 2113, 'end': 2117, 'pattern': 2095658839}, {'text': '56.3', 'start': 2121, 'end': 2125, 'pattern': 2095658839}, {'text': '27.8', 'start': 2128, 'end': 2132, 'pattern': 2095658839}, {'text': '74.0', 'start': 2151, 'end': 2155, 'pattern': 2095658839}, {'text': '19.4', 'start': 2158, 'end': 2162, 'pattern': 2095658839}, {'text': '75.4', 'start': 2166, 'end': 2170, 'pattern': 2095658839}, {'text': '18.7', 'start': 2173, 'end': 2177, 'pattern': 2095658839}, {'text': '2023', 'start': 2369, 'end': 2373, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 7621, 'keywords': \"['Administration, Oral', 'Adult', 'Antidepressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Banisteriopsis/*chemistry', 'Brain/blood supply/drug effects', 'Depressive Disorder, Major/*drug therapy/physiopathology', 'Female', 'Hallucinogens/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Plant Preparations/administration & dosage/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Recurrence', 'Time Factors', 'Tomography, Emission-Computed, Single-Photon', 'Treatment Outcome']\", 'text': 'Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.^\\nAyahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.', 'doi': '10.1097/jcp.0000000000000436', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/26650973/', 'secondary_title': 'J Clin Psychopharmacol', '_input_hash': -1408452966, '_task_hash': 1209935650, 'spans': [{'text': 'Ayahuasca', 'start': 43, 'end': 52, 'pattern': -1438173035}, {'text': 'Ayahuasca', 'start': 108, 'end': 117, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 305, 'end': 314, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 492, 'end': 501, 'pattern': -1438173035}, {'text': '17', 'start': 652, 'end': 654, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 715, 'end': 724, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 986, 'end': 995, 'pattern': -1438173035}, {'text': '14', 'start': 1014, 'end': 1016, 'pattern': 2095658839}, {'text': '21', 'start': 1022, 'end': 1024, 'pattern': 2095658839}, {'text': 'Ayahuasca', 'start': 1163, 'end': 1172, 'pattern': -1438173035}, {'text': '80', 'start': 1464, 'end': 1466, 'pattern': 2095658839}, {'text': '21', 'start': 1482, 'end': 1484, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1666, 'end': 1675, 'pattern': -1438173035}, {'text': 'Ayahuasca', 'start': 1684, 'end': 1693, 'pattern': -1438173035}, {'text': '47', 'start': 1779, 'end': 1781, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1827, 'end': 1836, 'pattern': -1438173035}], 'meta': {'pattern': '5, 5, 5, 5, 14, 5, 5, 14, 14, 5, 14, 14, 5, 5, 14, 5'}}\n",
      "0.5\n",
      "{'record_id': 4711, 'keywords': \"['Adolescent', 'Adult', 'Antipsychotic Agents/*therapeutic use', 'Benzodiazepines', 'Female', 'Follow-Up Studies', 'Hallucinogens/*adverse effects', 'Humans', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects', 'Olanzapine', 'Pirenzepine/analogs & derivatives/*therapeutic use', 'Psychiatric Status Rating Scales', 'Psychoses, Substance-Induced/*drug therapy/etiology/psychology']\", 'text': 'Ecstasy-induced psychotic disorder: six-month follow-up study.^\\nOBJECTIVE: To describe the psychiatric symptoms manifested by persons diagnosed for the first time as having ecstasy-induced psychotic disorder and to explore the evolution of their symptoms over a 6-month period. DESIGN: Observational study with a 6-month follow-up. METHOD: The subjects studied were 32 ecstasy consumers who were treated at two drug-dependency outpatient centers for hallucinatory-delusive manifestations and who were diagnosed as having ecstasy-induced psychotic disorder according to DSM-IV criteria. For the assessment of the intensity of the syndrome and its follow-up, the Brief Psychiatric Rating Scale (BPRS), the Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression (CGI) were used at the outset and after 1, 3 and 6 months. All subjects received treatment with olanzapine. RESULTS: The treatment program was completed by 96.9% of the patients. At the baseline assessment, a high incidence of symptoms of a severe psychiatric disorder was observed. From the first month the psychotic symptoms (BPRS) were considerably reduced with treatment, with the most severe positive symptoms remitting in the first 3 months. The three assessment indicators (BPRS, HDRS and CGI) showed a statistically significant clinical reduction over the 6 months of the assessment period. Furthermore, no relevant side effects were noted. CONCLUSIONS: In its initial manifestations, a drug-induced psychotic syndrome includes marked symptoms meeting the criteria of a severe psychotic disorder, with the presence of considerable positive and negative symptoms. Olanzapine has been shown to be very effective in these situations and its use is suggested as first-choice therapy.', 'doi': '10.1159/000059383', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/12065963/', 'secondary_title': 'Eur Addict Res', '_input_hash': -487644919, '_task_hash': -110722161, 'spans': [{'text': 'Ecstasy', 'start': 0, 'end': 7, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 173, 'end': 180, 'pattern': 611274830}, {'text': '32', 'start': 366, 'end': 368, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 369, 'end': 376, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 521, 'end': 528, 'pattern': 611274830}, {'text': '96.9', 'start': 935, 'end': 939, 'pattern': 2095658839}], 'meta': {'pattern': '8, 8, 14, 8, 8, 14'}}\n",
      "0.5\n",
      "{'record_id': 3095, 'keywords': \"['Adrenergic Uptake Inhibitors/*adverse effects', 'Adult', 'Analysis of Variance', 'Cannabis/*adverse effects', 'Female', 'Fenfluramine/administration & dosage/blood', 'Humans', 'Illicit Drugs/*adverse effects', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects', 'Neurosecretory Systems/*abnormalities', 'Prolactin/metabolism', 'Serotonin Agents/administration & dosage/blood', 'Time Factors']\", 'text': 'Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?.^\\nBACKGROUND: The purpose of this study was to investigate neuroendocrine function in ecstasy (3,4-methylenedioxymethamphetamine = MDMA) users and controls. METHODS: Prolactin response to d-fenfluramine was assessed in abstinent ecstasy users with concomitant use of cannabis only (n = 24, male/female 13/11) and in two control groups: healthy nonusers (n = 13, female) and exclusive cannabis users (n = 7, male). RESULTS: Prolactin response to d-fenfluramine was slightly blunted in female ecstasy users. Both male user samples exhibited a weak prolactin response to d-fenfluramine, but this was weaker in the group of cannabis users. Baseline prolactin and prolactin response to d-fenfluramine were associated with the extent of previous cannabis use. CONCLUSIONS: Endocrinological abnormalities of ecstasy users may be closely related to their coincident cannabis use. Cannabis use may be an important confound in endocrinological studies of ecstasy users and should be looked for more systematically in future studies.', 'doi': '10.1016/s0006-3223(01)01306-3', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/11983191/', 'secondary_title': 'Biol Psychiatry', '_input_hash': -1435137489, '_task_hash': 449150854, 'spans': [{'text': 'ecstasy', 'start': 45, 'end': 52, 'pattern': 611274830}, {'text': 'MDMA', 'start': 54, 'end': 58, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 73, 'end': 80, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 180, 'end': 187, 'pattern': 611274830}, {'text': 'MDMA', 'start': 225, 'end': 229, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 323, 'end': 330, 'pattern': 611274830}, {'text': '24', 'start': 380, 'end': 382, 'pattern': 2095658839}, {'text': 'male', 'start': 384, 'end': 388, 'pattern': -757571895}, {'text': 'female', 'start': 389, 'end': 395, 'pattern': 1547013372}, {'text': '13/11', 'start': 396, 'end': 401, 'pattern': 2095658839}, {'text': '13', 'start': 452, 'end': 454, 'pattern': 2095658839}, {'text': 'female', 'start': 456, 'end': 462, 'pattern': 1547013372}, {'text': 'male', 'start': 501, 'end': 505, 'pattern': -757571895}, {'text': 'female', 'start': 578, 'end': 584, 'pattern': 1547013372}, {'text': 'ecstasy', 'start': 585, 'end': 592, 'pattern': 611274830}, {'text': 'male', 'start': 605, 'end': 609, 'pattern': -757571895}, {'text': 'ecstasy', 'start': 895, 'end': 902, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1039, 'end': 1046, 'pattern': 611274830}], 'meta': {'pattern': '8, 7, 8, 8, 7, 8, 14, 12, 13, 14, 14, 13, 12, 13, 8, 12, 8, 8'}}\n",
      "0.5\n",
      "{'record_id': 7970, 'keywords': \"['Humans', '*Hallucinogens/therapeutic use', 'Depression', 'Anxiety/drug therapy', 'Anxiety Disorders/diagnosis/drug therapy', '*Neoplasms']\", 'text': 'The Impact of Psychedelic Drugs on Anxiety and Depression in Advanced Cancer or other Life-threatening Disease: A Systematic Review With Meta-analysis.^\\nOBJECTIVES: Life-threatening cancer or other diseases can induce anxiety and depressive symptoms. We performed a systematic review with meta-analyses of randomized controlled trials assessing patients with cancer or other life-threatening diseases using validated anxiety and depression scales. METHODS: PubMed was searched up to November 15, 2022 and citations were applied to prespecified inclusion criteria. Disease rating scales for anxiety or depression included the State-Trait Anxiety Inventory (STAI) (STAI Trait [STAI-T], STAI-State [STAI-S]), Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS) (HADS-Anxiety [HADS-A]; HADS-Depression [HADS-D]), Profile of Mood States (POMS), and the Hamilton Rating Scale for Depression (HAM-D or GRID-HAM-D-17). Safety outcomes included assessments of blood pressure and heart rate. RESULTS: Five trials, predominantly in cancer patients, had data assessing anxiety and depressive symptoms. These trials found promising results for psychedelics versus placebo in several anxiety and depression scales but increases in blood pressure and heart rate also occurred. There were some concerns of risk of bias because it is difficult to truly randomize a psychedelic trial and there was a high percentage of patients in the trials who had used psychedelics in the past. There was high heterogeneity for all analyses that we could not explain. CONCLUSIONS: Although the results are promising, future trials are needed to assess the optimal psychedelic, dose, number of sessions required, and how psychedelic naïve patients would respond both psychologically and hemodynamically before this therapy can be considered for widescale clinical use.', 'doi': '10.1097/coc.0000000000000998', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36907889/', 'secondary_title': 'Am J Clin Oncol', '_input_hash': -232332533, '_task_hash': 812088875, 'spans': [{'text': '15', 'start': 492, 'end': 494, 'pattern': 2095658839}, {'text': '2022', 'start': 496, 'end': 500, 'pattern': 2095658839}, {'text': 'D-17', 'start': 930, 'end': 934, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 7460, 'keywords': \"['Adolescent', 'Adult', 'Cross-Sectional Studies', 'Dose-Response Relationship, Drug', 'Female', 'Hallucinogens/*administration & dosage', 'Humans', 'Lysergic Acid Diethylamide/*administration & dosage', 'Male', 'Mental Disorders/epidemiology', 'Psilocybin/*administration & dosage', 'Substance-Related Disorders/*epidemiology', 'Surveys and Questionnaires', 'Young Adult', 'Lsd', 'Psychedelics', 'microdosing', 'psilocybin', 'substance use']\", 'text': 'Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.^\\nRATIONALE: Microdosing psychedelics - the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin - is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. OBJECTIVES: To examine the practices and demographics of a population of psychedelic microdosers - including their psychiatric diagnoses, prescription medications, and recreational substance use patterns - to develop a foundation on which to conduct future clinical research. METHODS: Participants (n = 909; M(age) = 26.9, SD = 8.6; male = 83.2%; White/European = 79.1%) recruited primarily from the online forum Reddit completed an anonymous online survey. Respondents who reported using LSD, psilocybin, or both for microdosing were grouped and compared with non-microdosing respondents using exploratory odds ratio testing on demographic variables, rates of psychiatric diagnoses, and past-year recreational substance use. RESULTS: Of microdosers, most reported using LSD (59.3%; M(dose) = 13\\u2009mcg, or 11.3% of one tab) or psilocybin (25.9%; M(dose) = 0.3\\u2009g of dried psilocybin mushrooms) on a one-day-on, two-days-off schedule. Compared with non-microdosers, microdosers were significantly less likely to report a history of substance use disorders (SUDs; OR = 0.17 (95% CI: 0.05-0.56)) or anxiety disorders (OR = 0.61 (95% CI: 0.41-0.91)). Microdosers were also more likely to report recent recreational substance use compared with non-microdosers (OR = 5.2 (95% CI: 2.7-10.8)). CONCLUSIONS: Well-designed randomized controlled trials are needed to evaluate the safety and tolerability of this practice in clinical populations and to test claims about potential benefits.', 'doi': '10.1177/0269881120908004', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/32108529/', 'secondary_title': 'J Psychopharmacol', '_input_hash': -462712261, '_task_hash': 1854087188, 'spans': [{'text': 'LSD', 'start': 201, 'end': 204, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 208, 'end': 218, 'pattern': 1563408733}, {'text': '909', 'start': 725, 'end': 728, 'pattern': 2095658839}, {'text': '26.9', 'start': 739, 'end': 743, 'pattern': 2095658839}, {'text': 'male', 'start': 755, 'end': 759, 'pattern': -757571895}, {'text': '83.2', 'start': 762, 'end': 766, 'pattern': 2095658839}, {'text': '79.1', 'start': 786, 'end': 790, 'pattern': 2095658839}, {'text': 'LSD', 'start': 911, 'end': 914, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 916, 'end': 926, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1193, 'end': 1196, 'pattern': -496918669}, {'text': '59.3', 'start': 1198, 'end': 1202, 'pattern': 2095658839}, {'text': '13', 'start': 1215, 'end': 1217, 'pattern': 2095658839}, {'text': '11.3', 'start': 1226, 'end': 1230, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1247, 'end': 1257, 'pattern': 1563408733}, {'text': '25.9', 'start': 1259, 'end': 1263, 'pattern': 2095658839}, {'text': 'psilocybin', 'start': 1291, 'end': 1301, 'pattern': 1563408733}, {'text': '0.17', 'start': 1486, 'end': 1490, 'pattern': 2095658839}, {'text': '95', 'start': 1492, 'end': 1494, 'pattern': 2095658839}, {'text': '0.05', 'start': 1500, 'end': 1504, 'pattern': 2095658839}, {'text': '0.56', 'start': 1505, 'end': 1509, 'pattern': 2095658839}, {'text': '0.61', 'start': 1539, 'end': 1543, 'pattern': 2095658839}, {'text': '95', 'start': 1545, 'end': 1547, 'pattern': 2095658839}, {'text': '0.41', 'start': 1553, 'end': 1557, 'pattern': 2095658839}, {'text': '0.91', 'start': 1558, 'end': 1562, 'pattern': 2095658839}, {'text': '95', 'start': 1685, 'end': 1687, 'pattern': 2095658839}, {'text': '10.8', 'start': 1697, 'end': 1701, 'pattern': 2095658839}], 'meta': {'pattern': '0, 1, 14, 14, 12, 14, 14, 0, 1, 0, 14, 14, 14, 1, 14, 1, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 3346, 'keywords': \"['Adolescent', 'Adult', 'Analysis of Variance', 'Antipsychotic Agents/*therapeutic use', 'Contingent Negative Variation/*drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Interactions', 'Electroencephalography', 'Evoked Potentials, Auditory/*drug effects', 'Female', 'Healthy Volunteers', 'Humans', 'Ketamine/*therapeutic use', 'Male', 'Nicotinic Agonists/*therapeutic use', 'Schizophrenia/*drug therapy', 'Young Adult', 'Ketamine', 'Mismatch negativity', 'NMDAR hypofunction', 'Nicotine', 'Schizophrenia']\", 'text': 'Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.^\\nN-methyl-d-aspartate glutamate receptor (NMDAR) hypofunction has been implicated in the pathophysiology of schizophrenia, including auditory processing abnormalities reflected by the mismatch negativity (MMN) event-related potential component. Evidence suggesting cognitive benefits from nicotine administration, together with the high rate of cigarette use in patients with schizophrenia, has stimulated interest in whether nicotine modulates NMDAR hypofunction. We examined the interactive effects of ketamine, an NMDAR antagonist that produces transient schizophrenia-like neurophysiological effects, and nicotine, a nicotinic acetylcholine receptor (nAChR) agonist, in 30 healthy volunteers to determine whether nicotine prevents or attenuates MMN abnormalities. Secondary analyses compared the profile of ketamine and schizophrenia effects on MMN using previously reported data from 24 schizophrenia patients (Hay et al. 2015). Healthy volunteers completed four test days, during which they received ketamine/placebo and nicotine/placebo in a double-blind, counterbalanced design. MMN to intensity, frequency, duration, and frequency+duration double deviant sounds was assessed each day. Ketamine decreased intensity, frequency, and double deviant MMN amplitudes, whereas nicotine increased intensity and double deviant MMN amplitudes. A ketamine×nicotine interaction indicated, however, that nicotine failed to attenuate the decrease in MMN associated with ketamine. Although the present dose of ketamine produced smaller decrements in MMN than those associated with schizophrenia, the profile of effects across deviant types did not differ between ketamine and schizophrenia. Results suggest that while ketamine and schizophrenia produce similar profiles of MMN effects across deviant types, nicotinic agonists may have limited potential to improve these putative NMDAR hypofunction-mediated impairments in schizophrenia.', 'doi': '10.1016/j.schres.2017.06.040', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/28711472/', 'secondary_title': 'Schizophr Res', '_input_hash': -2024316799, '_task_hash': 2069279619, 'spans': [{'text': 'ketamine', 'start': 674, 'end': 682, 'pattern': -1436149968}, {'text': '30', 'start': 844, 'end': 846, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 981, 'end': 989, 'pattern': -1436149968}, {'text': '24', 'start': 1059, 'end': 1061, 'pattern': 2095658839}, {'text': '2015', 'start': 1097, 'end': 1101, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1176, 'end': 1184, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1364, 'end': 1372, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1634, 'end': 1642, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1673, 'end': 1681, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1826, 'end': 1834, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1881, 'end': 1889, 'pattern': -1436149968}], 'meta': {'pattern': '9, 14, 9, 14, 14, 9, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 6635, 'keywords': \"['5 methoxy diisopropyltryptamine', 'alpha methyltryptamine', 'cannabis', 'ketamine', 'lysergide', 'midomafetamine', 'n,n dimethyltryptamine', 'tryptamine derivative', 'unclassified drug', 'adolescent', 'adult', 'article', 'Black person', 'child', 'controlled study', 'cross-sectional study', 'female', 'human', 'income', 'information processing', 'male', 'prevalence', 'priority journal', 'probability sample', 'risk factor', 'school child', 'self report', 'substance use', 'trend study', 'United States']\", 'text': 'Shifting characteristics of ecstasy users ages 12–34 in the United States, 2007–2014.^\\nBackground: Ecstasy/MDMA has been one of the most prevalent party drugs for decades, and powder ecstasy recently increased in popularity. We examined trends in use to determine who to best target for prevention and harm reduction. Methods: Secondary analysis of the 2007–2014 National Survey on Drug Use and Health, a repeated cross-sectional, nationally representative probability sample, was conducted. Linear trends in past-year ecstasy use and trends in demographic and other past-year substance use characteristics among ecstasy users were examined among participants ages 12–34 (N = 332,560). Results: Past-year prevalence of ecstasy use was stable across years at 2% (P = 0.693). Over time, the proportion of ecstasy users with a college degree increased from 11.5% in 2007/08 to 24.5% in 2013/14 (P < 0.001). The proportion of users who were age 12–17 decreased, as did proportions of users who are non-Hispanic black, and reported income <$20,000/year (Ps < 0.001). Prevalence of past-year use of marijuana, LSD, ketamine, and DMT/AMT/Foxy increased among ecstasy users (Ps < 0.05); DMT/AMT/Foxy use increased more than four-fold from 2.1% in 2007/08 to 8.7% in 2013/14. Perception of great risk associated with LSD use decreased among users and ease of obtaining LSD increased (Ps < 0.05). Past-year use of 5 or more other substances also increased over time (P < 0.05). Conclusions: Ecstasy use in the US appears to be increasing among those with college degrees and use of other substances among ecstasy users is growing—particularly use of otherwise rare substances such as tryptamines. Results inform prevention and harm reduction strategies in this increasingly shifting group of ecstasy users.', 'doi': '10.1016/j.drugalcdep.2017.09.011', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/29028555/', 'secondary_title': 'Drug and Alcohol Dependence', '_input_hash': 2080044590, '_task_hash': -2694246, 'spans': [{'text': 'ecstasy', 'start': 28, 'end': 35, 'pattern': 611274830}, {'text': '12–34', 'start': 47, 'end': 52, 'pattern': 2095658839}, {'text': '2007–2014.^', 'start': 75, 'end': 86, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 99, 'end': 106, 'pattern': 611274830}, {'text': 'MDMA', 'start': 107, 'end': 111, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 183, 'end': 190, 'pattern': 611274830}, {'text': '2007–2014', 'start': 353, 'end': 362, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 519, 'end': 526, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 613, 'end': 620, 'pattern': 611274830}, {'text': '12–34', 'start': 665, 'end': 670, 'pattern': 2095658839}, {'text': '332,560', 'start': 676, 'end': 683, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 719, 'end': 726, 'pattern': 611274830}, {'text': '0.693', 'start': 766, 'end': 771, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 803, 'end': 810, 'pattern': 611274830}, {'text': '11.5', 'start': 854, 'end': 858, 'pattern': 2095658839}, {'text': '2007/08', 'start': 863, 'end': 870, 'pattern': 2095658839}, {'text': '24.5', 'start': 874, 'end': 878, 'pattern': 2095658839}, {'text': '2013/14', 'start': 883, 'end': 890, 'pattern': 2095658839}, {'text': '0.001', 'start': 896, 'end': 901, 'pattern': 2095658839}, {'text': '12–17', 'start': 941, 'end': 946, 'pattern': 2095658839}, {'text': '20,000', 'start': 1036, 'end': 1042, 'pattern': 2095658839}, {'text': '0.001', 'start': 1054, 'end': 1059, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1104, 'end': 1107, 'pattern': -496918669}, {'text': 'ketamine', 'start': 1109, 'end': 1117, 'pattern': -1436149968}, {'text': 'DMT', 'start': 1123, 'end': 1126, 'pattern': -394200700}, {'text': 'ecstasy', 'start': 1152, 'end': 1159, 'pattern': 611274830}, {'text': '0.05', 'start': 1172, 'end': 1176, 'pattern': 2095658839}, {'text': 'DMT', 'start': 1179, 'end': 1182, 'pattern': -394200700}, {'text': '2007/08', 'start': 1239, 'end': 1246, 'pattern': 2095658839}, {'text': '2013/14', 'start': 1258, 'end': 1265, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1308, 'end': 1311, 'pattern': -496918669}, {'text': 'LSD', 'start': 1360, 'end': 1363, 'pattern': -496918669}, {'text': '0.05', 'start': 1380, 'end': 1384, 'pattern': 2095658839}, {'text': '0.05', 'start': 1461, 'end': 1465, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 1481, 'end': 1488, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1595, 'end': 1602, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1782, 'end': 1789, 'pattern': 611274830}], 'meta': {'pattern': '8, 14, 14, 8, 7, 8, 14, 8, 8, 14, 14, 8, 14, 8, 14, 14, 14, 14, 14, 14, 14, 14, 0, 9, 4, 8, 14, 4, 14, 14, 0, 0, 14, 14, 8, 8, 8'}}\n",
      "0.5\n",
      "{'record_id': 7214, 'keywords': \"['5-MeO-DMT', 'cognition', 'dose finding', 'psychedelic agents', 'psychoactive']\", 'text': 'A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,\\xa0N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.^\\n5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes. In preparation for a study in patients with depression, the present study GH001-HV-101 aimed to assess the impact of four different dose levels of a novel vaporized 5-MeO-DMT formulation (GH001) administered via inhalation as single doses of 2 (N = 4), 6 (N = 6), 12 (N = 4) and 18\\xa0mg (N = 4), and in an individualized dose escalation regimen (N = 4) on the safety, tolerability, and the dose-related psychoactive effects in healthy volunteers (N = 22). The psychedelic experience was assessed with a novel Peak Experience Scale (PES), the Mystical Experience Questionnaire (MEQ), the Ego Dissolution Inventory (EDI), the Challenging Experience Questionnaire (CEQ), and the 5-Dimensional Altered States of Consciousness Questionnaire (5D-ASC). Further aims were to assess the impact of 5-MeO-DMT on cognitive functioning, mood, and well-being. Higher doses of 5-MeO-DMT produced significant increments in the intensity of the psychedelic experience ratings as compared to the lowest 2\\xa0mg dose on all questionnaires, except the CEQ. Prominent effects were observed following single doses of 6, 12, and 18\\xa0mg on PES and MEQ ratings, while maximal effects on PES, MEQ, EDI, and 5D-ASC ratings were observed following individualized dose escalation of 5-MeO-DMT. Measures of cognition, mood, and well-being were not affected by 5-MeO-DMT. Vital signs at 1 and 3\\xa0h after administration were not affected and adverse events were generally mild and resolved spontaneously. Individualized dose escalation of 5-MeO-DMT may be preferable over single dose administration for clinical applications that aim to maximize the experience to elicit a strong therapeutic response.', 'doi': '10.3389/fphar.2021.760671', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/34912222/', 'secondary_title': 'Front Pharmacol', '_input_hash': -725015228, '_task_hash': 310486356, 'spans': [{'text': 'GH001', 'start': 134, 'end': 139, 'pattern': 2095658839}, {'text': 'DMT', 'start': 205, 'end': 208, 'pattern': -394200700}, {'text': 'GH001', 'start': 469, 'end': 474, 'pattern': 2095658839}, {'text': 'HV-101', 'start': 475, 'end': 481, 'pattern': 2095658839}, {'text': 'DMT', 'start': 566, 'end': 569, 'pattern': -394200700}, {'text': 'GH001', 'start': 583, 'end': 588, 'pattern': 2095658839}, {'text': '12', 'start': 659, 'end': 661, 'pattern': 2095658839}, {'text': '18', 'start': 674, 'end': 676, 'pattern': 2095658839}, {'text': '22', 'start': 844, 'end': 846, 'pattern': 2095658839}, {'text': 'DMT', 'start': 1187, 'end': 1190, 'pattern': -394200700}, {'text': 'DMT', 'start': 1261, 'end': 1264, 'pattern': -394200700}, {'text': '12', 'start': 1488, 'end': 1490, 'pattern': 2095658839}, {'text': '18', 'start': 1496, 'end': 1498, 'pattern': 2095658839}, {'text': 'DMT', 'start': 1649, 'end': 1652, 'pattern': -394200700}, {'text': 'DMT', 'start': 1725, 'end': 1728, 'pattern': -394200700}, {'text': 'DMT', 'start': 1901, 'end': 1904, 'pattern': -394200700}], 'meta': {'pattern': '14, 4, 14, 14, 4, 14, 14, 14, 14, 4, 4, 14, 14, 4, 4, 4'}}\n",
      "0.5\n",
      "{'record_id': 5118, 'keywords': \"['Psychedelics', 'ayahuasca', 'consciousness', 'dimethyltryptamine', 'serotonin']\", 'text': 'Psychological and physiological effects of extended DMT.^\\nN,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make DMT a powerful tool for the neuroscientific study of consciousness and preliminary results show its potential role in treating mental health conditions. In a within-subjects, placebo-controlled study, we investigated a novel method of DMT administration involving a bolus injection paired with a constant-rate infusion, with the goal of extending the DMT experience. Pharmacokinetic parameters of DMT estimated from plasma data of a previous study of bolus intravenous DMT were used to derive dose regimens necessary to keep subjects in steady levels of immersion into the DMT experience over an extended period of 30\\u2009min, and four dose regimens consisting of a bolus loading dose and a slow-rate infusion were tested in eleven healthy volunteers (seven male, four female, mean age\\u2009±\\u2009SD\\u2009=\\u200937.09\\u2009±\\u20098.93\\u2009years). The present method is effective for extending the DMT experience in a stable and tolerable fashion. While subjective effects were maintained over the period of active infusion, anxiety ratings remained low and heart rate habituated within 15\\u2009min, indicating psychological and physiological safety of extended DMT. Plasma DMT concentrations increased consistently starting 10\\u2009min into DMT administration, whereas psychological effects plateaued into the desired steady state, suggesting the development of acute psychological tolerance to DMT. Taken together, these findings demonstrate the safety and effectiveness of continuous IV DMT administration, laying the groundwork for the further development of this method of administration for basic and clinical research.', 'doi': '10.1177/02698811231196877', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/37897244/', 'secondary_title': 'J Psychopharmacol', '_input_hash': -1211733400, '_task_hash': 280603747, 'spans': [{'text': 'DMT', 'start': 82, 'end': 85, 'pattern': -394200700}, {'text': 'DMT', 'start': 279, 'end': 282, 'pattern': -394200700}, {'text': 'DMT', 'start': 514, 'end': 517, 'pattern': -394200700}, {'text': 'DMT', 'start': 630, 'end': 633, 'pattern': -394200700}, {'text': 'DMT', 'start': 676, 'end': 679, 'pattern': -394200700}, {'text': 'DMT', 'start': 748, 'end': 751, 'pattern': -394200700}, {'text': 'DMT', 'start': 852, 'end': 855, 'pattern': -394200700}, {'text': '30', 'start': 894, 'end': 896, 'pattern': 2095658839}, {'text': 'male', 'start': 1033, 'end': 1037, 'pattern': -757571895}, {'text': 'female', 'start': 1044, 'end': 1050, 'pattern': 1547013372}, {'text': '37.09', 'start': 1068, 'end': 1073, 'pattern': 2095658839}, {'text': '8.93', 'start': 1076, 'end': 1080, 'pattern': 2095658839}, {'text': 'DMT', 'start': 1139, 'end': 1142, 'pattern': -394200700}, {'text': '15', 'start': 1328, 'end': 1330, 'pattern': 2095658839}, {'text': 'DMT', 'start': 1398, 'end': 1401, 'pattern': -394200700}, {'text': 'DMT', 'start': 1410, 'end': 1413, 'pattern': -394200700}, {'text': '10', 'start': 1461, 'end': 1463, 'pattern': 2095658839}, {'text': 'DMT', 'start': 1473, 'end': 1476, 'pattern': -394200700}, {'text': 'DMT', 'start': 1627, 'end': 1630, 'pattern': -394200700}, {'text': 'DMT', 'start': 1721, 'end': 1724, 'pattern': -394200700}], 'meta': {'pattern': '4, 4, 4, 4, 4, 4, 4, 14, 12, 13, 14, 14, 4, 14, 4, 4, 14, 4, 4, 4'}}\n",
      "0.5\n",
      "{'record_id': 8247, 'keywords': \"['Adolescent', 'Adult', 'Cognition/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Excitatory Amino Acid Antagonists/administration & dosage/*pharmacology', 'Female', 'Humans', 'Ketamine/administration & dosage/*pharmacology', 'Male', '*Schizophrenic Psychology', 'Semantics', '*Substance-Related Disorders', 'Young Adult']\", 'text': \"Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?.^\\nAcute administration of the N-methyl-D-aspartate receptor antagonist ketamine induces schizophrenia-like symptoms in healthy volunteers; furthermore, a window on ketamine's chronic effects is provided by regular recreational users. The current study utilized both acute ketamine administration in healthy volunteers and chronic ketamine abusers to investigate semantic processing, one of the key cognitive deficits in schizophrenia. Semantic processing was examined using a semantic priming paradigm. In experiment 1, acute effects of low (75 ng/mL) and high (150 ng/mL) ketamine doses were compared in a placebo-controlled double-blind independent group design with 48 participants. In experiment 2, 19 regular recreational ketamine users were compared with 19 ketamine-naive polydrug controls and 26 non-drug-using controls. In both experiments, semantic priming parameters were manipulated to distinguish between ketamine's effects on (1) automatic and strategic processing and (2) the facilitation and inhibition components of semantic priming for strongly (directly) related primes and targets. Acute effects of ketamine on semantic priming for weakly (indirectly) related primes and targets were also assessed in experiment 1. Acutely, ketamine impaired the employment of strategic mechanisms but not automatic processing within both the direct and indirect semantic priming tasks. Acute ketamine administration also induced clear schizophrenia-like symptoms. Schizotypy traits in the cognitive and perceptual domains tended to correlate with increased semantic priming in long-term ketamine users. In summary, acute and chronic ketamine-induced changes partially mirrored the findings on semantic priming in schizophrenia.\", 'doi': '10.1097/JCP.0b013e31819a4b91', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/19512973/', 'secondary_title': 'J Clin Psychopharmacol', '_input_hash': -1745574053, '_task_hash': 1301204417, 'spans': [{'text': 'ketamine', 'start': 29, 'end': 37, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 154, 'end': 162, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 247, 'end': 255, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 355, 'end': 363, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 413, 'end': 421, 'pattern': -1436149968}, {'text': '75', 'start': 625, 'end': 627, 'pattern': 2095658839}, {'text': '150', 'start': 645, 'end': 648, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 656, 'end': 664, 'pattern': -1436149968}, {'text': '48', 'start': 752, 'end': 754, 'pattern': 2095658839}, {'text': '19', 'start': 786, 'end': 788, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 810, 'end': 818, 'pattern': -1436149968}, {'text': '19', 'start': 844, 'end': 846, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 847, 'end': 855, 'pattern': -1436149968}, {'text': '26', 'start': 884, 'end': 886, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1001, 'end': 1009, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1202, 'end': 1210, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1327, 'end': 1335, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1479, 'end': 1487, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1674, 'end': 1682, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1720, 'end': 1728, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 9, 14, 14, 9, 14, 14, 9, 14, 9, 14, 9, 9, 9, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 1903, 'keywords': \"['alcohol', 'cannabis', 'midomafetamine', 'adult', 'article', 'Bayesian learning', 'cannabis use', 'cognition', 'controlled study', 'convenience sample', 'Dutchman', 'female', 'human', 'human tissue', 'latent class analysis', 'lifespan', 'major clinical study', 'male', 'multinomial logistic regression', 'questionnaire', 'social media', 'social norm', 'substance use', 'young adult']\", 'text': \"What Do Young Adults Expect from the Recreational Use of Ecstasy (3,4-Methylenedioxymethamphetamine/Molly)? A Latent Class Analysis of a Convenience Sample of Dutch Young Adults.^\\nIntroduction: This study offers insights into Dutch young people's expected social and personal consequences of ecstasy use. Substance use expectancies are assumed to be an essential component in explaining substance use behaviour and, therefore, the development of effective substance use prevention and treatment strategies. Method: Dutch young adults with an online interest in drug-related social media posts were targeted with an online survey about their use of alcohol and drugs. This resulted in a convenience sample (N = 4182, 73.4% female, M<sub>age</sub> = 21.11), of which 35.5% had used ecstasy at least once in their life and 29.3% had used ecstasy last year. Latent class analyses were used to identify subgroups based on both positive and negative expectancies of ecstasy use. Cross-class differences were examined using multinomial logistic regression. Results: This study yielded four distinct classes: only negative expectancies (13.6%), high positive and negative expectancies (23.5%), low to moderate positive and negative expectancies (20.6%), and mostly positive expectancies (22.4%). These classes differed significantly in lifetime experience with ecstasy use, intention to use ecstasy, perception of harmfulness and availability, and social norms regarding the use of ecstasy. Conclusion: Findings show that ecstasy use expectancies can be used to create meaningful classes of users and non-users, and that these classes are different enough to warrant varied prevention approaches. Expectancies young people have regarding the use of ecstasy are associated with various ecstasy use-related variables and should be taken into consideration when developing and implementing preventive interventions.\", 'doi': '10.1159/000530330', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/37271136/', 'secondary_title': 'European Addiction Research', '_input_hash': -176710950, '_task_hash': -1925037063, 'spans': [{'text': 'Ecstasy', 'start': 57, 'end': 64, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 292, 'end': 299, 'pattern': 611274830}, {'text': '4182', 'start': 710, 'end': 714, 'pattern': 2095658839}, {'text': '73.4', 'start': 716, 'end': 720, 'pattern': 2095658839}, {'text': 'female', 'start': 722, 'end': 728, 'pattern': 1547013372}, {'text': '21.11', 'start': 748, 'end': 753, 'pattern': 2095658839}, {'text': '35.5', 'start': 765, 'end': 769, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 780, 'end': 787, 'pattern': 611274830}, {'text': '29.3', 'start': 820, 'end': 824, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 835, 'end': 842, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 960, 'end': 967, 'pattern': 611274830}, {'text': '13.6', 'start': 1129, 'end': 1133, 'pattern': 2095658839}, {'text': '23.5', 'start': 1178, 'end': 1182, 'pattern': 2095658839}, {'text': '20.6', 'start': 1238, 'end': 1242, 'pattern': 2095658839}, {'text': '22.4', 'start': 1280, 'end': 1284, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1353, 'end': 1360, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1383, 'end': 1390, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1474, 'end': 1481, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1514, 'end': 1521, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1741, 'end': 1748, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1777, 'end': 1784, 'pattern': 611274830}], 'meta': {'pattern': '8, 8, 14, 14, 13, 14, 14, 8, 14, 8, 8, 14, 14, 14, 14, 8, 8, 8, 8, 8, 8'}}\n",
      "0.5\n",
      "{'record_id': 3635, 'keywords': \"['adult', 'article', 'compartment model', 'controlled study', 'drug effect', 'drug therapy', 'elimination half-life', 'female', 'human', 'human experiment', 'human tissue', 'kinetics', 'major clinical study', 'male', 'maximum concentration', 'oral drug administration', 'pharmacodynamics', 'pharmacokinetic parameters', 'pharmacokinetics', 'lysergide']\", 'text': 'Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide administration in healthy participants.^\\nAims: Lysergic acid diethylamide (LSD) is currently investigated for several neurological and psychiatric illnesses. Various studies have investigated the pharmacokinetics and the pharmacokinetic–pharmacodynamic relationship of LSD in healthy participants, but data on urinary recovery and confirmatory studies are missing. Methods: The present study characterized the pharmacokinetics, pharmacokinetic–pharmacodynamic relationship and urinary recovery of LSD at doses of 85 and 170 μg administered orally in 28 healthy participants. The plasma concentrations and subjective effects of LSD were continuously evaluated over a period of 24 h. Urine was collected during 3 time intervals (0–8, 8–16 and 16–24 h after LSD administration). Pharmacokinetic parameters were determined using compartmental modelling. Concentration–subjective effect relationships were described using pharmacokinetic–pharmacodynamic modelling. Results: Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/mL (1.6–2.0) and 3.4 ng/mL (3.0–3.8) after the administration of 85 and 170 μg LSD, respectively. Maximal concentrations were achieved on average after 1.7 h. Elimination half-lives were 3.7 h (3.4–4.1) and 4.0 h (3.6–4.4), for 85 and 170 μg LSD, respectively. Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD. Urinary recovery was dose proportional. Mean (±standard deviation) durations of subjective effects were 9.3 ± 3.2 and 11 ± 3.7 h, and maximal effects (any drug effects) were 77 ± 18% and 87 ± 13% after 85 and 170 μg of LSD, respectively. Conclusion: The present novel study validates previous findings. LSD exhibited dose-proportional pharmacokinetics and first-order elimination kinetics and dose-dependent duration and intensity of subjective effects. LSD is extensively metabolized and shows dose-proportional urinary recovery.', 'doi': '10.1111/bcp.15887', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/37596682/', 'secondary_title': 'British Journal of Clinical Pharmacology', '_input_hash': -1838266788, '_task_hash': -877607268, 'spans': [{'text': 'LSD', 'start': 166, 'end': 169, 'pattern': -496918669}, {'text': 'LSD', 'start': 360, 'end': 363, 'pattern': -496918669}, {'text': 'LSD', 'start': 588, 'end': 591, 'pattern': -496918669}, {'text': '85', 'start': 604, 'end': 606, 'pattern': 2095658839}, {'text': '170', 'start': 611, 'end': 614, 'pattern': 2095658839}, {'text': '28', 'start': 641, 'end': 643, 'pattern': 2095658839}, {'text': 'LSD', 'start': 718, 'end': 721, 'pattern': -496918669}, {'text': '24', 'start': 767, 'end': 769, 'pattern': 2095658839}, {'text': '8–16', 'start': 823, 'end': 827, 'pattern': 2095658839}, {'text': '16–24', 'start': 832, 'end': 837, 'pattern': 2095658839}, {'text': 'LSD', 'start': 846, 'end': 849, 'pattern': -496918669}, {'text': '95', 'start': 1066, 'end': 1068, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1099, 'end': 1102, 'pattern': -496918669}, {'text': '85', 'start': 1195, 'end': 1197, 'pattern': 2095658839}, {'text': '170', 'start': 1202, 'end': 1205, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1209, 'end': 1212, 'pattern': -496918669}, {'text': '85', 'start': 1358, 'end': 1360, 'pattern': 2095658839}, {'text': '170', 'start': 1365, 'end': 1368, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1372, 'end': 1375, 'pattern': -496918669}, {'text': '24', 'start': 1476, 'end': 1478, 'pattern': 2095658839}, {'text': '16', 'start': 1482, 'end': 1484, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1520, 'end': 1523, 'pattern': -496918669}, {'text': '11', 'start': 1643, 'end': 1645, 'pattern': 2095658839}, {'text': '77', 'start': 1699, 'end': 1701, 'pattern': 2095658839}, {'text': '18', 'start': 1704, 'end': 1706, 'pattern': 2095658839}, {'text': '87', 'start': 1712, 'end': 1714, 'pattern': 2095658839}, {'text': '13', 'start': 1717, 'end': 1719, 'pattern': 2095658839}, {'text': '85', 'start': 1727, 'end': 1729, 'pattern': 2095658839}, {'text': '170', 'start': 1734, 'end': 1737, 'pattern': 2095658839}, {'text': 'LSD', 'start': 1744, 'end': 1747, 'pattern': -496918669}, {'text': 'LSD', 'start': 1828, 'end': 1831, 'pattern': -496918669}, {'text': 'LSD', 'start': 1979, 'end': 1982, 'pattern': -496918669}], 'meta': {'pattern': '0, 0, 0, 14, 14, 14, 0, 14, 14, 14, 0, 14, 0, 14, 14, 0, 14, 14, 0, 14, 14, 0, 14, 14, 14, 14, 14, 14, 14, 0, 0, 0'}}\n",
      "0.5\n",
      "{'record_id': 9225, 'keywords': \"['*brain function', '*decision making', '*drug screening', '*ketamine', '*psychiatry', '*society', 'Area under the curve', 'Continuous infusion', 'Dissection', 'Drug development', 'Drug effect', 'Edoxudine', 'Electrophysiology', 'Esketamine', 'Event related potential', 'Functional magnetic resonance imaging', 'Heart rate', 'Human', 'Imaging', 'Low drug dose', 'Male', 'Model', 'Multivariate analysis of covariance', 'Parameters', 'Physiological stress', 'Placebo', 'Positive and Negative Syndrome Scale', 'Reaction time', 'Recording', 'Schizophrenia', 'Stress', 'Volunteer', 'brain function', 'decision making', 'drug screening', 'psychiatry', 'society']\", 'text': 'Differential ketamine effects on clinical, behavioral and brain function outcome measures: a simultaneous fmri/eeg study.^\\nBackground: Various ketamine models of schizophrenia are used for testing novel compounds. Questions remain whether electrophysiological and functional imaging outcome measures offer any advantages compared to clinical and behavioral measures in the context of drug trials. Here we tested whether a possible confounder of ketamine action, the physiological stress response, differentially affects these outcome measures. Methods: Randomized, cross‐over, placebo‐controlled pharmaimaging study in 24 male volunteers. Low‐dose S‐ketamine (bolus prior to functional imaging: 0.1 mg/kg during 5 min, thereafter continuous infusion: 0.0156 mg/kg/min reduced by 10% every ten minutes) or placebo was administered while performing a visual oddball reaction time task during fMRI with simultaneous recording of event‐related potentials (P300) and surrogate endpoint measures of the physiological stress response: electrodermal activity (EDA) and heart rate. Pre‐post imaging psychopathological status was assessed using the PANSS scale. Results: Comparable separation of drug conditions was achieved with area under the curve (AUC) values of 0.8‐1.0 in the clinical (PANSS), behavioral (reaction hit and false alarm rate), peripheral physiological (EDA, heart rate), electrophyiological (P300) and fMRI (ROIs) domains. Analysis of multivariate covariance structure revealed that clinical/behavioral but not EEG/fMRI AUC residuals are dramatically affected by stress parameters (heart rate, EDA). Conclusions: Our ketamine experiment provides an instructive example how functional imaging and electrophysiology can aid the dissection of partial drug effects. These partial effects can be confounders leading to wrong decisions in the process of drug development when exclusively relying on clinical/behavioral outcome measures.', 'doi': '10.1016/j.biopsych.2012.02.013', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/38591002/', 'secondary_title': 'Biological psychiatry', '_input_hash': 1731777203, '_task_hash': 2089132778, 'spans': [{'text': 'ketamine', 'start': 13, 'end': 21, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 143, 'end': 151, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 445, 'end': 453, 'pattern': -1436149968}, {'text': '24', 'start': 619, 'end': 621, 'pattern': 2095658839}, {'text': 'male', 'start': 622, 'end': 626, 'pattern': -757571895}, {'text': '0.0156', 'start': 751, 'end': 757, 'pattern': 2095658839}, {'text': '10', 'start': 779, 'end': 781, 'pattern': 2095658839}, {'text': 'P300', 'start': 952, 'end': 956, 'pattern': 2095658839}, {'text': 'P300', 'start': 1403, 'end': 1407, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1628, 'end': 1636, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 12, 14, 14, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 4070, 'keywords': \"['enhancement', 'health effects', 'interview', 'microdose', 'psychedelic', 'qualitative', 'LIFE-THREATENING CANCER', 'PSILOCYBIN TREATMENT', 'COGNITIVE ENHANCERS', 'USER PERCEPTIONS', 'INTERNET', 'ANXIETY', 'DEPRESSION', 'DEPENDENCE', 'TRIAL', 'SELF']\", 'text': \"Powerful substances in tiny amounts: An interview study of psychedelic microdosing.^\\nAims: This article presents a qualitative interview study of people who microdose with psychedelic drugs, which means that the user takes about one tenth of an ordinary recreational dose. Design: Respondents (n = 21) were recruited at several Internet fora for individual interviews via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job and relationship and extensive entheogen experience. Results: Respondents tended to experiment with microdosing in phases, reporting mostly positive consequences from this form of drug use. Reported effects included improved mood, cognition, and creativity, which often served to counteract symptoms especially from conditions of anxiety and depression. There were also reports of various challenges with psychedelic microdosing, and some did not find the practice worth continuing. Conclusion: The study obtained evidence of a group of users taking small doses of psychedelics not for the purpose of intoxication but to enhance everyday functioning. While the study's findings are not generalisable, they may inform subsequent investigations with research questions and hypotheses.\", 'doi': '10.1177/1455072517753339', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/32934512/', 'secondary_title': 'NORDIC STUDIES ON ALCOHOL AND DRUGS', '_input_hash': -1967228564, '_task_hash': -690129833, 'spans': [{'text': '21', 'start': 298, 'end': 300, 'pattern': 2095658839}, {'text': 'male', 'start': 413, 'end': 417, 'pattern': -757571895}, {'text': '30s', 'start': 456, 'end': 459, 'pattern': 2095658839}], 'meta': {'pattern': '14, 12, 14'}}\n",
      "0.5\n",
      "{'record_id': 6808, 'keywords': \"['emotion', 'insight', 'mediation', 'Psychedelic', 'therapy', 'well-being', 'Adult', 'Aged', 'Awareness', 'Female', 'Hallucinogens', 'Humans', 'Male', 'Middle Aged', 'Principal Component Analysis', 'Prospective Studies', 'Psychometrics', 'Surveys and Questionnaires', 'Young Adult', 'psychedelic agent', 'article', 'behavior change', 'convergent validity', 'Cronbach alpha coefficient', 'human', 'human experiment', 'internal consistency', 'major clinical study', 'mental health', 'neurobiology', 'questionnaire', 'wellbeing', 'drug effect', 'prospective study', 'psychometry']\", 'text': 'Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.^\\nIntroduction: As their name suggests, ‘psychedelic’ (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight after a psychedelic experience: the Psychological Insight Scale (PIS). Methods: The PIS is a six- to seven-item questionnaire that enquires about psychological insight after a psychedelic experience (PIS-6) and accompanied behavioural changes (PIS item 7). In total, 886 participants took part in a study in which the PIS and other questionnaires were completed in a prospective fashion in relation to a planned psychedelic experience. For validation purposes, data from 279 participants were analysed from a non-specific ‘global psychedelic survey’ study. Results: Principal components analysis of PIS scores revealed a principal component explaining 73.57% of the variance, which displayed high internal consistency at multiple timepoints throughout the study (average Cronbach’s α = 0.94). Criterion validity was confirmed using the global psychedelic survey study, and convergent validity was confirmed via the Therapeutic-Realizations Scale. Furthermore, PIS scores significantly mediated the relationship between emotional breakthrough and long-term well-being. Conclusion: The PIS is complementary to current subjective measures used in psychedelic studies, most of which are completed in relation to the acute experience. Insight – as measured by the PIS – was found to be a key mediator of long-term psychological outcomes following a psychedelic experience. Future research may investigate how insight varies throughout a psychedelic process, its underlying neurobiology and how it impacts behaviour and mental health. © The Author(s) 2022.', 'doi': '10.1177/02698811211066709', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/34983255/', 'secondary_title': 'Journal of Psychopharmacology', '_input_hash': 566432381, '_task_hash': -1650515673, 'spans': [{'text': '886', 'start': 663, 'end': 666, 'pattern': 2095658839}, {'text': '279', 'start': 867, 'end': 870, 'pattern': 2095658839}, {'text': '73.57', 'start': 1048, 'end': 1053, 'pattern': 2095658839}, {'text': '0.94', 'start': 1182, 'end': 1186, 'pattern': 2095658839}, {'text': '2022', 'start': 1941, 'end': 1945, 'pattern': 2095658839}], 'meta': {'pattern': '14, 14, 14, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 1891, 'keywords': \"['Humans', '*Ketamine/adverse effects', '*Depressive Disorder, Major/drug therapy', '*Electroconvulsive Therapy/adverse effects', 'Myalgia/drug therapy', 'Antidepressive Agents/adverse effects', 'Ect', 'Ketamine', 'Mdd', 'Meta-analysis', 'Mood disorders', 'Trd']\", 'text': \"Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis.^\\nBACKGROUND: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). METHODS: We searched MEDLINE, Web of Science, Embase, PsycINFO, Google Scholar, Cochrane Library and trial registries, which were the ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform, without restrictions on publication date. SELECTION CRITERIA: randomized controlled trials or cohorts comparing ketamine versus ECT in patients with TRD. RESULTS: Eight studies met the inclusion criteria (of 2875 retrieved). Random-effects models comparing ketamine and ECT regarding the following outcomes were conducted: a) reduction of depressive symptoms severity through scales, g\\xa0=\\xa0-0.12, p\\xa0=\\xa00.68; b) response to therapy, RR\\xa0=\\xa00.89, p\\xa0=\\xa00.51; c) reported side-effects: dissociative symptoms, RR\\xa0=\\xa05.41, p\\xa0=\\xa00.06; nausea, RR\\xa0=\\xa00.73, p\\xa0=\\xa00.47; muscle pain, RR\\xa0=\\xa00.25, p\\xa0=\\xa00.02; and headache, RR\\xa0=\\xa00.39, p\\xa0=\\xa00.08. Influential & subgroup analyses were performed. LIMITATIONS: Methodological issues with high risk of bias in some of the source material, reduced number of eligible studies with high in-between heterogeneity and small sample sizes. CONCLUSION: Our study showed no evidence to support the superiority of ketamine over ECT for severity of depressive symptoms and response to therapy. Regarding side effects, there was a statistically significant decreased risk of muscle pain in patients treated with ketamine compared to ECT.\", 'doi': '10.1016/j.jad.2023.02.152', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36907464/', 'secondary_title': 'J Affect Disord', '_input_hash': 2141002577, '_task_hash': -1591737749, 'spans': [{'text': 'ketamine', 'start': 32, 'end': 40, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 225, 'end': 233, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 416, 'end': 424, 'pattern': -1436149968}, {'text': 'CRD42022349220', 'start': 469, 'end': 483, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 836, 'end': 844, 'pattern': -1436149968}, {'text': '2875', 'start': 932, 'end': 936, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 981, 'end': 989, 'pattern': -1436149968}, {'text': '-0.12', 'start': 1112, 'end': 1117, 'pattern': 2095658839}, {'text': '0.68', 'start': 1123, 'end': 1127, 'pattern': 2095658839}, {'text': '0.89', 'start': 1158, 'end': 1162, 'pattern': 2095658839}, {'text': '0.51', 'start': 1168, 'end': 1172, 'pattern': 2095658839}, {'text': '5.41', 'start': 1228, 'end': 1232, 'pattern': 2095658839}, {'text': '0.06', 'start': 1238, 'end': 1242, 'pattern': 2095658839}, {'text': '0.73', 'start': 1257, 'end': 1261, 'pattern': 2095658839}, {'text': '0.47', 'start': 1267, 'end': 1271, 'pattern': 2095658839}, {'text': '0.25', 'start': 1291, 'end': 1295, 'pattern': 2095658839}, {'text': '0.02', 'start': 1301, 'end': 1305, 'pattern': 2095658839}, {'text': '0.39', 'start': 1326, 'end': 1330, 'pattern': 2095658839}, {'text': '0.08', 'start': 1336, 'end': 1340, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1645, 'end': 1653, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1841, 'end': 1849, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 9, 14, 9, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 7074, 'keywords': \"['Adult', 'Analgesics/*therapeutic use', 'Anti-Anxiety Agents/administration & dosage', 'Cognition/drug effects', 'Depressive Disorder, Treatment-Resistant/*psychology', 'Double-Blind Method', 'Female', 'Humans', 'Ketamine/*therapeutic use', 'Male', 'Midazolam/administration & dosage', 'Middle Aged', 'Psychiatric Status Rating Scales/statistics & numerical data', 'Suicidal Ideation', 'Suicide/psychology', '*Suicide Prevention', 'antidepressants', 'biological markers', 'clinical trials', 'depression', 'mood disorders', 'suicide/self-harm']\", 'text': \"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.^\\nBACKGROUND: Preliminary evidence suggests intravenous ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide. In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit suicidal cognition (Implicit Association Test; IAT) previously linked to suicidal behavior. METHOD: Symptomatic patients with treatment-resistant unipolar major depression (inadequate response to ≥3 antidepressants) were assessed using a composite index of explicit suicidal ideation (Beck Scale for Suicidal Ideation, Montgomery-Asberg Rating Scale suicide item, Quick Inventory of Depressive Symptoms suicide item) and the IAT to assess suicidality implicitly. Measures were taken at baseline and 24 hr following a single subanesthetic dose of ketamine (n = 36) or midazolam (n = 21), a psychoactive placebo agent selected for its similar, rapid anesthetic effects. Twenty four hours postinfusion, explicit suicidal cognition was significantly reduced in the ketamine but not the midazolam group. RESULTS: Fifty three percent of ketamine-treated patients scored zero on all three explicit suicide measures at 24 hr, compared with 24% of the midazolam group (χ(2) = 4.6; P = .03). Implicit associations between self- and escape-related words were reduced following ketamine (P = .01; d = .58) but not midazolam (P = .68; d = .09). Ketamine-specific decreases in explicit suicidal cognition were largest in patients with elevated suicidal cognition at baseline, and were mediated by decreases in nonsuicide-related depressive symptoms. CONCLUSIONS: Intravenous ketamine produces rapid reductions in suicidal cognition over and above active placebo. Further study is warranted to test ketamine's antisuicidal effects in higher-risk samples.\", 'doi': '10.1002/da.22253', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/24668760/', 'secondary_title': 'Depress Anxiety', '_input_hash': -1910058024, '_task_hash': 756532202, 'spans': [{'text': 'ketamine', 'start': 11, 'end': 19, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 185, 'end': 193, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 365, 'end': 373, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 423, 'end': 431, 'pattern': -1436149968}, {'text': '24', 'start': 1020, 'end': 1022, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1067, 'end': 1075, 'pattern': -1436149968}, {'text': '36', 'start': 1081, 'end': 1083, 'pattern': 2095658839}, {'text': '21', 'start': 1103, 'end': 1105, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1282, 'end': 1290, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1352, 'end': 1360, 'pattern': -1436149968}, {'text': '24', 'start': 1432, 'end': 1434, 'pattern': 2095658839}, {'text': '24', 'start': 1453, 'end': 1455, 'pattern': 2095658839}, {'text': '.03', 'start': 1497, 'end': 1500, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1587, 'end': 1595, 'pattern': -1436149968}, {'text': '.01', 'start': 1601, 'end': 1604, 'pattern': 2095658839}, {'text': '.58', 'start': 1610, 'end': 1613, 'pattern': 2095658839}, {'text': '.68', 'start': 1638, 'end': 1641, 'pattern': 2095658839}, {'text': '.09', 'start': 1647, 'end': 1650, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 1653, 'end': 1661, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1882, 'end': 1890, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 2005, 'end': 2013, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 9, 14, 14, 9, 9, 14, 14, 14, 9, 14, 14, 14, 14, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 5930, 'keywords': \"['Adult', 'Anxiety Disorders/*drug therapy', 'Depressive Disorder/*drug therapy', 'Female', 'Hallucinogens/*therapeutic use', 'Humans', 'Lysergic Acid Diethylamide/therapeutic use', 'Psilocybin/therapeutic use', 'Anxiety associated with life-threatening disease', 'Depression', 'Psychedelics']\", 'text': 'Classical psychedelics for the treatment of depression and anxiety: A systematic review.^\\nBACKGROUND: Depression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to traditional treatments. This review aims to determine the efficacy and tolerability of psychedelics in the management of resistant depression. METHODS: Clinical trials investigating psychedelics in patients with depression and/or anxiety were searched via MEDLINE, EMBASE and PsychINFO. Efficacy was assessed by measuring symptom improvement from baseline, and tolerability was evaluated by noting the incidence and type of adverse effects reported. Risk of bias was assessed. RESULTS: Seven studies, with 130 patients, were analysed in this review. Three were conducted in patients with depression, two in patients with anxiety and two in patients with both. In a supportive setting, ayahuasca, psilocybin, and LSD consistently produced immediate and significant anti-depressant and anxiolytic effects that were endured for several months. Psychedelics were well-tolerated. The most common adverse effects were transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure. LIMITATIONS: At present, the number of studies on this subject is very limited; and the number of participating patients within these is also limited as the treatment under investigations is a relatively novel concept. CONCLUSIONS: Though further evidence is required, psychedelics appear to be effective in significantly reducing symptoms of depression and anxiety and are well-tolerated.', 'doi': '10.1016/j.jad.2019.07.076', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/31382100/', 'secondary_title': 'J Affect Disord', '_input_hash': 787598850, '_task_hash': 2030156080, 'spans': [{'text': 'ayahuasca', 'start': 377, 'end': 386, 'pattern': -1438173035}, {'text': 'psilocybin', 'start': 388, 'end': 398, 'pattern': 1563408733}, {'text': 'LSD', 'start': 430, 'end': 433, 'pattern': -496918669}, {'text': '130', 'start': 1001, 'end': 1004, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1180, 'end': 1189, 'pattern': -1438173035}, {'text': 'psilocybin', 'start': 1191, 'end': 1201, 'pattern': 1563408733}, {'text': 'LSD', 'start': 1207, 'end': 1210, 'pattern': -496918669}], 'meta': {'pattern': '5, 1, 0, 14, 5, 1, 0'}}\n",
      "0.5\n",
      "{'record_id': 2800, 'keywords': \"['midomafetamine', 'alcohol', 'amphetamine derivative', 'cannabis', 'central stimulant agent', 'cocaine', 'diamorphine', 'gammahydroxibutirate', 'unclassified drug', 'adolescent', 'adult', 'aged', 'agitation', 'alcoholism', 'anxiety', 'article', 'awareness', 'cannabis addiction', 'clinical evaluation', 'clinical feature', 'cocaine dependence', 'consultation', 'convulsion', 'death', 'delirium', 'disease severity', 'drug abuse', 'drug dependence', 'drug intoxication', 'emergency ward', 'female', 'follow up', 'heart palpitation', 'heroin dependence', 'hospital admission', 'human', 'intensive care unit', 'major clinical study', 'male', 'medical history', 'mental health care', 'motor dysfunction', 'patient care', 'risk factor', 'substance abuse', 'thought disorder']\", 'text': 'Visits to the emergency department due to ecstasy (MDMA) and amphetamine derivative consumption: Epidemiological, clinical and evolutional profile.^\\nObjectives: To describe clinical and epidemiologic characteristics of emergency department visits related with ecstasy usage, determine the rate of re-visits of the patients and their related factors. Material and methods: The clinical histories of the patients coming to the Emergency Department for ecstasy-related problems were reviewed during 89 consecutive months in order to define the epidemiological and clinical profile. The computerized system of admission was used to study re-visits to the emergency department, reviewing the clinical history of the re-visits to see if they were related with drug consumption. Results: The study included 498 cases (71% male, mean age 26.5 years). The majority of the patients were attended on the weekend (66.6%) and at night (57%). Main complaints were anxiety or altered thoughts (32.8%), agitation (17.2%), impaired awareness level (7.2%) and convulsions or abnormal movements (5.6%). A total of 81% of the patients had consumed other substances besides ecstasy, mainly ethanol (53%), cocaine (36%) and gammahydroxibutirate (liquid ecstasy, 25%). Twenty six patients (5%) required admission to hospital (6 in the intensive care unit) and 4 died (0.8%). Fifteen percent of the patients were re-attended in the same ED for drug-related problems after a mean follow-up of 3 years, the new visit being more frequent during the first months. The need for an urgent psychiatric visit (OR: 6.3; 95% CI: 2.912.8) and hospital admission (OR: 3.5; 95% CI: 1.58.4) during their first ED attendance were independently associated with a greater risk of re-attendance. Conclusions: Ecstasy consumption frequently leads to an ED visit, sometimes due to severe medical complications, and at least 15% of patients will need urgent care again for drug-related problems within the next 3 years. This likelihood increases along with increased severity of the index episode (need of psychiatric consultation or hospital admission). © 2009 ElsevierEspaña, S.L.Todoslosderechosreservados.', 'doi': '10.1016/j.rce.2010.01.013', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/20673888/', 'secondary_title': 'Revista Clinica Espanola', '_input_hash': -2146202387, '_task_hash': -1253654448, 'spans': [{'text': 'ecstasy', 'start': 42, 'end': 49, 'pattern': 611274830}, {'text': 'MDMA', 'start': 51, 'end': 55, 'pattern': -495411397}, {'text': 'ecstasy', 'start': 260, 'end': 267, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 450, 'end': 457, 'pattern': 611274830}, {'text': '89', 'start': 496, 'end': 498, 'pattern': 2095658839}, {'text': '498', 'start': 800, 'end': 803, 'pattern': 2095658839}, {'text': '71', 'start': 811, 'end': 813, 'pattern': 2095658839}, {'text': 'male', 'start': 815, 'end': 819, 'pattern': -757571895}, {'text': '26.5', 'start': 830, 'end': 834, 'pattern': 2095658839}, {'text': '66.6', 'start': 902, 'end': 906, 'pattern': 2095658839}, {'text': '57', 'start': 923, 'end': 925, 'pattern': 2095658839}, {'text': '32.8', 'start': 979, 'end': 983, 'pattern': 2095658839}, {'text': '17.2', 'start': 998, 'end': 1002, 'pattern': 2095658839}, {'text': '81', 'start': 1095, 'end': 1097, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1153, 'end': 1160, 'pattern': 611274830}, {'text': '53', 'start': 1178, 'end': 1180, 'pattern': 2095658839}, {'text': '36', 'start': 1193, 'end': 1195, 'pattern': 2095658839}, {'text': 'ecstasy', 'start': 1231, 'end': 1238, 'pattern': 611274830}, {'text': '25', 'start': 1240, 'end': 1242, 'pattern': 2095658839}, {'text': '95', 'start': 1587, 'end': 1589, 'pattern': 2095658839}, {'text': '2.912.8', 'start': 1595, 'end': 1602, 'pattern': 2095658839}, {'text': '95', 'start': 1637, 'end': 1639, 'pattern': 2095658839}, {'text': '1.58.4', 'start': 1645, 'end': 1651, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 1767, 'end': 1774, 'pattern': 611274830}, {'text': '15', 'start': 1880, 'end': 1882, 'pattern': 2095658839}, {'text': '2009', 'start': 2112, 'end': 2116, 'pattern': 2095658839}], 'meta': {'pattern': '8, 7, 8, 8, 14, 14, 14, 12, 14, 14, 14, 14, 14, 14, 8, 14, 14, 8, 14, 14, 14, 14, 14, 8, 14, 14'}}\n",
      "0.5\n",
      "{'record_id': 7466, 'keywords': \"['Nmda', 'antidepressant', 'cancer', 'end of life', 'esketamine', 'ketamine', 'major depressive disorder', 'palliative care', 'psychedelics', 'quality of life', 'supportive care']\", 'text': 'A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study).^\\nAntidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer and palliative care populations. Herein, the objective was to determine the feasibility, safety, tolerability and preliminary efficacy of intranasal racemic ketamine for major depressive disorder (MDD) in patients with advanced cancer. We conducted a single-arm, open-label phase II trial at the Princess Margaret Cancer Centre in Toronto, ON, Canada. Participants with advanced cancer with moderate to severe MDD received three flexible doses of intranasal (IN) ketamine (50−150 mg) over a one-week period. The primary efficacy outcome was an antidepressant response and remission rates as determined by the Montgomery−Åsberg Depression Rating Scale (MADRS) from baseline to the Day 8 primary endpoint. Twenty participants were enrolled in the trial, receiving at least one dose of IN ketamine, with fifteen participants receiving all three doses. The Day 8 antidepressant response (MADRS decreased by >50%) and remission (MADRS < 10 on Day 8) rates were high at 70% and 45%, respectively. Mean MADRS scores decreased significantly from baseline (mean MADRS of 31, standard deviation 7.6) to Day 8 (11 +/− 7.4) with an overall decrease of 20 points (p < 0.001). Antidepressant effects were partially sustained in the second week in the absence of additional ketamine doses, with a Day 14 mean MADRS score of 14 +/− 9.9. Common adverse effects included fatigue, dissociation, nausea, dysgeusia and headaches; almost all adverse effects were mild and transient, resolving within 2 h of each ketamine dose with one dropout related to adverse effects (negative dissociative episode). Given these promising findings, larger, controlled trials are merited.', 'doi': '10.3390/cancers15020400', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36672348/', 'secondary_title': 'Cancers (Basel)', '_input_hash': -1172464606, '_task_hash': -1707384411, 'spans': [{'text': 'Ketamine', 'start': 52, 'end': 60, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 271, 'end': 279, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 525, 'end': 533, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 831, 'end': 839, 'pattern': -1436149968}, {'text': '50−150', 'start': 841, 'end': 847, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1154, 'end': 1162, 'pattern': -1436149968}, {'text': '50', 'start': 1272, 'end': 1274, 'pattern': 2095658839}, {'text': '10', 'start': 1300, 'end': 1302, 'pattern': 2095658839}, {'text': '70', 'start': 1332, 'end': 1334, 'pattern': 2095658839}, {'text': '45', 'start': 1340, 'end': 1342, 'pattern': 2095658839}, {'text': '31', 'start': 1430, 'end': 1432, 'pattern': 2095658839}, {'text': '11', 'start': 1468, 'end': 1470, 'pattern': 2095658839}, {'text': '20', 'start': 1508, 'end': 1510, 'pattern': 2095658839}, {'text': '0.001', 'start': 1523, 'end': 1528, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1627, 'end': 1635, 'pattern': -1436149968}, {'text': '14', 'start': 1654, 'end': 1656, 'pattern': 2095658839}, {'text': '14', 'start': 1677, 'end': 1679, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1858, 'end': 1866, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 9, 14, 14, 14, 14, 14, 14, 14, 14, 9, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 2998, 'keywords': \"['Adult', 'Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/*therapeutic use', 'Anxiety/*drug therapy/metabolism', 'Anxiety Disorders/*drug therapy/metabolism', 'Depression/*drug therapy/metabolism', 'Depressive Disorder, Major/*drug therapy/metabolism', 'Depressive Disorder, Treatment-Resistant/drug therapy/metabolism', 'Female', 'Humans', 'Ketamine/*therapeutic use', 'Male', 'Middle Aged', 'Obsessive-Compulsive Disorder/drug therapy/metabolism', 'Receptors, N-Methyl-D-Aspartate/metabolism', 'Stress Disorders, Post-Traumatic/drug therapy/metabolism', 'Young Adult', 'Ketamine', 'dose-response', 'generalized anxiety disorder', 'social anxiety disorder']\", 'text': \"Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.^\\nThe N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of ketamine in 12 patients with refractory generalized anxiety disorder and/or social anxiety disorder who were not currently depressed, using an ascending single dose study design (0.25, 0.5, 1 mg/kg administered subcutaneously) at weekly intervals. Within 1 h of dosing, patients reported reduced anxiety, which persisted for up to seven days. A dose-response profile was noted for anxiolytic effects, dissociative side effects, and changes in blood pressure and heart rate, with minor changes at 0.25 mg/kg, and progressively greater and more durable changes at the higher doses. Ten of 12 patients were treatment responders at 0.5-1 mg/kg. Ketamine was safe and well tolerated in this population. Ketamine may be a potential therapeutic alternative for patients with refractory generalized anxiety disorder/social anxiety disorder. Along with its demonstrated effectiveness in patients with treatment-resistant depression, obsessive compulsive disorder and post-traumatic stress disorder, these data raise the intriguing possibility that ketamine may have broad efficacy in disorders characterized by negative emotional states, and that these disorders may share a common precipitating neurobiology.\", 'doi': '10.1177/0269881117705089', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/28441895/', 'secondary_title': 'J Psychopharmacol', '_input_hash': -17510431, '_task_hash': -1399727913, 'spans': [{'text': 'Ketamine', 'start': 0, 'end': 8, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 155, 'end': 163, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 394, 'end': 402, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 503, 'end': 511, 'pattern': -1436149968}, {'text': '12', 'start': 515, 'end': 517, 'pattern': 2095658839}, {'text': '0.25', 'start': 682, 'end': 686, 'pattern': 2095658839}, {'text': '0.25', 'start': 999, 'end': 1003, 'pattern': 2095658839}, {'text': '12', 'start': 1090, 'end': 1092, 'pattern': 2095658839}, {'text': 'Ketamine', 'start': 1144, 'end': 1152, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1201, 'end': 1209, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1542, 'end': 1550, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 9, 14, 14, 14, 14, 9, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 1886, 'keywords': \"['Bdnf', 'antidepressant', 'ayahuasca', 'biomarker', 'cortisol', 'depression', 'psychedelics', 'treatment-resistant']\", 'text': 'Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial.^\\nSerotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as suggested in a recent randomized controlled trial with ayahuasca for treatment-resistant depression. Preclinical and clinical studies have suggested that serum brain-derived neurotrophic factor (BDNF) levels increase after treatment with serotoninergic antidepressants, but the exact role of BDNF as a biomarker for diagnostic and treatment of major depression is still poorly understood. Here we investigated serum BDNF levels in healthy controls (N = 45) and patients with treatment-resistant depression (N = 28) before (baseline) and 48 h after (D2) a single dose of ayahuasca or placebo. In our sample, baseline serum BDNF levels did not predict major depression and the clinical characteristics of the patients did not predict their BDNF levels. However, at baseline, serum cortisol was a predictor of serum BDNF levels, where lower levels of serum BDNF were detected in a subgroup of subjects with hypocortisolemia. Moreover, at baseline we found a negative correlation between BDNF and serum cortisol in volunteers with eucortisolemia. After treatment (D2) we observed higher BDNF levels in both patients and controls that ingested ayahuasca (N = 35) when compared to placebo (N = 34). Furthermore, at D2 just patients treated with ayahuasca (N = 14), and not with placebo (N = 14), presented a significant negative correlation between serum BDNF levels and depressive symptoms. This is the first double-blind randomized placebo-controlled clinical trial that explored the modulation of BDNF in response to a psychedelic in patients with depression. The results suggest a potential link between the observed antidepressant effects of ayahuasca and changes in serum BDNF, which contributes to the emerging view of using psychedelics as an antidepressant. This trial is registered at http://clinicaltrials.gov (NCT02914769).', 'doi': '10.3389/fpsyg.2019.01234', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/31231276/', 'secondary_title': 'Front Psychol', '_input_hash': -24712411, '_task_hash': -271644911, 'spans': [{'text': 'Ayahuasca', 'start': 74, 'end': 83, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 278, 'end': 287, 'pattern': -1438173035}, {'text': '45', 'start': 676, 'end': 678, 'pattern': 2095658839}, {'text': '28', 'start': 734, 'end': 736, 'pattern': 2095658839}, {'text': '48', 'start': 760, 'end': 762, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 793, 'end': 802, 'pattern': -1438173035}, {'text': 'ayahuasca', 'start': 1362, 'end': 1371, 'pattern': -1438173035}, {'text': '35', 'start': 1377, 'end': 1379, 'pattern': 2095658839}, {'text': '34', 'start': 1411, 'end': 1413, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1462, 'end': 1471, 'pattern': -1438173035}, {'text': '14', 'start': 1477, 'end': 1479, 'pattern': 2095658839}, {'text': '14', 'start': 1508, 'end': 1510, 'pattern': 2095658839}, {'text': 'ayahuasca', 'start': 1864, 'end': 1873, 'pattern': -1438173035}, {'text': 'NCT02914769', 'start': 2039, 'end': 2050, 'pattern': 2095658839}], 'meta': {'pattern': '5, 5, 14, 14, 14, 5, 5, 14, 14, 5, 14, 14, 5, 14'}}\n",
      "0.5\n",
      "{'record_id': 4451, 'keywords': \"['Administration, Oral', 'Adolescent', 'Adrenergic Uptake Inhibitors/administration & dosage/metabolism/*pharmacology', 'Adult', 'Body Temperature/drug effects/physiology', 'Cardiovascular Physiological Phenomena/*drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Hallucinogens/administration & dosage/metabolism/*pharmacology', 'Heart Rate/drug effects/physiology', 'Hemodynamics/*drug effects', 'Humans', 'Inpatients', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/administration &', 'dosage/metabolism/*pharmacology', 'Perception/*drug effects', 'Surveys and Questionnaires']\", 'text': 'Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.^\\nA randomized, within-subject, double-blind, inpatient study of the physiological and subjective effects of oral 3,4-methylenedioxymethamphetamine (MDMA) was conducted in human volunteers with previous MDMA experience. Placebo, low (1.0 mg/kg), and high (1.6 mg/kg) doses of oral MDMA were administered in a controlled inpatient setting at least 7 days apart to 6 African American (4 male, 2 female) and 2 white (both male) volunteers (mean [SE] age, 21.1 [0.8] years; weight, 77.2 [7.7] kg). 3,4-Methylenedioxymethamphetamine doses were 46 to 150 mg, in the range of typical recreational doses. Participants completed all sessions without clinically significant adverse events. 3,4-Methylenedioxymethamphetamine produced significant dose-dependent increases in heart rate (highest, 132 bpm), systolic (highest, 171 mm Hg) and diastolic (highest, 102 mm Hg) blood pressure, and subjective responses for energy level, closeness to others, mind racing, heightened senses, and high (evaluated by visual analog scales). Peak effects occurred 1 to 2 hours after dose, with no secondary peak. There were no significant effects on body temperature (measured at tympanic membrane), respiratory rate, or blood oxygen saturation (by pulse oximetry). Although most physiological and subjective parameters were significantly correlated with MDMA plasma concentrations, correlation coefficients were low and clinically insignificant, eliminating the ability to predict effects from single plasma concentrations. These findings suggest that oral MDMA in typical recreational doses produces short-term effects on cardiovascular function and subjective state but that temperature effects may result from interaction with environmental and subject factors.', 'doi': '10.1097/JCP.0b013e31817ef470', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/18626271/', 'secondary_title': 'J Clin Psychopharmacol', '_input_hash': 2077946809, '_task_hash': 1142688774, 'spans': [{'text': 'MDMA', 'start': 256, 'end': 260, 'pattern': -495411397}, {'text': 'MDMA', 'start': 310, 'end': 314, 'pattern': -495411397}, {'text': 'MDMA', 'start': 388, 'end': 392, 'pattern': -495411397}, {'text': 'male', 'start': 492, 'end': 496, 'pattern': -757571895}, {'text': 'female', 'start': 500, 'end': 506, 'pattern': 1547013372}, {'text': 'male', 'start': 526, 'end': 530, 'pattern': -757571895}, {'text': '21.1', 'start': 559, 'end': 563, 'pattern': 2095658839}, {'text': '77.2', 'start': 585, 'end': 589, 'pattern': 2095658839}, {'text': '46', 'start': 646, 'end': 648, 'pattern': 2095658839}, {'text': '150', 'start': 652, 'end': 655, 'pattern': 2095658839}, {'text': '132', 'start': 891, 'end': 894, 'pattern': 2095658839}, {'text': '171', 'start': 920, 'end': 923, 'pattern': 2095658839}, {'text': '102', 'start': 955, 'end': 958, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1437, 'end': 1441, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1640, 'end': 1644, 'pattern': -495411397}], 'meta': {'pattern': '7, 7, 7, 12, 13, 12, 14, 14, 14, 14, 14, 14, 14, 7, 7'}}\n",
      "0.5\n",
      "{'record_id': 216, 'keywords': \"['Humans', '*Ketamine/therapeutic use', 'Suicidal Ideation', 'Depression/drug therapy', '*Depressive Disorder, Treatment-Resistant/psychology', 'Quality of Life', 'Antidepressive Agents/therapeutic use', 'Personality Disorders/complications/drug therapy', 'Double-Blind Method', 'Personality', 'Treatment Outcome', 'Comorbidity', 'Ketamine', 'Psychiatric', 'Treatment resistant depression']\", 'text': 'Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.^\\nOBJECTIVE: To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities. METHODS: A randomized double-blind parallel-arm controlled study on 36 patients with TRD. Patients were divided into two treatment groups: ketamine (K group) and placebo (P group). Patients in the K and P groups received one infusion of medicine per week for two weeks. All participants were assessed using the Structured Interview for the Five-Factor Personality Model (SIFFM), Hamilton Depression Rating Scale (HDRS), Suicide Probability Scale (SPS), and Symptom Checklist 90 (SCL 90). RESULTS: After treatment, there was a significant decrease in the total HDRS and SPS scores in the K group compared to the P group, but the magnitude of response was not influenced by the presence of other psychiatric symptoms. Regression model, only receive ketamine treatment was significant factor for improve suicide and depression scores. LIMITATIONS: lack of data on other outcomes that are important to patients (e.g., quality of life, cognition) and need for a larger sample size. CONCLUSIONS: Ketamine infusions in TRD reduce suicidal ideation and depression despite the presence other psychiatric and personality disorders.', 'doi': '10.1016/j.jad.2023.01.005', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36623562/', 'secondary_title': 'J Affect Disord', '_input_hash': -1998174534, '_task_hash': -72295214, 'spans': [{'text': 'ketamine', 'start': 44, 'end': 52, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 218, 'end': 226, 'pattern': -1436149968}, {'text': '36', 'start': 478, 'end': 480, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 549, 'end': 557, 'pattern': -1436149968}, {'text': '90', 'start': 885, 'end': 887, 'pattern': 2095658839}, {'text': '90', 'start': 893, 'end': 895, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1157, 'end': 1165, 'pattern': -1436149968}, {'text': 'Ketamine', 'start': 1400, 'end': 1408, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 14, 9, 14, 14, 9, 9'}}\n",
      "0.5\n",
      "{'record_id': 4265, 'keywords': \"['Humans', 'Anxiety', '*Hallucinogens/therapeutic use', 'Psilocybin/therapeutic use', '*Psychiatry', 'Quality of Life', 'Double-Blind Method', 'Depression', 'psilocybin', 'psychedelics', 'treatment-resistant depression']\", 'text': 'The psychedelic renaissance: the next trip for psychiatry?.^\\nThe psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode network activity. At the cellular level, psychedelics promote synaptogenesis and neural plasticity. Prompted by the promising preliminary studies, a randomized, double-blind trial has recently been launched across Europe and North America to investigate the efficacy of psilocybin in TRD. One of these centres is based in Ireland - CHO Area 7 and Tallaght University Hospital. The outcome of this trial will determine whether psilocybin with psychological support will successfully translate into the psychiatric clinic for the benefit of patients.', 'doi': '10.1017/ipm.2019.39', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/31543078/', 'secondary_title': 'Ir J Psychol Med', '_input_hash': 362904740, '_task_hash': -1443842005, 'spans': [{'text': 'psilocybin', 'start': 177, 'end': 187, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 826, 'end': 836, 'pattern': 1563408733}, {'text': 'psilocybin', 'start': 982, 'end': 992, 'pattern': 1563408733}], 'meta': {'pattern': '1, 1, 1'}}\n",
      "0.5\n",
      "{'record_id': 4888, 'keywords': \"['DNA methylation', 'Hpa', 'Mdma', 'MDMA-assisted therapy', 'Nr3c1', 'Ptsd', 'epigenetics', 'glucocorticoid receptor']\", 'text': 'Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD.^\\nBACKGROUND: Previous research has demonstrated that epigenetic changes in specific hypothalamic-pituitary-adrenal (HPA) genes may predict successful psychotherapy in post-traumatic stress disorder (PTSD). A recent Phase 3 clinical trial reported high efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for treating patients with severe PTSD compared to a therapy with placebo group (NCT03537014). This raises important questions regarding potential mechanisms of MDMA-assisted therapy. In the present study, we examined epigenetic changes in three key HPA axis genes before and after MDMA and placebo with therapy. As a pilot sub-study to the parent clinical trial, we assessed potential HPA epigenetic predictors for treatment response with genomic DNA derived from saliva (MDMA, n = 16; placebo, n = 7). Methylation levels at all 259 CpG sites annotated to three HPA genes (CRHR1, FKBP5, and NR3C1) were assessed in relation to treatment response as measured by the Clinician-Administered PTSD Scale (CAPS-5; Total Severity Score). Second, group (MDMA vs. placebo) differences in methylation change were assessed for sites that predicted treatment response. RESULTS: Methylation change across groups significantly predicted symptom reduction on 37 of 259 CpG sites tested, with two sites surviving false discovery rate (FDR) correction. Further, the MDMA-treatment group showed more methylation change compared to placebo on one site of the NR3C1 gene. CONCLUSION: The findings of this study suggest that therapy-related PTSD symptom improvements may be related to DNA methylation changes in HPA genes and such changes may be greater in those receiving MDMA-assisted therapy. These findings can be used to generate hypothesis driven analyses for future studies with larger cohorts.', 'doi': '10.3389/fpsyt.2023.959590', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36815187/', 'secondary_title': 'Front Psychiatry', '_input_hash': 95745867, '_task_hash': -971039287, 'spans': [{'text': 'MDMA', 'start': 100, 'end': 104, 'pattern': -495411397}, {'text': 'NCT03537014', 'start': 561, 'end': 572, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 641, 'end': 645, 'pattern': -495411397}, {'text': 'MDMA', 'start': 762, 'end': 766, 'pattern': -495411397}, {'text': 'MDMA', 'start': 953, 'end': 957, 'pattern': -495411397}, {'text': '16', 'start': 963, 'end': 965, 'pattern': 2095658839}, {'text': '259', 'start': 1010, 'end': 1013, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1227, 'end': 1231, 'pattern': -495411397}, {'text': '37', 'start': 1425, 'end': 1427, 'pattern': 2095658839}, {'text': '259', 'start': 1431, 'end': 1434, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1530, 'end': 1534, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1833, 'end': 1837, 'pattern': -495411397}], 'meta': {'pattern': '7, 14, 7, 7, 7, 14, 14, 7, 14, 14, 7, 7'}}\n",
      "0.5\n",
      "{'record_id': 2490, 'keywords': \"['Humans', '*Ketamine', '*Bipolar Disorder/drug therapy', '*Depressive Disorder, Major/diagnosis', 'Canada', 'Antidepressive Agents/therapeutic use', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Infusions, Intravenous', 'Depression/diagnosis', 'bipolar disorder', 'depression', 'effectiveness', 'efficacy', 'esketamine', 'function', 'ketamine', 'major depressive disorder', 'patient-reported outcomes', 'quality of life']\", 'text': 'Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.^\\nBACKGROUND: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. METHODS: This study was conducted in a community clinic in Mississauga, Ontario (Canadian Rapid Treatment Centre of Excellence; Braxia Health). In this observational study (NCT04209296), patients with treatment-resistant bipolar I/II depression (n\\xa0=\\xa066) received four sub-anesthetic doses of IV ketamine (0.5-0.75\\u2009mg/kg) over a two-week period. Symptoms of depression, suicidality, anxiety, and functioning were assessed with validated self-report measures. RESULTS: Statistically and clinically significant antidepressant effects were observed in the overall sample, as measured by the Quick Inventory for Depression Symptomatology-Self Report-16 (QIDS-SR(16) ) with further reductions in depressive symptoms observed after each subsequent infusion (n\\xa0=\\xa066; mean QIDS-SR(16) reduction of 6.08+/-1.39; p\\u2009<\\u20090.0001). Significant reductions of suicidal thoughts (QIDS-SR(16) -Suicide Item) and anxiety (Generalized Anxiety Disorder-7) were also observed with functional improvements on the Sheehan Disability Scale (p\\u2009<\\u20090.0001 on all measures). Moreover, the response rate (QIDS-SR(16) total score decrease ≥50% from baseline) was 35% and remission rate (QIDS-SR(16) total score ≤5) was 20% after four infusions. Infusions were generally well tolerated with treatment-emergent hypomania observed in only three patients (4.5%) with zero cases of mania or psychosis. CONCLUSIONS: Real-world effectiveness of IV ketamine for bipolar depression was observed. Repeated doses were associated with greater symptom reduction and adequate tolerability.', 'doi': '10.1111/bdi.13284', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36516343/', 'secondary_title': 'Bipolar Disord', '_input_hash': 1753161031, '_task_hash': -1208835639, 'spans': [{'text': 'ketamine', 'start': 37, 'end': 45, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 198, 'end': 206, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 366, 'end': 374, 'pattern': -1436149968}, {'text': 'NCT04209296', 'start': 602, 'end': 613, 'pattern': 2095658839}, {'text': '66', 'start': 679, 'end': 681, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 724, 'end': 732, 'pattern': -1436149968}, {'text': '0.75', 'start': 738, 'end': 742, 'pattern': 2095658839}, {'text': 'Report-16', 'start': 1067, 'end': 1076, 'pattern': 2095658839}, {'text': 'SR(16', 'start': 1083, 'end': 1088, 'pattern': 2095658839}, {'text': '66', 'start': 1184, 'end': 1186, 'pattern': 2095658839}, {'text': 'SR(16', 'start': 1198, 'end': 1203, 'pattern': 2095658839}, {'text': '6.08+/-1.39', 'start': 1218, 'end': 1229, 'pattern': 2095658839}, {'text': '0.0001', 'start': 1235, 'end': 1241, 'pattern': 2095658839}, {'text': 'SR(16', 'start': 1294, 'end': 1299, 'pattern': 2095658839}, {'text': '0.0001', 'start': 1446, 'end': 1452, 'pattern': 2095658839}, {'text': 'SR(16', 'start': 1505, 'end': 1510, 'pattern': 2095658839}, {'text': '≥50', 'start': 1533, 'end': 1536, 'pattern': 2095658839}, {'text': '35', 'start': 1557, 'end': 1559, 'pattern': 2095658839}, {'text': 'SR(16', 'start': 1586, 'end': 1591, 'pattern': 2095658839}, {'text': '20', 'start': 1613, 'end': 1615, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1835, 'end': 1843, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 14, 9, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 9'}}\n",
      "0.5\n",
      "{'record_id': 4424, 'keywords': \"['Humans', '*Hallucinogens/adverse effects', 'Psilocybin/therapeutic use', 'Lysergic Acid Diethylamide/therapeutic use', 'Depression/drug therapy', '*Depressive Disorder, Major/drug therapy', 'Ayahuasca', 'Depression', 'Illness-related distress', 'Lsd', 'Psilocybin', 'Psychedelic therapy']\", 'text': 'Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.^\\nBACKGROUND: Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. METHODS: Fourteen psychedelic therapy studies, utilising psilocybin, ayahuasca, or LSD, were systematically reviewed. For the meta-analysis, standardised mean differences were calculated for seven randomised controlled trials. RESULTS: The systematic review indicated significant short- and long-term reduction of depressive symptoms in all conditions studied after administration of psilocybin, ayahuasca, or LSD, with psychological support. In the meta-analysis, symptom reduction was significantly indicated in three timepoints out of four, including 1-day, 1-week, and 3-5\\xa0weeks, supporting the results of the systematic review, with the exception of the 6-8\\xa0weeks follow-up point which was less conclusive. LIMITATIONS: The absence of required data for 2 studies necessitated the less precise use of graphical extraction and imputation. The small sample size in all but one study negatively affected the statistical power. None of the studies had long-term follow-up without also utilising the cross-over method, which did not allow for long-term results to be included in the meta-review. CONCLUSIONS: This review indicates an association between psychedelic therapy and significant reduction of depressive symptoms at several time points. However, the small number of studies, and low sample sizes, calls for careful interpretation of results. This suggests the need for more randomised clinical trials of psychedelic therapy, with larger and more diverse samples.', 'doi': '10.1016/j.jad.2022.09.168', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/36209780/', 'secondary_title': 'J Affect Disord', '_input_hash': 1063260065, '_task_hash': -1679487507, 'spans': [{'text': 'psilocybin', 'start': 485, 'end': 495, 'pattern': 1563408733}, {'text': 'ayahuasca', 'start': 497, 'end': 506, 'pattern': -1438173035}, {'text': 'LSD', 'start': 511, 'end': 514, 'pattern': -496918669}, {'text': 'psilocybin', 'start': 812, 'end': 822, 'pattern': 1563408733}, {'text': 'ayahuasca', 'start': 824, 'end': 833, 'pattern': -1438173035}, {'text': 'LSD', 'start': 838, 'end': 841, 'pattern': -496918669}], 'meta': {'pattern': '1, 5, 0, 1, 5, 0'}}\n",
      "0.5\n",
      "{'record_id': 5460, 'keywords': \"['midomafetamine', 'catecholamine', 'metirosine', 'serotonin', 'accuracy', 'adult', 'article', 'catecholamine brain level', 'catecholamine depletion', 'catecholamine nerve cell', 'clinical article', 'cognition', 'controlled study', 'depth perception', 'female', 'human', 'impulsiveness', 'male', 'priority journal', 'psychologic test', 'serotonin brain level', 'serotoninergic nerve cell', 'sleep', 'task performance', 'verbal behavior', 'working memory']\", 'text': 'The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users.^\\n(±) 3, 4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug of abuse and a brain serotonin (5-HT) neurotoxin in animals. Growing evidence suggests that humans who use MDMA recreationally can also develop 5-HT neurotoxic injury, although functional consequences have been difficult to identify. Twenty-five abstinent MDMA users and 23 non-MDMA using controls were studied to determine whether pharmacologic depletion of brain catecholamines by alpha-methyl-para-tyrosine (AMPT) would differentially effect MDMA users on measures of cognition and sleep, two processes dually modulated by brain serotonergic and catecholaminergic neurons. During a 5-day in-patient study, all subjects underwent formal neuropsychiatric testing, repeated computerized cognitive testing, and all-night sleep studies. At baseline, MDMA users had performance deficits on tasks of verbal and visuospatial working memory and displayed increased behavioral impulsivity on several computerized tasks, reflecting a tendency to perform quickly at the expense of accuracy. Baseline sleep architecture was also altered in abstinent MDMA users compared to controls. AMPT produced differential effects in MDMA users compared to controls on several cognitive and sleep measures. Differences in cognitive performance, impulsivity, and sleep were significantly correlated with MDMA use. These data extend findings from earlier studies demonstrating cognitive deficits, behavioral impulsivity, and sleep alterations in abstinent MDMA users, and suggest that lasting effects of MDMA lead to alterations in the ability to modulate behaviors reciprocally influenced by 5-HT and catecholamines. More research is needed to determine potential relationships between sleep abnormalities, cognitive deficits and impulsive behavior in abstinent MDMA users. © 2007 Nature Publishing Group All rights reserved.', 'doi': '10.1038/sj.npp.1301302', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/17203011/', 'secondary_title': 'Neuropsychopharmacology', '_input_hash': -1115487607, '_task_hash': -100408899, 'spans': [{'text': 'MDMA', 'start': 128, 'end': 132, 'pattern': -495411397}, {'text': 'MDMA', 'start': 181, 'end': 185, 'pattern': -495411397}, {'text': 'MDMA', 'start': 325, 'end': 329, 'pattern': -495411397}, {'text': 'MDMA', 'start': 474, 'end': 478, 'pattern': -495411397}, {'text': '23', 'start': 489, 'end': 491, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 496, 'end': 500, 'pattern': -495411397}, {'text': 'MDMA', 'start': 663, 'end': 667, 'pattern': -495411397}, {'text': 'MDMA', 'start': 966, 'end': 970, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1258, 'end': 1262, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1329, 'end': 1333, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1498, 'end': 1502, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1649, 'end': 1653, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1697, 'end': 1701, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1956, 'end': 1960, 'pattern': -495411397}, {'text': '2007', 'start': 1970, 'end': 1974, 'pattern': 2095658839}], 'meta': {'pattern': '7, 7, 7, 7, 14, 7, 7, 7, 7, 7, 7, 7, 7, 7, 14'}}\n",
      "0.5\n",
      "{'record_id': 2913, 'keywords': \"['midomafetamine', 'adult', 'article', 'Australia', 'brief patient health questionnaire', 'depression', 'disease association', 'female', 'Goldberg depression scale', 'human', 'longitudinal study', 'major clinical study', 'major depression', 'male', 'assessment of humans', 'priority journal', 'rating scale', 'self report', 'social psychology', 'symptom assessment']\", 'text': 'Ecstasy use and depression: A 4-year longitudinal study among an Australian general community sample.^\\nRationale: Longitudinal, population-based studies can better assess the relationship of ecstasy use with depression. Objectives: We examined whether change in ecstasy use was associated with change in depressive symptoms/probable depression over a 4-year period, among a large Australian sample. Methods: The Personality and Total Health project is a longitudinal general community study of Australians from Canberra and Queanbeyan. Data from the youngest cohort when aged 24-30 (N = 2, 128) and 4 years later (N = 1, 977) was included. The Goldberg depression scale and the Brief Patient Health Questionnaire measured depressive symptoms and probable depression, respectively. Multilevel growth models also considered demographics, psychosocial characteristics, and other drug use. Results: Ecstasy use was not associated with long-term depressive symptoms or greater odds of depression in multivariate analyses. Users had more self-reported depressive symptoms when using ecstasy compared to not using. However, differences between people who had and had not ever used ecstasy largely accounted for this. Other factors were more important in the prediction of depression. Conclusions: It would be premature to conclude that ecstasy use is not related to the development of long-term depressive symptoms, given the relatively low level of ecstasy and other drug use in this community sample. Results showed that other factors need to be considered when investigating ecstasy use and depression. © 2013 Springer-Verlag Berlin Heidelberg.', 'doi': '10.1007/s00213-013-3132-7', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/23681160/', 'secondary_title': 'Psychopharmacology', '_input_hash': -77054421, '_task_hash': -1215221506, 'spans': [{'text': 'Ecstasy', 'start': 0, 'end': 7, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 191, 'end': 198, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 262, 'end': 269, 'pattern': 611274830}, {'text': '24', 'start': 576, 'end': 578, 'pattern': 2095658839}, {'text': '30', 'start': 579, 'end': 581, 'pattern': 2095658839}, {'text': '128', 'start': 590, 'end': 593, 'pattern': 2095658839}, {'text': '977', 'start': 621, 'end': 624, 'pattern': 2095658839}, {'text': 'Ecstasy', 'start': 895, 'end': 902, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1077, 'end': 1084, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1174, 'end': 1181, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1329, 'end': 1336, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1443, 'end': 1450, 'pattern': 611274830}, {'text': 'ecstasy', 'start': 1571, 'end': 1578, 'pattern': 611274830}, {'text': '2013', 'start': 1601, 'end': 1605, 'pattern': 2095658839}], 'meta': {'pattern': '8, 8, 8, 14, 14, 14, 14, 8, 8, 8, 8, 8, 8, 14'}}\n",
      "0.5\n",
      "{'record_id': 2332, 'keywords': \"['efficacy & side effects & other aspects of clinical experience with oral ketamine', '29–81 yr olds with chronic neuropathic pain', 'retrospective study', 'Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Analgesics', 'Chronic Disease', 'Female', 'Humans', 'Ketamine', 'Male', 'Middle Aged', 'Nervous System Diseases', 'Pain', 'Retrospective Studies', 'Chronic Pain', 'Drug Therapy', 'Nervous System Disorders', 'Pain Management', 'Side Effects (Drug)']\", 'text': 'Clinical experience with oral ketamine.^\\nKetamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist used for analgesia in patients with chronic pain. This article describes a retrospective review of 21 Ss (aged 29–81 yrs) with chronic neuropathic pain who were treated with oral ketamine as an adjunct to ongoing therapy with individualized combinations of opioids, anticonvulsants, and antidepressants. Ss were treated with oral ketamine starting at a divided dose of 100 mg/day and titrating upwards by 40 mg/day until efficacy was reached, or until side effects became limiting. A retrospective chart review was conducted to evaluate the analgesic efficacy and side effects of the treatment. Nine Ss discontinued ketamine because of intolerable side effects, 4 Ss experienced few or no side effects but had no discernible benefit, 4 others had equivocal responses. Four Ss had continued oral ketamine for long periods. One patient has had no significant benefit or side effects but continues to use ketamine 500 mg/day and 3 people used doses ranging from 100–240 mg day for over 1 year duration and have reported improvements in pain and decreased use of analgesics. The analgesic benefits of ketamine appeared to be most pronounced in, but not limited to, patients with pain histories of less than 5 years. (PsycINFO Database Record (c) 2018 APA, all rights reserved)', 'doi': '10.1016/S0885-3924(99)00011-1', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/10355218/', 'secondary_title': 'Journal of Pain and Symptom Management', '_input_hash': 306458641, '_task_hash': 2146609799, 'spans': [{'text': 'Ketamine', 'start': 41, 'end': 49, 'pattern': -1436149968}, {'text': '21', 'start': 217, 'end': 219, 'pattern': 2095658839}, {'text': '29–81', 'start': 229, 'end': 234, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 297, 'end': 305, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 448, 'end': 456, 'pattern': -1436149968}, {'text': '100', 'start': 487, 'end': 490, 'pattern': 2095658839}, {'text': '40', 'start': 523, 'end': 525, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 734, 'end': 742, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 913, 'end': 921, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1020, 'end': 1028, 'pattern': -1436149968}, {'text': '500', 'start': 1029, 'end': 1032, 'pattern': 2095658839}, {'text': '100–240', 'start': 1077, 'end': 1084, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1215, 'end': 1223, 'pattern': -1436149968}, {'text': '2018', 'start': 1360, 'end': 1364, 'pattern': 2095658839}], 'meta': {'pattern': '9, 14, 14, 9, 9, 14, 14, 9, 9, 9, 14, 14, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 652, 'keywords': \"['Ketamine', 'Suicidal ideation', 'Meta-analysis', 'Clinical Trials']\", 'text': 'Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis.^\\nThe current systematic review and meta-analysis aimed at exploring acute effects of intravenous (IV) ketamine, an antagonist of N-methyl-D-aspartate (NMDA), in subjects with current suicidal ideation. We included clinical trials testing a single IV dose of ketamine and assessing changes in suicidal ideation within 4h after treatment. Meta-analyses based on random-effects models, were carried out generating pooled standardized mean differences (SMDs) between endpoint and baseline scores. Heterogeneity among studies was estimated using the I² index. We searched main Electronic Databases, identifying five studies that met our inclusion criteria. The trials included 99 subjects treated with IV ketamine bolus or infusion. Data showed a large (SMD=−0.92; 95%CI: −1.40 to −0.44; p <0.001) and consistent (I² =21.6%) decrease of suicidal ideation, with effects comparable between IV bolus and infusion ketamine. Additional analyses confirmed the efficacy of ketamine across different time points. However, relevant, emerging evidence should be considered as ‘very low’ so far. Randomized, controlled and adequately powered trials are needed. (PsycINFO Database Record (c) 2017 APA, all rights reserved)', 'doi': '10.1016/j.neubiorev.2017.03.010', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/28342764/', 'secondary_title': 'Neuroscience and Biobehavioral Reviews', '_input_hash': -1381477505, '_task_hash': -2112018010, 'spans': [{'text': 'Ketamine', 'start': 0, 'end': 8, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 175, 'end': 183, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 331, 'end': 339, 'pattern': -1436149968}, {'text': '99', 'start': 745, 'end': 747, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 773, 'end': 781, 'pattern': -1436149968}, {'text': 'SMD=−0.92', 'start': 822, 'end': 831, 'pattern': 2095658839}, {'text': '95%CI', 'start': 833, 'end': 838, 'pattern': 2095658839}, {'text': '−1.40', 'start': 840, 'end': 845, 'pattern': 2095658839}, {'text': '−0.44', 'start': 849, 'end': 854, 'pattern': 2095658839}, {'text': '0.001', 'start': 859, 'end': 864, 'pattern': 2095658839}, {'text': '21.6', 'start': 886, 'end': 890, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 978, 'end': 986, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1034, 'end': 1042, 'pattern': -1436149968}, {'text': '2017', 'start': 1248, 'end': 1252, 'pattern': 2095658839}], 'meta': {'pattern': '9, 9, 9, 14, 9, 14, 14, 14, 14, 14, 14, 9, 9, 14'}}\n",
      "0.5\n",
      "{'record_id': 4645, 'keywords': \"['Adult', 'Analysis of Variance', 'Attention/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Hallucinogens/administration & dosage/*adverse effects', 'Humans', 'Impulsive Behavior/*chemically induced', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*adverse effects', 'Psychomotor Performance/*drug effects', 'Reaction Time/drug effects', '*Sleep Deprivation', 'Time Factors']\", 'text': 'Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night.^\\nINTRODUCTION: Previous studies on the acute effects of MDMA on psychomotor performance and impulsivity showed that MDMA acts as a stimulant. These studies assessed performance during daytime, whereas in real life, dance-attendees leaving a party use the drug during the night. OBJECTIVES: The present study aimed to assess the effects of nocturnal doses of MDMA on psychomotor performance and impulsivity during the night and after a night of sleep deprivation. MATERIALS AND METHODS: Fourteen healthy subjects participated in a double-blind, placebo-controlled, two-way within-subject study. The treatment was MDMA (75 and 50 mg) divided over the evening or double placebo. Psychomotor and impulsivity tasks were conducted four times throughout the evening and night. A vigilance test was conducted once, at 5 A.M.,: and a sleepiness scale was presented to the subjects ten times throughout the evening and night. RESULTS: MDMA impaired tracking performance in a simple tracking task. Divided attention task performance was also impaired as indicated by a decrease in secondary task performance under the influence of MDMA compared with placebo. MDMA did not affect impulsivity measures. Vigilance performance decreased as a function of time on task, but this decrement was less during MDMA treatment compared to placebo. After the administration of MDMA, the sleepiness scale scores were lower during the night when compared with placebo. This difference between MDMA and placebo disappeared in the morning. CONCLUSION: It is concluded that nocturnal doses of MDMA may produce impairments of tracking performance and divided attention throughout the night that are additive to performance impairment produced by sleep loss.', 'doi': '10.1007/s00213-006-0679-6', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/17219216/', 'secondary_title': 'Psychopharmacology (Berl)', '_input_hash': -185601359, '_task_hash': 1237079590, 'spans': [{'text': 'MDMA', 'start': 36, 'end': 40, 'pattern': -495411397}, {'text': 'MDMA', 'start': 174, 'end': 178, 'pattern': -495411397}, {'text': 'MDMA', 'start': 234, 'end': 238, 'pattern': -495411397}, {'text': 'MDMA', 'start': 476, 'end': 480, 'pattern': -495411397}, {'text': 'MDMA', 'start': 730, 'end': 734, 'pattern': -495411397}, {'text': '75', 'start': 736, 'end': 738, 'pattern': 2095658839}, {'text': '50', 'start': 743, 'end': 745, 'pattern': 2095658839}, {'text': 'MDMA', 'start': 1043, 'end': 1047, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1238, 'end': 1242, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1266, 'end': 1270, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1406, 'end': 1410, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1470, 'end': 1474, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1584, 'end': 1588, 'pattern': -495411397}, {'text': 'MDMA', 'start': 1681, 'end': 1685, 'pattern': -495411397}], 'meta': {'pattern': '7, 7, 7, 7, 7, 14, 14, 7, 7, 7, 7, 7, 7, 7'}}\n",
      "0.5\n",
      "{'record_id': 121, 'keywords': \"['Antidepressive Agents/adverse effects', 'Depression', '*Depressive Disorder, Major/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Humans', '*Ketamine/adverse effects', 'Adverse events', 'Dissociative', 'Ketamine', 'Major depressive disorder', 'Side effects']\", 'text': \"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.^\\nBACKGROUND: Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects. This study sought to comprehensively assess side effects (SEs) associated with a single subanesthetic-dose intravenous ketamine infusion. A secondary aim was to examine the relationship between Clinician-Administered Dissociative States Scale (CADSS) scores and dissociative symptoms reported on a comprehensive, clinician-administered SE questionnaire. METHODS: Data from 188 participants were pooled from four placebo-controlled, crossover ketamine trials and one open-label study (n\\u202f=\\u202f163 with either treatment-resistant major depressive disorder or bipolar disorder and 25 healthy controls). SEs were actively solicited in a standardized fashion and monitored over the time-course of each study. Statistical analyses assessed the effect of drug (ketamine, placebo) on SEs and measured the relationship between CADSS total score and SEs contemporaneously endorsed during structured interviews. RESULTS: Forty-four of 120 SEs occurred in at least 5% of participants over all trials. Thirty-three of these 44 SEs were significantly associated with active drug administration (versus placebo). The most common SE was feeling strange/weird/loopy. Most SEs peaked within an hour of ketamine administration and resolved completely by two hours post-infusion. No serious drug-related adverse events or increased ketamine craving/abuse post-administration were observed. A positive correlation was found between dissociative SEs and total CADSS score. LIMITATIONS: The post-hoc nature of the analysis; the limited generalizability of a single subanesthetic-dose ketamine infusion; and the lack of formal measures to assess ketamine's cognitive, urological, or addictive potential. CONCLUSIONS: No long-lasting significant SEs occurred over the approximately three-month follow-up period.\", 'doi': '10.1016/j.jad.2019.11.028', 'pubmed_url': 'https://pubmed.ncbi.nlm.nih.gov/31791675/', 'secondary_title': 'J Affect Disord', '_input_hash': 1521979954, '_task_hash': 49272501, 'spans': [{'text': 'ketamine', 'start': 74, 'end': 82, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 146, 'end': 154, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 369, 'end': 377, 'pattern': -1436149968}, {'text': '188', 'start': 623, 'end': 626, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 692, 'end': 700, 'pattern': -1436149968}, {'text': '163', 'start': 738, 'end': 741, 'pattern': 2095658839}, {'text': '25', 'start': 824, 'end': 826, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1000, 'end': 1008, 'pattern': -1436149968}, {'text': '120', 'start': 1170, 'end': 1173, 'pattern': 2095658839}, {'text': '44', 'start': 1257, 'end': 1259, 'pattern': 2095658839}, {'text': 'ketamine', 'start': 1430, 'end': 1438, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1558, 'end': 1566, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1807, 'end': 1815, 'pattern': -1436149968}, {'text': 'ketamine', 'start': 1868, 'end': 1876, 'pattern': -1436149968}], 'meta': {'pattern': '9, 9, 9, 14, 9, 14, 14, 9, 14, 14, 9, 9, 9, 9'}}\n"
     ]
    }
   ],
   "source": [
    "for score, eg in matcher(stream):\n",
    "    print(score)\n",
    "    print(eg)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
